

CITATION REPORT

List of articles citing

How to improve R&D productivity: the pharmaceutical industry's grand challenge

DOI: 10.1038/nrd3078

Nature Reviews Drug Discovery, 2010, 9, 203-14.

Source: <https://exaly.com/paper-pdf/48517335/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2268	The Repurposing Drugs in Oncology (ReDO) Project. 2014 , 8, 442		89
2267	Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective. 2010 , 13, 1269-84		91
2266	Prediction of exposure-response relationships to support first-in-human study design. 2010 , 12, 750-8		34
2265	Cell-based assays: fuelling drug discovery. 2010 , 398, 227-38		141
2264	Cardiovascular drug discovery in the academic setting: building infrastructure, harnessing strengths, and seeking synergies. 2010 , 3, 431-7		2
2263	Drug discovery in a multidimensional world: systems, patterns, and networks. 2010 , 3, 438-47		50
2262	How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue. 2010 , 15, 411-5		21
2261	Overcoming psychological barriers to good discovery decisions. 2010 , 15, 561-9		25
2260	Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can improve productivity. 2010 , 15, 766-72		4
2259	Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. 2010 , 62, 724-31		86
2258	Faktoren für die Auswahl organischer Reaktionen in der medizinischen Chemie und die Anwendung dieser Reaktionen in Arrays (kleinen fokussierten Bibliotheken). 2010 , 122, 8258-8267		48
2257	Factors determining the selection of organic reactions by medicinal chemists and the use of these reactions in arrays (small focused libraries). 2010 , 49, 8082-91		208
2256	Accelerating proof of concept for small molecule drugs using solid-state chemistry. 2010 , 99, 3665-75		18
2255	The enrichment window approach as a means of dealing with placebo response in antidepressant clinical trials. 2010 , 88, 592-4		5
2254	Developing pharmacogenetic evidence throughout clinical development. 2010 , 88, 867-70		11
2253	Open-minded to open innovation and precompetitive collaboration. 2010 , 87, 511-5		15
2252	Rare diseases, orphan drugs and their regulation: questions and misconceptions. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 921-9	64.1	105

2251 New drug development and clinical trial. **2010**, 53, 753

2250 New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options. **2010**,

11

2249 Training translators for smart drug discovery. **2010**, 2, 26cm12

12

2248 ResearchWatch. **2010**, 10, 366-370

2247 Opening up to precompetitive collaboration. **2010**, 2, 52cm26

40

2246 How to conduct research in the pharmaceutical industry? Facing the dilemma: small, autonomous teams versus large, integrated centers. **2010**, 5, 813-8

3

2245 Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. **2010**, 50, 31S-46S

18

2244 The Mycobacterium tuberculosis drugome and its polypharmacological implications. **2010**, 6, e1000976

82

2243 NIMH-funded pragmatic trials: moving on. **2010**, 35, 2489-90

15

2242 Cardiovascular system assessment best practices: a Safety Pharmacology Society meeting. **2010**, 9, 855-866

11

2241 Biomarkers in Parkinson's disease: a venture capitalist's perspective. **2010**, 4, 731-5

3

2240 Opinion: The future of pharmaceutical R&D: somewhere between open and reverse innovation?. **2010**, 2, 1399-403

18

2239 Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery. **2010**, 5, 681-90

19

2238 Attention bias modification training and the new interventions research. **2010**, 68, 978-9

7

2237 Pharma embraces open source models. **2010**, 28, 631-4

18

2236 Reducing the Risk of Drug Attrition Associated with Physicochemical Properties. **2010**, 45, 393-407

56

2235 Drug Discovery in Academia- the third way?. **2010**, 5, 909-19

39

2234 Comparative effectiveness research: the view from a pharmaceutical company. **2010**, 28, 915-22

7

2233	Linking molecular feature space and disease terms for the immunosuppressive drug rapamycin. 2011 , 7, 2863-71	2
2232	Impact of ion class and time on oral drug molecular properties. 2011 , 2, 91-105	72
2231	20 years of DNA-encoded chemical libraries. 2011 , 47, 12747-53	107
2230	Application of drug efficiency index in drug discovery: a strategy towards low therapeutic dose. 2011 , 6, 913-20	20
2229	Incentives for R&D for New Antimicrobial Drugs. 2011 , 18, 331-350	7
2228	The preschool ADHD Treatment Study (PATS) as the culmination of twenty years of clinical trials in pediatric psychopharmacology. 2011 , 50, 427-30	7
2227	Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals. 2011 , 30, 583-90	24
2226	Integrated decision support for assessing chemical liabilities. 2011 , 51, 1840-7	30
2225	Literature analysis for systematic drug repurposing: a case study from Biovista. 2011 , 8, 103-108	12
2224	Antimicrobials for bacterial bioterrorism agents. 2011 , 6, 667-76	10
2223	The zebrafish: a powerful platform for in vivo, HTS drug discovery. 2011 , 9, 354-61	75
2222	Iminosugars as therapeutic agents: recent advances and promising trends. 2011 , 3, 1513-21	208
2221	Biochemical pathway modeling tools for drug target detection in cancer and other complex diseases. 2011 , 487, 319-69	15
2220	Open innovation for phenotypic drug discovery: The PD2 assay panel. 2011 , 16, 588-602	51
2219	Drug target identification from protein dynamics using quantitative pathway analysis. 2011 , 10, 2679-83	13
2218	The development of label-free cellular assays for drug discovery. 2011 , 6, 1285-98	48
2217	Quality by design in lead optimization: a new strategy to address productivity in drug discovery. 2011 , 11, 515-20	5
2216	From genes to therapeutic targets for psychiatric disorders - what to expect?. 2011 , 11, 563-71	20

2215	The cost of drug development: a systematic review. 2011 , 100, 4-17	297
2214	Strategies for the discovery of therapeutic aptamers. 2011 , 6, 75-87	30
2213	Nanomedicine(s) under the microscope. 2011 , 8, 2101-41	698
2212	An assessment of R&D productivity in the pharmaceutical industry. 2011 , 32, 683-5	12
2211	Development of biomarkers for multiple sclerosis as a neurodegenerative disorder. 2011 , 95, 670-85	40
2210	Anti- α therapeutics in Alzheimer's disease: the need for a paradigm shift. 2011 , 69, 203-13	303
2209	The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. 2011 , 60, 36-44	133
2208	Resolution of controversies in drug/receptor interactions by protein structure. Limitations and pharmacological solutions. 2011 , 60, 3-6	10
2207	Molecular obesity, potency and other addictions in drug discovery. 2011 , 2, 349-355	255
2206	Collaboration versus outsourcing: the need to think outside the box. 2011 , 3, 1995-2020	12
2205	Application of NMR and molecular docking in structure-based drug discovery. 2012 , 326, 1-34	32
2204	The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. 2011 , 6, 251-68	63
2203	The pharmaceutical industry needs more innovation in bioprocesses. 2011 , 3, 1737-40	0
2202	ISCTM: Implementing phase 2 dose finding adaptive clinical trials. 2011 , 21, 167-74	
2201	Safety of medicines and the use of animals in research. 2011 , 378, 127-8	5
2200	The secrets of a successful clinical trial: compliance, compliance, and compliance. 2011 , 11, 107-10	42
2199	Induced Pluripotent Stem Cells as Human Disease Models. 2011 , 46, 369-383	3
2198	High Content and Throughput Drug Discovery. 2011 ,	

2197	Innovation as Consumption: Analysis of Consumers' Innovation Efficiency. 2011 ,		8
2196	Incentives for R&D for New Antimicrobial Drugs. 2011 ,		
2195	Live cell in vitro and in vivo imaging applications: accelerating drug discovery. 2011 , 3, 141-70		53
2194	Phase I trials: from traditional to newer approaches part II. 2011 , 17, 277-84		11
2193	Comparative efficacy and effectiveness: an opportunity for clinical pharmacology. 2011 , 90, 761-3		8
2192	[Precompetitive research, a synergy of public and private resources: for what purpose, how and in what framework?]. 2011 , 66, 301-7		1
2191	Probing the links between in vitro potency, ADMET and physicochemical parameters. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 197-208	64.1	333
2190	Impact of high-throughput screening in biomedical research. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 188-95	64.1	768
2189	A stronger role for science. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 159	64.1	5
2188	Managing the health of early-stage discovery. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 171-2	64.1	3
2187	The productivity crisis in pharmaceutical R&D. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 428-38	64.1	620
2186	Crowd sourcing in drug discovery. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 241-2	64.1	38
2185	Valuation of biomarkers. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 253-4	64.1	10
2184	Mining for therapeutic gold. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 397	64.1	72
2183	US academic drug discovery. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 409-10	64.1	84
2182	What constitutes an optimal portfolio of pharmaceutical compounds?. 2011 , 89, 304-11		3
2181	Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics. 2011 , 89, 460-3		10
2180	Have animal models of disease helped or hindered the drug discovery process?. 2011 , 1245, 1-2		11

2179	Alchemical free energy methods for drug discovery: progress and challenges. 2011 , 21, 150-60	382
2178	Comparative genomics allowed the identification of drug targets against human fungal pathogens. 2011 , 12, 75	74
2177	Creativity, innovation and lean sigma: a controversial combination?. 2011 , 16, 50-7	65
2176	Lead optimization in the nondrug-like space. 2011 , 16, 158-63	24
2175	Does process excellence handcuff drug development?. 2011 , 16, 377-81	8
2174	Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition. 2011 , 16, 382-97	18
2173	The role of translational bioinformatics in drug discovery. 2011 , 16, 426-34	39
2172	Deploying continuous improvement across the drug discovery value chain. 2011 , 16, 467-71	7
2171	Drug discovery management, small is still beautiful: Why a number of companies get it wrong. 2011 , 16, 476-84	23
2170	Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory. 2011 , 16, 609-18	11
2169	Follow-on drugs: how far should chemists look?. 2011 , 16, 722-32	25
2168	Animal models of asthma: value, limitations and opportunities for alternative approaches. 2011 , 16, 659-70	99
2167	Drug discovery in the next decade: innovation needed ASAP. 2011 , 16, 779-92	59
2166	Alternative business models for drug discovery. 2011 , 16, 643-5	10
2165	Drug development in the light of translational science: shine or shade?. 2011 , 16, 1076-83	28
2164	The significance of G protein-coupled receptor crystallography for drug discovery. 2011 , 63, 901-37	163
2163	Getting physical to fix pharma. 2011 , 3, 692-5	19
2162	Trends in the exploitation of novel drug targets. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 579-90	64.1 608

2161	How were new medicines discovered?. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 507-19	64.1	1254
2160	The influence of the 'organizational factor' on compound quality in drug discovery. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 749-65	64.1	132
2159	Fragment-based lead discovery: challenges and opportunities. 2011 , 25, 607-10		19
2158	DemQSAR: predicting human volume of distribution and clearance of drugs. 2011 , 25, 1121-33		21
2157	¶¶ ivermectin ethyl secoester, a conjugated ivermectin derivative with leishmanicidal activity but without inhibitory effect on mammalian P-type ATPases. 2011 , 383, 101-7		8
2156	Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice. 2011 , 10, 150		17
2155	The institutional review board is an impediment to human research: the result is more animal-based research. 2011 , 6, 12		11
2154	Virtual screening using molecular simulations. 2011 , 79, 1940-51		128
2153	Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress. 2011 , 100, 3044-3054		
2152	Looking to the future of research in pediatric anxiety disorders. 2011 , 28, 88-98		14
2151	Scientific literature mining for drug discovery: a case study on obesity. 2011 , 72, 201-208		5
2150	Drugs against leishmaniasis: Overview of market needs and pipeline. 2011 , 72, 463-470		5
2149	Open mind, open collaboration. 2011 , 5, 701-3		
2148	The need for academic generalists. 2011 , 22, 1807-9		
2147	Nonprofit pharma: solutions to what ails the industry. 2011 , 18, 3437-40		6
2146	Biomedical research and health advances. 2011 , 364, 567-71		30
2145	Clinical pharmacology as a foundation for translational science. 2011 , 90, 10-3		8
2144	Identifying R&D outliers. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 653-4	64.1	18

2143	The precompetitive space: time to move the yardsticks. 2011 , 3, 76cm10		22
2142	Reengineering translational science: the time is right. 2011 , 3, 90cm17		337
2141	What principles should govern the use of managed entry agreements?. 2011 , 27, 77-83		92
2140	Early prediction of proarrhythmic cardiotoxicity in the drug development process. 2011 , 91, 7-8		
2139	Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. 2011 , 108, 12943-8		177
2138	Expanding precompetitive space. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 883	64.1	2
2137	Making the case for precompetitive clinical development. 2011 , 4, 562-562		3
2136	The impact of mergers on pharmaceutical R&D. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 559-60	64.1	74
2135	Design-for-Six-Sigma for Development of a Bioprocess Quality-by-Design Framework. 2011 , 65, 254-86		10
2134	New approaches to rewarding pharmaceutical innovation. 2011 , 183, 681-5		27
2133	A computational approach to finding novel targets for existing drugs. 2011 , 7, e1002139		88
2132	Lessons from the Fersht laboratory could be vital for the future of the pharmaceutical industry. 2011 , 24, 65-7		
2131	Therapeutic antibodies for brain disorders. 2011 , 3, 84ps20		13
2130	Translating discoveries into medicine: psychiatric drug development in 2011. 2012 , 37, 281-3		18
2129	New era for novel CNS drug development. 2012 , 37, 278-80		6
2128	New medications for substance use disorders: challenges and opportunities. 2012 , 37, 290-2		47
2127	Acetaminophen-induced hepatotoxicity in a liver tissue model consisting of primary hepatocytes assembling around an endothelial cell network. 2012 , 40, 169-77		23
2126	In vivo chemical screening for modulators of hematopoiesis and hematological diseases. 2012 , 2012, 851674		3

2125	The translational dialogue in spinal cord injury research. 2012 , 50, 352-7	23
2124	Measuring the value of public-private partnerships in the pharmaceutical sciences. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 419	64.1 11
2123	Data mining methodologies for pharmacovigilance. 2012 , 14, 35-42	15
2122	Next-generation treatments for mental disorders. 2012 , 4, 155ps19	111
2121	Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery. 2012 , 109, 4609-14	43
2120	A virtual national laboratory for reengineering clinical translational science. 2012 , 4, 118cm2	16
2119	Recalibrating intellectual property rights to enhance translational research collaborations. 2012 , 4, 122cm3	25
2118	Aging biology and novel targets for drug discovery. 2012 , 67, 168-74	40
2117	Learning from hackers: open-source clinical trials. 2012 , 4, 132cm5	6
2116	Animal models in an age of personalized medicine. 2012 , 9, 47-64	14
2115	Challenges in sexual medicine. 2012 , 9, 537-42	6
2114	Was phenserine a failure or were investigators misled by methods?. 2012 , 9, 1174-81	11
2113	An alternative approach to drug discovery for Alzheimer's disease dementia. 2012 , 4, 1681-8	29
2112	Plasma cortisol and noradrenalin concentrations in pigs: automated sampling of freely moving pigs housed in the PigTurn [®] versus manually sampled and restrained pigs. 2012 , 21, 197-205	17
2111	Value proposition for therapeutic monoclonal antibodies and Fc fusion proteins. 2012 , 15-595	
2110	Improving success of novel therapeutics for cognitive aspects of psychiatric disease: a bridge too far?. 2012 , 5, 601-3	
2109	Disrupting cancer cells' biocircuits with interactome-based drugs: is 'clinical' innovation realistic?. 2012 , 9, 349-53	14
2108	Issues facing therapeutic monoclonal antibodies for the future. 2012 , 439-595	1

2107	Yale Center for Clinical Investigation: leveraging industry partnerships and research cores. 2012 , 5, 435-6	
2106	The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 168	64.1 28
2105	Canada's laws on pharmaceutical intellectual property: the case for fundamental reform. 2012 , 184, 543-9	7
2104	SEAing change in R&D. 2012 , 5, 721-721	1
2103	A framework for pharmaceutical value-based innovations. 2012 , 1, 3-7	6
2102	Gaining confidence in high-throughput screening. 2012 , 109, 649-50	17
2101	An expanding role for cell biologists in drug discovery and pharmacology. 2012 , 23, 4162-4	12
2100	Building Value Through Biomarkers: The Smarter Development Imperative. 2012 , 46, 397-403	1
2099	CPT: Pharmacometrics and Systems Pharmacology. 2012 , 1, e8	53
2098	Clinical and translational oral health research: prospects for the future. 2012 , 91, 633-6	3
2097	Building a life sciences innovation ecosystem. 2012 , 4, 157fs37	7
2096	Development of Drugs from Plants: Regulation and Evaluation. 2012 , 62, 385-408	
2095	Syndicate Innovation Venturing: Translating Academic Innovations into Commercial Successes. 2012 , 3, 70-83	6
2094	From free to free market: cost recovery in federally funded clinical research. 2012 , 4, 141cm7	3
2093	U.S. basic research: delayed drug development. 2012 , 337, 1605	3
2092	A mechanistic, model-based approach to safety assessment in clinical development. 2012 , 1, e13	32
2091	A methodology to identify efficient collaborative practices of decision-making in industrial projects, based on enterprise process modeling. 2012 , 45, 1339-1346	
2090	Healthcare payers: a gate or translational bridge to personalized medicine?. 2012 , 9, 73-84	4

2089 From mathematics to drug development. **2012**, 28,

2088 Personalized therapy. **2012**, 7, S401-3

2087 Clinical trials in drug development: a minimalistic approach. **2012**, 24, 332-7

2

2086 The Drug Discovery and Development Process. **2012**, 39-70

2085 Role of ADME Studies in Selecting Drug Candidates: Dependence of ADME Parameters on Physicochemical Properties. **2012**, 1

4

2084 Reformulating the 'inventive step' in patent law to achieve an appropriate balance between patent holders and the public. **2012**, 1, 69

0

2083 The impact of pharmacogenomics research on drug development. **2012**, 27, 2-8

19

2082 Pharmacodynamic end points in early-phase oncology trials. **2012**, 2, 679-687

2081 The impact of carbon-hydrogen bond dissociation energies on the prediction of the cytochrome P450 mediated major metabolic site of drug-like compounds. **2012**, 56, 48-55

28

2080 Designing regenerative biomaterial therapies for the clinic. **2012**, 4, 160sr4

180

2079 Chapter 6:Phenotypic and In Vivo Screening: Lead Discovery and Drug Repurposing. **2012**, 86-93

4

2078 Introduction: Drug Discovery in Difficult Times. **2012**, 1-9

2077 ADME of biologics-what have we learned from small molecules?. **2012**, 14, 410-9

41

2076 The Role of Ionic Liquids in the Pharmaceutical Manufacturing Processes. **2012**, 469-496

2075 Innovation and Firm Growth: Is R&D Worth It?. **2012**, 19, 45-62

85

2074 R-group template CoMFA combines benefits of "ad hoc" and topomer alignments using 3D-QSAR for lead optimization. **2012**, 26, 805-19

15

2073 Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit. **2012**, 8, 445-52

37

2072 Target-based drug discovery, genetic diseases, and biologics. **2012**, 61, 892-8

8

2071	Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. 2012 , 61, 1266-75	53
2070	Translational research in infectious disease: current paradigms and challenges ahead. 2012 , 159, 430-53	34
2069	Circular Cone: a novel approach for protein ligand shape matching using modified PCA. 2012 , 108, 168-75	
2068	The role of protein structural analysis in the next generation sequencing era. 2014 , 336, 67-98	12
2067	A portfolio-based approach to optimize proof-of-concept clinical trials. 2012 , 22, 596-607	4
2066	Envisioning the Future: Medicine in the Year 2050. 2012 , 1, 89-99	2
2065	Drug repositioning for personalized medicine. 2012 , 4, 27	144
2064	Strategies for the generation, validation and application of in silico ADMET models in lead generation and optimization. 2012 , 8, 1435-46	16
2063	Recent trends and applications in 3D virtual screening. 2012 , 15, 749-69	12
2062	Two-start design within a Sephadex inflammatory model—a means to generate reliable ED50 data whilst significantly reducing the number of animals used. 2012 , 25, 223-7	
2061	The Valley of Death in anticancer drug development: a reassessment. 2012 , 33, 173-80	54
2060	Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. 2012 , 30, 858-67	395
2059	Cancer biomarkers: selecting the right drug for the right patient. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 201-14	64.1 202
2058	Relating molecular properties and in vitro assay results to in vivo drug disposition and toxicity outcomes. 2012 , 55, 6455-66	47
2057	The influence of lipophilicity in drug discovery and design. 2012 , 7, 863-75	336
2056	Diagnosing the decline in pharmaceutical R&D efficiency. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 191-200	64.1 1152
2055	Ion channel drug discovery: challenges and future directions. 2012 , 4, 661-79	44
2054	Metabolic disease drug discovery- "hitting the target" is easier said than done. 2012 , 15, 19-24	28

2053	R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies. 2012 , 17, 818-23	4
2052	Analysis of the success rates of new drug development in Japan and the lag behind the US. 2012 , 104, 241-6	16
2051	Structure-based drug screening for G-protein-coupled receptors. 2012 , 33, 268-72	229
2050	Drug discovery in pharmaceutical industry: productivity challenges and trends. 2012 , 17, 1088-102	275
2049	Nation-scale adoption of new medicines by doctors: an application of the Bass diffusion model. 2012 , 12, 248	16
2048	Is belief larger than fact: expectations, optimism and reality for translational stem cell research. 2012 , 10, 133	42
2047	Simulating the drug discovery pipeline: a Monte Carlo approach. 2012 , 4, 32	6
2046	Basic Principles of Preformulation Studies. 2012 , 1-35	
2045	Medications development to treat alcohol dependence: a vision for the next decade. 2012 , 17, 513-27	154
2044	The Eight Criteria Defining a Good Chemical Manufacturing Process. 2012 , 16, 1697-1706	95
2043	Computational drug discovery. 2012 , 33, 1131-40	146
2042	Why is publication of negative clinical trial data important?. 2012 , 167, 1395-7	9
2041	Biomarker development for myasthenia gravis. 2012 , 1275, 101-6	13
2040	The determination and interpretation of the therapeutic index in drug development. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 751-61	64.1 314
2039	Nanocarriers as Nanomedicines: Design Concepts and Recent Advances. 2012 , 4, 337-440	10
2038	Microwave and continuous flow technologies in drug discovery. 2012 , 7, 1107-28	17
2037	Bioactive secondary metabolites from marine microbes for drug discovery. 2012 , 65, 363-87	30
2036	Utility of Greater Wax Moth Larva (<i>Galleria mellonella</i>) for Evaluating the Toxicity and Efficacy of New Antimicrobial Agents. 2012 , 78, 25-53	86

2035	Portfolio Decisions in Early Development. 2012 , 26, 77-84	3
2034	CHAPTER 20: The Possibilities and Limitations of Animal Models for Psychiatric Disorders. 2012 , 534-557	11
2033	Factors influencing non-approval of new drugs in Europe. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 903-464.1	25
2032	Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. 2012 , 84, 882-90	103
2031	Metrics and the effective computational scientist: process, quality and communication. 2012 , 17, 935-41	2
2030	Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare. 2012 , 17, 1242-8	14
2029	What is the most important approach in current drug discovery: doing the right things or doing things right?. 2012 , 17, 1166-9	19
2028	Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. 2012 , 18, 717-22	30
2027	Discovery of small molecule cancer drugs: successes, challenges and opportunities. 2012 , 6, 155-76	363
2026	Analysing stratified medicine business models and value systems: innovation-regulation interactions. 2012 , 29, 709-19	18
2025	Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network. 2012 , 4, 778-88	41
2024	Increasing the success rate for Alzheimer's disease drug discovery and development. 2012 , 7, 367-70	22
2023	Comparison of the quantification of a therapeutic protein using nominal and accurate mass MS/MS. 2012 , 4, 605-15	31
2022	Role of Genomics and RNA-seq in Studies of Fungal Virulence. 2012 , 6, 267-274	3
2021	Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical trials. 2012 , 60, 2049-52	17
2020	A decade in drug discovery. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 3	64.1 4
2019	The innovative medicines initiative: a European response to the innovation challenge. 2012 , 91, 418-25	60
2018	Commercializing biomedical research through securitization techniques. 2012 , 30, 964-75	63

2017	Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting. 2012 , 55, 2227-41	53
2016	Assessing the efficacy of molecularly targeted agents on cell line-based platforms by using system identification. 2012 , 13 Suppl 6, S11	6
2015	The comparative analysis of in vivo and in vitro transcriptome data based on systems biology. 2012 , 6, 280-292	2
2014	R&D incentives for neglected diseases. 2012 , 7, e50835	3
2013	Detection of nanolevel drug metabolites in an organotypic culture of primary human hepatocytes and porcine hepatocytes with special reference to a two-compartment model. 2012 , 7, 5859-72	3
2012	Big Pharma, Little Science? A Bibliometric Perspective on Big Pharma's R&D Decline. 2012 ,	4
2011	Ion channel screening: advances in technologies and analysis. 2012 , 3, 86	2
2010	Tinnitus: network pathophysiology-network pharmacology. 2012 , 6, 1	97
2009	R&D Costs and Returns to New Drug Development: A Review of the Evidence. 2012 ,	8
2008	The biotechnology sector. 194-345	
2007	. 2012 ,	15
2006	Pharmaceutical strategy and the evolving role of merger and acquisition. 116-193	0
2005	CNS drug development [Phase III]. 92-99	
2004	Phase I trials: from traditional to newer approaches. 55-69	
2003	Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. 2012 , 55, 4527-38	150
2002	Finding the sweet spot: the role of nature and nurture in medicinal chemistry. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 355-65	64.1 295
2001	The impact of network biology in pharmacology and toxicology. 2012 , 23, 221-35	22
2000	Chapter 2: Clinical Need and Rationale for Multi-Target Drugs in Psychiatry. 2012 , 14-31	2

1999	Predicting new indications for approved drugs using a proteochemometric method. 2012 , 55, 6832-48	103
1998	Biosynthetic medicinal chemistry of natural product drugs. 2012 , 3, 854	29
1997	Revisiting lab-on-a-chip technology for drug discovery. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 620-32	64.1 362
1996	The effects of intralaboratory modifications to media composition and cell source on the expression of pharmaceutically relevant transporters and metabolizing genes in the Caco-2 cell line. 2012 , 101, 3962-78	8
1995	Third-generation sequencing techniques and applications to drug discovery. 2012 , 7, 231-43	42
1994	Outlook for the next 5 years in drug innovation. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 435-6	64.1 45
1993	Top journals selectivity index and the-tool drugs. 2012 , 91, 131-142	12
1992	Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening. 2012 , 35, 245-60	19
1991	Animal Models in Cardiovascular MRI Research: Value and Limitations. 2012 , 5, 99-108	3
1990	Thermal analysis and calorimetry. 2012 , 64, 383	1
1989	Learning from Failures or Failing to Learn? Lessons from Pharmaceutical R&D. 2012 , 9, 45-58	21
1988	Drug discovery in the next decade: innovation needed ASAP. 2012 , 17 Suppl, S31-44	13
1987	Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram). 2012 , 17, 409-12	69
1986	Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. 2012 , 17, 419-24	475
1985	Relevance of systems pharmacology in drug discovery. 2012 , 17, 665-70	34
1984	Collaborative approaches to anticancer drug discovery and development: a Cancer Research UK perspective. 2012 , 17, 185-7	14
1983	Combining imaging and pathway profiling: an alternative approach to cancer drug discovery. 2012 , 17, 203-14	16
1982	Absorptive, innovative and adaptive capabilities and their impact on project and project portfolio performance. 2012 , 30, 621-635	71

1981	Advances and applications of binding affinity prediction methods in drug discovery. 2012 , 30, 244-50	52
1980	Chemoproteomic approaches to drug target identification and drug profiling. 2012 , 20, 1973-8	79
1979	Improving animal models for nervous system disorders. 2012 , 11, 753-6	5
1978	Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic pain states in humans and rats. 2012 , 153, 42-55	127
1977	Integrating pharmacology and clinical pharmacology in pharmaceutical companies. 2012 , 73, 927-30	
1976	Drug development in pediatric psychiatry: current status, future trends. 2012 , 6, 7	5
1975	Parallel drug development. 2012 , 73, 24-34	4
1974	Assessing the performance of amorphous solid dispersions. 2012 , 101, 1355-77	255
1973	The inevitable QSAR renaissance. 2012 , 26, 35-8	49
1972	Can we really do computer-aided drug design?. 2012 , 26, 121-4	2
1971	The future of molecular dynamics simulations in drug discovery. 2012 , 26, 15-26	179
1970	On the importance of synthetic organic chemistry in drug discovery: reflections on the discovery of antidiabetic agent ertugliflozin. 2013 , 4, 101-111	27
1969	Model based design and analysis of phase II HIV-1 trials. 2013 , 40, 487-96	6
1968	Physics and Its Interfaces with Medicinal Chemistry and Drug Design. 2013 , 43, 268-280	1
1967	Model-based drug discovery: implementation and impact. 2013 , 18, 764-75	51
1966	Validating therapeutic targets through human genetics. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 581-94	405
1965	A new approach to assess drug development performance. 2013 , 18, 420-7	8
1964	Metabolically re-modeling the drug pipeline. 2013 , 13, 778-85	28

1963	Can emerging drug classes improve R&D productivity?. 2013 , 18, 607-9	15
1962	The Cinderella effect: searching for the best fit between mouse models and human diseases. 2013 , 133, 2509-2513	12
1961	Compensating for literature annotation bias when predicting novel drug-disease relationships through Medical Subject Heading Over-representation Profile (MeSHOP) similarity. 2013 , 6 Suppl 2, S3	9
1960	Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). 2013 , 85, 1297-305	14
1959	Models for open innovation in the pharmaceutical industry. 2013 , 18, 1133-7	76
1958	Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents: an editorial. 2013 , 56, 7715-8	20
1957	Re-engineering the early development process for pulmonary drug-delivery products. 2013 , 4, 883-5	1
1956	Sustainable rare diseases business and drug access: no time for misconceptions. 2013 , 8, 109	19
1955	The noninflammatory role of high mobility group box 1/Toll-like receptor 2 axis in the self-renewal of mammary cancer stem cells. 2013 , 27, 4731-44	62
1954	Mapping the translational science policy 'valley of death'. 2013 , 2, 14	39
1953	Cancer drug discovery by repurposing: teaching new tricks to old dogs. 2013 , 34, 508-17	235
1952	Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. 2013 , 20, 1521-31	28
1951	Questions regarding the predictive value of one evolved complex adaptive system for a second: exemplified by the SOD1 mouse. 2013 , 113, 231-53	25
1950	The New Geography of Innovation. 2013 ,	1
1949	PHARMACOECONOMICS AND DRUG PRICING. 2013 , 125-136	
1948	Alzheimer's disease drug development: translational neuroscience strategies. 2013 , 18, 128-38	22
1947	Open innovation and intellectual property: time for a reboot?. 2013 , 18, 907-9	4
1946	High-throughput metabolic genotoxicity screening with a fluidic microwell chip and electrochemiluminescence. 2013 , 13, 4554-62	24

1945	The effect of network biology on drug toxicology. 2013 , 9, 1409-18		10
1944	Exploring the biologically relevant chemical space for drug discovery. 2013 , 53, 2820-8		33
1943	Chemical predictive modelling to improve compound quality. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 948-62	64.1	157
1942	Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches. 2013 , 18, 1143-55		96
1941	Translational research in nicotine dependence. 2013 , 3, a012153		9
1940	Predicting drug-target interactions using probabilistic matrix factorization. 2013 , 53, 3399-409		108
1939	From molecule to market access: drug regulatory science as an upcoming discipline. 2013 , 719, 9-15		11
1938	Human genetics as a foundation for innovative drug development. 2013 , 31, 975-8		34
1937	Drug dealers: \$20 trillion of in-licensing payments. 2013 , 18, 1027-9		2
1936	Pharmaceutical innovation and public policy: The case for a new strategy for drug discovery and development. 2013 , 40, 393-405		16
1935	Sex and the basic scientist: is it time to embrace Title IX?. 2013 , 4, 13		13
1934	Business oriented EU human cell and tissue product legislation will adversely impact Member States' health care systems. 2013 , 14, 525-60		30
1933	Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. 2013 , 18, 1043-51		32
1932	Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. 2013 , 5, 369-91		49
1931	2,2'-Dithienyl diselenide pro-oxidant activity accounts for antibacterial and antifungal activities. 2013 , 168, 563-8		25
1930	New avenues for anti-epileptic drug discovery and development. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 757-76	64.1	399
1929	Report on the 10th anniversary of international drug discovery science and technology conference, 8 - 10 november 2012, nanjing, china. 2013 , 8, 357-61		1
1928	The 3R principle: advancing clinical application of human pluripotent stem cells. 2013 , 4, 21		11

1927	Building a microphysiological skin model from induced pluripotent stem cells. 2013 , 4 Suppl 1, S2	24
1926	. 2013 ,	
1925	Screening reactive metabolites bioactivated by multiple enzyme pathways using a multiplexed microfluidic system. 2013 , 138, 171-8	14
1924	Bringing together the academic drug discovery community. <i>Nature Reviews Drug Discovery</i> , 2013 , 12, 811-2	64.1 46
1923	How can attrition rates be reduced in cancer drug discovery?. 2013 , 8, 363-8	71
1922	The cost-effectiveness of periodic safety update reports for biologicals in Europe. 2013 , 93, 433-42	12
1921	Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. 2013 , 57, 2458-68	183
1920	The failure of the antidepressant drug discovery process is systemic. 2013 , 27, 407-13; discussion 413-6	38
1919	Discontinued drugs in 2011: oncology drugs. 2013 , 22, 9-34	14
1918	Multicomponent reactions - opportunities for the pharmaceutical industry. 2013 , 10, e15-20	103
1917	NIH TRND program: successes in preclinical therapeutic development. 2013 , 34, 87-9	7
1916	Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture. 2013 , 1284, 17-27	102
1915	Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism. 2013 , 109, 319-28	14
1914	Leveraging concept-based approaches to identify potential phyto-therapies. 2013 , 46, 602-14	7
1913	Investigation of the influence of molecular topology on ligand binding. 2013 , 40, 22-9	0
1912	Targeting melanoma by small molecules: challenges ahead. 2013 , 26, 464-9	9
1911	Critical factors for process improvement in pharmaceutical research. 2013 , 25, 141-152	9
1910	Industrielle Anwendungen der Diels-Alder-Reaktion. 2013 , 125, 3912-3955	46

1909	Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery. 2013 , 67, 69-81	33
1908	Integration of models and experimentation to optimise the production of potential biotherapeutics. 2013 , 18, 1250-5	20
1907	The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives. 2013 , 18, 853-62	33
1906	Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?. 2013 , 9, 50-7	23
1905	Preclinical Development of Oncology Drugs. 2013 , 543-565	1
1904	An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin. 2013 , 75, 404-14	22
1903	The path to oncology drug target validation: an industry perspective. 2013 , 986, 3-13	4
1902	Impact of biomarker usage on oncology drug development. 2013 , 38, 62-7	17
1901	Expanding medicinal chemistry space. 2013 , 18, 298-304	61
1900	Industrial applications of the Diels-Alder reaction. 2013 , 52, 3822-63	170
1899	Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. 2013 , 56, 3033-47	93
1898	Managing Life Science Innovations in Public Research Through Holistic Performance Measures. 2013 , 83-94	
1897	Molecular dynamics simulations in drug design. 2013 , 993, 95-113	43
1896	Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations. 2013 , 9, 737-51	10
1895	Discovery of innovative therapeutics: today's realities and tomorrow's vision. 1. Criticisms faced by the pharmaceutical industry. 2013 , 56, 5659-72	11
1894	Discovery of New Medicines. 2013 , 1-31	
1893	Challenges and opportunities of drug repositioning. 2013 , 34, 267-72	222
1892	What has Happened to R&D Productivity?. 2013 , 25-48	

1891	Improving R&D Output. 2013 , 71-95	
1890	Open Innovation in Drug Discovery research comes of age. 2013 , 18, 315-7	7
1889	Torching the Haystack: modelling fast-fail strategies in drug development. 2013 , 18, 331-6	9
1888	Transcriptional data: a new gateway to drug repositioning?. 2013 , 18, 350-7	153
1887	A chemistry wiki to facilitate and enhance compound design in drug discovery. 2013 , 18, 141-7	8
1886	Beyond the scope of Free-Wilson analysis: building interpretable QSAR models with machine learning algorithms. 2013 , 53, 1324-36	32
1885	Translational research: the changing landscape of drug discovery. 2013 , 18, 487-94	32
1884	Pharmacotherapy of amphetamine-type stimulant dependence: an update. 2013 , 32, 449-60	81
1883	Drug-drug interaction studies: regulatory guidance and an industry perspective. 2013 , 15, 629-45	164
1882	Access to cancer medications in low- and middle-income countries. 2013 , 10, 314-22	62
1881	Concise review: the relevance of human stem cell-derived organoid models for epithelial translational medicine. 2013 , 31, 417-22	79
1880	Chip-based liver equivalents for toxicity testing--organotypicalness versus cost-efficient high throughput. 2013 , 13, 3481-95	80
1879	'Smart' non-viral delivery systems for targeted delivery of RNAi to the lungs. 2013 , 4, 59-76	11
1878	DNA-encoded Chemical Libraries. 2013 , 353-399	1
1877	Yeast as a Model in High-Throughput Screening of Small-Molecule Libraries. 2013 , 455-482	2
1876	Four disruptive strategies for removing drug discovery bottlenecks. 2013 , 18, 265-71	25
1875	CHAPTER 5:Temperature- and pH-sensitive Polymeric Micelles for Drug Encapsulation, Release and Targeting. 2013 , 115-147	8
1874	Drug Discovery Using Human iPSC Based Disease Models and Functional Hepatic Cells. 2013 , 95-103	

1873	Neural stem cells as tools for drug discovery: novel platforms and approaches. 2013 , 8, 1083-94	14
1872	Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation. 2013 , 13, 615-25	27
1871	Metabolomics and its potential in drug development. 2013 , 85, 12-20	50
1870	The innovative medicines initiative: a public private partnership model to foster drug discovery. 2013 , 6, e201303017	19
1869	Inferring drug-disease associations from integration of chemical, genomic and phenotype data using network propagation. 2013 , 6 Suppl 3, S4	41
1868	Reducing Drug Attrition: Safety Pharmacology. 2013 , 139-158	
1867	Discontinued drugs in 2012: oncology drugs. 2013 , 22, 1627-44	26
1866	Drug repurposing in pediatrics and pediatric hematology oncology. 2013 , 18, 4-10	30
1865	Drug repurposing a reality: from computers to the clinic. 2013 , 6, 95-7	19
1864	Induced pluripotent stem cells in cardiovascular drug discovery. 2013 , 112, 534-48	90
1863	Early evaluation and value-based pricing of regenerative medicine technologies. 2013 , 8, 747-58	15
1862	Projecting expenditure on medicines in the UK NHS. 2013 , 31, 933-57	4
1861	Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor. 2013 , 32, 336-50	25
1860	Content Development Strategies for the Successful Implementation of Data Mining Technologies. 2013 , 209-240	
1859	Impact of biomarkers on clinical trial risk. 2013 , 14, 1645-58	5
1858	A fully unsupervised compartment-on-demand platform for precise nanoliter assays of time-dependent steady-state enzyme kinetics and inhibition. 2013 , 85, 4761-9	71
1857	Plug and Play? Interconnected multifunctional chips for enhancing efficiency of biopharmaceutical R&D. 2013 , 1, 225-228	5
1856	Using economic optimization to design high-throughput screens. 2013 , 5, 9-11	2

1855	Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease. 2013 , 13, 456-66	3
1854	How academia and the pharmaceutical industry can work together: the president's lecture, annual meeting of the American Thoracic Society, San Francisco, California. 2013 , 10, 31-8	17
1853	SwissBioisostere: a database of molecular replacements for ligand design. 2013 , 41, D1137-43	75
1852	Stochastic and Deterministic Models of Cellular p53 Regulation. 2013 , 3, 64	20
1851	Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis. 2013 , 25, 679-85	13
1850	The first 7 days of a quit attempt predicts relapse: validation of a measure for screening medications for nicotine dependence. 2013 , 7, 249-54	34
1849	Biomarkers, putative surrogates, surrogates, and decision making. 2013 , 6, 6-7	7
1848	'Innovation' in health care coverage decisions: all talk and no substance?. 2013 , 18, 57-60	9
1847	Investigation of Characteristics of Japanese Clinical Trials in Terms of Data Variability. 2013 , 47, 430-437	2
1846	An end to the myth: there is no drug development pipeline. 2013 , 5, 171cm1	31
1845	Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. 2013 , 54, 397-401	39
1844	The current development of CNS drug research. 2013 , 16, 1687-93	36
1843	Can Financial Engineering Cure Cancer?. 2013 , 103, 406-411	24
1842	Drugs in search of diseases. 2013 , 5, 186fs18	12
1841	New Drug Development. 2013 , 33-40	
1840	Curing consortium fatigue. 2013 , 5, 200fs35	25
1839	Combined analysis of pharmacokinetic and efficacy data of preclinical studies with statins markedly improves translation of drug efficacy to human trials. 2013 , 347, 635-44	23
1838	Factors Related to Regulatory Approval of Late-Stage Development Compounds: Analysis of Japanese Pharmaceutical Company Activities, 1995-2007. 2013 , 47, 261-267	1

1837	Public-Private Partnerships in Biomarker Research. 2013 , 474-483	
1836	Patient-specific stem cells and cardiovascular drug discovery. 2013 , 310, 2039-40	27
1835	Translational Bioinformatics Approaches to Drug Development. 2013 , 2, 470-489	20
1834	Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications. 2013 , 108, 1962-8	15
1833	Protein replacement therapies for rare diseases: a breeze for regulatory approval?. 2013 , 5, 178fs10	16
1832	Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs. 2013 , 136, 242-9	69
1831	An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. 2013 , 32, 1433-9	66
1830	Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for 'Orphan' Molecules. 2013 , 32, 133-138	109
1829	Advanced intravital subcellular imaging reveals vital three-dimensional signalling events driving cancer cell behaviour and drug responses in live tissue. 2013 , 280, 5177-97	9
1828	Chemical genetics and its potential in cardiac stem cell therapy. 2013 , 169, 318-27	4
1827	Drug design and discovery: translational biomedical science varies among countries. 2013 , 6, 409-13	2
1826	Drug library screening against metronidazole-sensitive and metronidazole-resistant <i>Trichomonas vaginalis</i> isolates. 2013 , 89, 479-84	23
1825	Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patients. 2013 , 53, 1294-302	8
1824	Importance and hurdles to drug discovery for neurological disease. 2013 , 74, 441-6	11
1823	A high-throughput clinical assay for testing drug facilitation of exposure therapy. 2013 , 30, 631-7	20
1822	VinaMPI: facilitating multiple receptor high-throughput virtual docking on high-performance computers. 2013 , 34, 2212-21	45
1821	Computational Toxicology Experience and Applications for Risk Assessment in the Pharmaceutical Industry. 2013 , 171-193	
1820	Developability assessment as an early de-risking tool for biopharmaceutical development. 2013 , 1, 29-50	38

1819	Vaccine development costs: a review. 2013 , 12, 1495-501	13
1818	An entirely automated method to score DSS-induced colitis in mice by digital image analysis of pathology slides. 2013 , 6, 855-65	23
1817	Drug and disease model resources: a consortium to create standards and tools to enhance model-based drug development. 2013 , 2, e34	30
1816	Partnering for therapeutics discovery. 2013 , 93, 24-5	2
1815	Computation as the mechanistic bridge between precision medicine and systems therapeutics. 2013 , 93, 117-28	30
1814	Governance, Regulation and Innovation. 2013 ,	2
1813	Cost-effectiveness analysis of microdose clinical trials in drug development. 2013 , 28, 187-95	14
1812	Open innovation: public-private partnerships in pharmaceutical R&D. 2013 , 142, 32-8	
1811	Pre-Clinical Assessment of the Potential Intrinsic Hepatotoxicity of Candidate Drugs. 2013 ,	7
1810	Current tendencies in antimicrobial research: medicinal chemistry of antibacterial agents and advances in the use of computational methodologies. 2013 , 13, 3011-2	
1809	Optimisation and validation of a high throughput screening compatible assay to identify inhibitors of the plasma membrane calcium ATPase pump—a novel therapeutic target for contraception and malaria. 2013 , 16, 217-30	12
1808	New targets for drug discovery against malaria. 2013 , 8, e59968	15
1807	Drug repurposing: translational pharmacology, chemistry, computers and the clinic. 2013 , 13, 2328-36	15
1806	Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. 2013 , 74, 966-73	56
1805	Toward developmental models of psychiatric disorders in zebrafish. 2013 , 7, 79	69
1804	Identification of PPAR α ligands with One-dimensional Drug Profile Matching. 2013 , 7, 917-28	4
1803	The role of information, bioinformatics and genomics. 2013 , 77-94	1
1802	Drug discovery and development. 2013 , 321-334	1

1801	Molecular Biotechnology: From DNA Sequence to Therapeutic Protein. 2013 , 1-18	1
1800	The Three Rs - do we need a new principle?. 2013 , 41, P56-7	1
1799	Why are we failing to implement imaging studies with radiolabelled new molecular entities in early oncology drug development?. 2014 , 2014, 269605	4
1798	Label-free drug discovery. 2014 , 5, 52	48
1797	Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease. 2014 , 3, 311-6	10
1796	The importance of epitope binning for biological drug discovery. 2014 , 11, 109-12	10
1795	R&D implementation in a department of laboratory medicine and pathology: a systematic review based on pharmaceutical companies. 2015 , 7, 70-82	2
1794	Human Brain Imaging of Opioid Receptors. 2014 , 81-98	3
1793	. 2014 ,	36
1792	Rational Design of Multifunctional Nanoscale Self-Assembled Soft Materials for Biomedical Delivery Application. 2014 , 55-73	1
1791	Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets. 2014 , 3, 40	4
1790	Recipe Development Process Re-Design with ANSI/ISA-88 Batch Control Standard in the Pharmaceutical Industry. 2014 , 6, 16	4
1789	. 2014 ,	1
1788	Lost in translation: the need for better tools. 2014 , 42, P41-5	
1787	Opening the door to innovation. 2014 , 6, 812-9	12
1786	AACR Cancer Progress Report 2014. 2014 , 20, S1-S112	41
1785	Anticancer Drug Registration and Regulation. 2014 , 583-607	
1784	The rise of systems pharmacology in drug discovery and development. 2014 , 6, 1731-4	14

1783	Cheminformatics for medicinal chemistry: in silico model to enable the discovery of potent and safer anti-cocci agents. 2014 , 6, 2013-28		32
1782	Advances in multiparameter optimization methods for de novo drug design. 2014 , 9, 803-17		46
1781	Zebrafish: A marvel of high-throughput biology for 21 century toxicology. 2014 , 1, 341-352		61
1780	References. 2014 , 175-189		
1779	The significance of meaning: why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it?. 2014 , 55, 438-56		104
1778	Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 638-40	64.1	11
1777	Embedding sustainable practices into pharmaceutical R&D: what are the challenges?. 2014 , 6, 1373-6		6
1776	Pharmaceutical regulation in Europe and its impact on corporate R&D. 2014 , 4, 23		14
1775	An automated synthesis-purification-sample-management platform for the accelerated generation of pharmaceutical candidates. 2014 , 19, 176-82		23
1774	Application of an in vitro OAT assay in drug design and optimization of renal clearance. 2014 , 44, 657-65		10
1773	Homopharma: a new concept for exploring the molecular binding mechanisms and drug repurposing. 2014 , 15 Suppl 9, S8		6
1772	From computational modelling of the intrinsic apoptosis pathway to a systems-based analysis of chemotherapy resistance: achievements, perspectives and challenges in systems medicine. 2014 , 5, e1258		22
1771	Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. 2014 , 7, 161-5		21
1770	Integrative approach in the era of failing drug discovery and development. 2014 , 3, 211-216		13
1769	Introduction. 2014 , 1-17		1
1768	Capital Allocation: Evidence, Analytical Methods, and Assessment Guidance. 2014 , 26, 48-74		2
1767	Exploiting structural information for drug-target assessment. 2014 , 6, 319-31		19
1766	Discovering novel neuroactive drugs through high-throughput behavior-based chemical screening in the zebrafish. 2014 , 5, 153		56

1765	Integrating internal and external bioanalytical support to deliver a diversified pharmaceutical portfolio. 2014 , 6, 1311-9	8
1764	The battle of Alzheimer's Disease - the beginning of the future Unleashing the potential of academic discoveries. 2014 , 5, 102	15
1763	Pharmacoeconomic Considerations in CNS Drug Development. 2014 , 375-397	
1762	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. 2014 , 10, S430-52	57
1761	Biomarkers for the development of new medications for cocaine dependence. 2014 , 39, 202-19	29
1760	Proposing advancement criteria for efficient DMPK triage of new chemical entities. 2014 , 6, 131-9	6
1759	Measuring soluble biomarkers in clinical trials: do tiered approaches to the analysis and validation of assays provide an answer to the fit-for-purpose challenge?. 2014 , 6, 605-9	4
1758	Introduction to Toxicogenomics-Based Cellular Models. 2014 , 3-11	4
1757	Open innovation in practice: diffusion of knowledge and use in Swedish bio-pharmaceutical firms. 2014 , 8, 137	9
1756	Managing eHealth. 2014 ,	1
1755	Research and Development Costs and Productivity in Biopharmaceuticals. 2014 , 249-255	1
1754	How can we discover safer drugs?. 2014 , 6, 481-3	11
1753	Improving efficiency of initial tests for efficacy in smoking cessation drug discovery. 2014 , 9, 1259-64	10
1752	Using molecular profiled human tissue to accelerate drug discovery. 2014 , 9, 1383-7	1
1751	. 2014 ,	
1750	Reducing the variability of compound management delivery using visual management systems. 2014 , 19, 171-5	1
1749	Potential strategies for increasing drug-discovery productivity. 2014 , 6, 515-27	16
1748	Drug discovery in paediatric oncology: roadblocks to progress. 2014 , 11, 732-9	21

1747	Economic analysis of opportunities to accelerate Alzheimer's disease research and development. 2014 , 1313, 17-34	48
1746	When Research Meets Development: Antecedents and Implications of Transfer Speed. 2014 , 31, 1181-1198	17
1745	Ethical considerations of experimental interventions in the Ebola outbreak. 2014 , 384, 1896-1899	91
1744	Refocusing on R&D model or redefining marketing strategy? Anticipating sustainability for generic pharmaceutical industry. 2014 , 14, 81-90	0
1743	The Past, Present, and Future of Chemical Risk Assessment. 2014 , 3-23	2
1742	From the era of genome analysis to the era of genomic drug discovery: a pioneering example of rheumatoid arthritis. 2014 , 86, 432-40	12
1741	Research and development productivity map: visualization of industry status. 2014 , 39, 175-80	10
1740	Ghrelin and motilin receptor agonists: time to introduce bias into drug design. 2014 , 26, 149-55	26
1739	Assessing the challenges of multi-scope clinical research sites: an example from NIH HIV/AIDS clinical trials networks. 2014 , 20, 149-57	3
1738	Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry. 2014 , 38, 1196-9	9
1737	Diversity-oriented synthesis as a tool for chemical genetics. 2014 , 19, 16506-28	29
1736	Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs. 2014 , 19, 297-303	6
1735	Opportunities for computational techniques for multi-omics integrated personalized medicine. 2014 , 19, 545-558	2
1734	A theoretical examination of the relative importance of evolution management and drug development for managing resistance. 2014 , 281,	32
1733	A Quantitative Process for Enhancing End of Phase 2 Decisions. 2014 , 6, 67-77	14
1732	Bench-to-bench bottlenecks in translation. 2014 , 6, 250fs32	5
1731	Pharmaceutical R&D performance by firm size: approval success rates and economic returns. 2014 , 21, 26-34	23
1730	Evaluation of tumor size response metrics to predict survival in oncology clinical trials. 2014 , 95, 386-93	42

1729	Use patents can be useful: the case of rescued drugs. 2014 , 6, 248fs30	4
1728	Histopathology: A Canvas and Landscape of Disease in Drug and Diagnostic Development. 2014 , 1-26	
1727	Grassroots Innovation: A Promising Innovation Paradigm for Pharmaceutical Companies. 2014 , 119-148	5
1726	High-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markers. 2014 , 9, e88338	39
1725	Parallel discovery of Alzheimer's therapeutics. 2014 , 6, 241cm5	34
1724	The therapeutic potential of medicinal foods. 2014 , 2014, 354264	32
1723	Inhibition of microglia activation as a phenotypic assay in early drug discovery. 2014 , 19, 17-31	36
1722	Stratified high-throughput screening sets enable flexible screening strategies from a single plated collection. 2014 , 19, 369-78	10
1721	Building an Integrated Early Clinical Development Platform to Improve the Path to Proof of Concept. 2014 , 48, 546-551	
1720	Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs. 2014 , 38, 27-32	10
1719	Medical innovation then and now: perspectives of innovators responsible for transformative drugs. 2014 , 42, 564-75	4
1718	Big Pharma, little science?. 2014 , 81, 22-38	77
1717	Collaborative practices for medicinal chemistry research across the big pharma and not-for-profit interface. 2014 , 19, 496-501	6
1716	Cell-based drug testing; this world is not flat. 2014 , 69-70, vii-xi	17
1715	Towards the realisation of lead-oriented synthesis. 2014 , 19, 813-9	39
1714	Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis. 2014 , 94, 162-9	31
1713	Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. 2014 , 87, 150-61	224
1712	The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. 2014 , 54, 9-26	200

1711	Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. 2014 , 19, 171-82	122
1710	Mathematical modeling in cancer drug discovery. 2014 , 19, 145-50	44
1709	Towards a sustainable system of drug development. 2014 , 19, 1711-1720	31
1708	Effect of liquid-handling accuracy on assay performance. 2014 , 19, 153-62	5
1707	The present and future role of microfluidics in biomedical research. 2014 , 507, 181-9	1776
1706	Exploring QSAR studies on 4-substituted quinazoline derivatives as antimalarial compounds for the development of predictive models. 2014 , 23, 1397-1405	16
1705	Medical prevention and treatment of postpartum hemorrhage: a comparison of different guidelines. 2014 , 289, 555-67	25
1704	Reducing attrition in drug development: smart loading preclinical safety assessment. 2014 , 19, 341-7	60
1703	Developments in preclinical cancer imaging: innovating the discovery of therapeutics. 2014 , 14, 314-28	112
1702	Seeding Open Innovation Drug Discovery and Translational Collaborations to Leverage Government Funding: A Case Study of Strategic Partnership between Sanford-Burnham and Mayo Clinic. 2014 , 451-486	
1701	Finding the Middle Ground: Drug Discovery Technology in the Era of Academic Screening Centers. 2014 , 487-498	
1700	Open Innovation-Based Drug Discovery in Europe: Some Examples of National and Transnational European Initiatives Integrating Chemistry, Biology, and Technology Platforms. 2014 , 499-515	
1699	Using Market-Driven Collaboration to Accelerate Innovation in Biomedicine. 2014 , 653-661	
1698	Unraveling structural mechanisms of allosteric drug action. 2014 , 35, 256-64	97
1697	Current Social, Clinical, and Scientific Environment of Pharmaceutical R&D. 2014 , 1-21	
1696	Polypharmacology and Adverse Bioactivity Profiles Predict Potential Toxicity and Drug-Related Adrs. 2014 , 23-45	2
1695	Multiparameter Optimization of ADMET for Drug Design. 2014 , 145-166	1
1694	Integrated Assessment and Clinical Translation of In Vitro Off-Target Safety Pharmacology Risks. 2014 , 397-406	

1693	Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. 2014 , 95, 617-26		81
1692	Nonlinear dimensionality reduction for visualizing toxicity data: distance-based versus topology-based approaches. 2014 , 9, 1047-59		8
1691	Front Matter. 2014 , i-xxv		
1690	Reported Applications of DNA-Encoded Library Chemistry. 2014 , 319-347		8
1689	Systems biology-embedded target validation: improving efficacy in drug discovery. 2014 , 6, 1-11		13
1688	In vivo imaging of specific drug-target binding at subcellular resolution. 2014 , 5, 3946		56
1687	Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 419-31	64.1	806
1686	User community vs. producer innovation development efficiency: A first empirical study. 2014 , 43, 190-201		109
1685	Systems biology, complexity, and the impact on antiepileptic drug discovery. 2014 , 38, 131-42		27
1684	SRChing for the substrates of Src. 2014 , 33, 4537-47		36
1683	Rings in drugs. 2014 , 57, 5845-59		1190
1682	Impact of distance-based metric learning on classification and visualization model performance and structure-activity landscapes. 2014 , 28, 61-73		7
1681	Opening the lead generation toolbox. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 3-4	64.1	16
1680	Halogen bond: its role beyond drug-target binding affinity for drug discovery and development. 2014 , 54, 69-78		222
1679	Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments. 2014 , 69-70, 170-8		20
1678	Multi-algorithm and multi-model based drug target prediction and web server. 2014 , 35, 419-31		5
1677	NINDS translational programs: priming the pump of neurotherapeutics discovery and development. 2014 , 84, 515-20		3
1676	Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development. 2014 , 79-80, 50-67		99

1675	iSyn: WebGL-Based Interactive De Novo Drug Design. 2014 ,	4
1674	Future directions for research in autism spectrum disorders. 2014 , 43, 828-43	42
1673	A linearization approach for the model-based analysis of combined aggregate and individual patient data. 2014 , 33, 1460-76	6
1672	Expanding the scope of drug repurposing in pediatrics: the Children's Pharmacy Collaborative. 2014 , 19, 1696-1698	17
1671	New perspectives and lessons learned in the identification of impurities in drug development. 2014 , 19, 1691-1695	1
1670	Improving and accelerating drug development for nervous system disorders. 2014 , 84, 546-53	118
1669	Medicines for the mind: policy-based "pull" incentives for creating breakthrough CNS drugs. 2014 , 84, 554-63	47
1668	Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone. 2014 , 29, 962-9	13
1667	Advancing the Drug Discovery and Development Process. 2014 , 126, 9280-9292	16
1666	Overcoming obstacles to repurposing for neurodegenerative disease. 2014 , 1, 512-8	34
1665	Barriers to advancing nanotechnology to better improve and translate nanomedicines. 2014 , 8, 265-275	14
1664	Design Some New Type-I c-met Inhibitors Based on Molecular Docking and Topomer CoMFA Research. 2014 , 33, 536-43	10
1663	Development of anti-inflammatory drugs - the research and development process. 2014 , 114, 7-12	11
1662	Improving Physical Properties via C?H Oxidation: Chemical and Enzymatic Approaches. 2014 , 126, 12287-12292 ₁₃	
1661	Predicting putative adverse drug reaction related proteins based on network topological properties. 2014 , 6, 2692	9
1660	The synergy of the whole: building a global system for clinical trials to accelerate medicines development. 2014 , 36, 1356-70	3
1659	Lead Discovery and Lead Modification. 2014 , 19-122	5
1658	Should pharmacometrics be training the next R&D president?. 2014 , 95, 579-80	2

1657	Simultaneous virtual prediction of anti-Escherichia coli activities and ADMET profiles: A cheminformatic complementary approach for high-throughput screening. 2014 , 16, 78-84	39
1656	9.07 High-Throughput Purification in Support of Pharmaceutical Discovery. 2014 , 160-180	2
1655	Label-free in situ monitoring of histone deacetylase drug target engagement by matrix-assisted laser desorption ionization-mass spectrometry biotyping and imaging. 2014 , 86, 4642-7	55
1654	Pharmaceutical portfolio management: global disease burden and corporate performance metrics. 2014 , 17, 732-8	4
1653	Regenerative Medicine Ethics. 2014 ,	3
1652	High-throughput screening (HTS) for the identification of novel antiviral scaffolds. 2014 , 3, 79-83	6
1651	Drug Life Cycle. 2014 , 1-11	
1650	Screening technologies for small molecule discovery: the state of the art. 2014 , 21, 1162-70	103
1649	Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning. 2014 , 9, 1265-79	1
1648	More multiarm randomised trials of superiority are needed. 2014 , 384, 283-4	82
1647	Efficient hit and lead compound evaluation strategy based on off-rate screening by surface plasmon resonance. 2014 , 57, 2843-4	7
1646	Predicting the activity and toxicity of new psychoactive substances: a pharmaceutical industry perspective. 2014 , 6, 739-45	4
1645	The current state of drug discovery and a potential role for NMR metabolomics. 2014 , 57, 5860-70	47
1644	Target Selection and Validation in Drug Discovery. 2014 , 1-72	
1643	Exploiting large-scale drug-protein interaction information for computational drug repurposing. 2014 , 15, 210	13
1642	Concordance and predictive value of two adverse drug event data sets. 2014 , 14, 74	1
1641	Alzheimer's disease drug-development pipeline: few candidates, frequent failures. 2014 , 6, 37	1023
1640	Cost efficiency of pharmaceutical firms manufacturing drugs for specific diseases prevalent in India: A data envelopment analysis approach. 2014 , 14, 5-19	

1639	Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. 2014 , 21, 1115-42	336
1638	An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation. 2014 , 231, 1-11	25
1637	Bigger data, collaborative tools and the future of predictive drug discovery. 2014 , 28, 997-1008	19
1636	Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery. 2014 , 31, 414-35	43
1635	Advancing the drug discovery and development process. 2014 , 53, 9128-40	53
1634	The discovery of first-in-class drugs: origins and evolution. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 577-641	308
1633	Phenotypic screening in cancer drug discovery - past, present and future. <i>Nature Reviews Drug Discovery</i> , 2014 , 13, 588-602	64.1 307
1632	Supervised extensions of chemography approaches: case studies of chemical liabilities assessment. 2014 , 6, 20	3
1631	Overcoming the current deadlock in antibiotic research. 2014 , 22, 165-7	95
1630	Academic, Commercial, and Biodefense Case Studies for Collaborative Drug Discovery: Potential for Disrupting Drug Discovery. 2014 , 303-317	
1629	Collaborative Innovation in Pharmaceutical Industry: Approaches and Requirements. 2014 , 255-266	1
1628	Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives. 2014 , 57-73	
1627	Accelerating Innovation in the Bioscience Revolution. 2014 , 195-212	
1626	Nonindustrial Pharmaceutical Research in the BRIC Countries: Lessons for Drug Discovery Partnerships with Academic and Governmental Institutions. 2014 , 159-172	
1625	NIH workshop on clinical translation of molecular imaging probes and technology--meeting report. 2014 , 16, 595-604	3
1624	Metaphors in Nanomedicine: The Case of Targeted Drug Delivery. 2014 , 8, 1-17	20
1623	Engineering and evaluating drug delivery particles in microfluidic devices. 2014 , 190, 139-49	88
1622	Corporate reporting of intellectual capital: evidence from the Bangladeshi pharmaceutical sector. 2014 , 22, 98-127	28

1621	Back to the future with phenotypic screening. 2014 , 5, 503-13	77
1620	Drug repositioning by integrating target information through a heterogeneous network model. 2014 , 30, 2923-30	178
1619	Hepatic organoids for microfluidic drug screening. 2014 , 14, 3290-9	106
1618	Efalizumab (Raptiva). 2014 , 1531-1544	
1617	Improving physical properties via C-H oxidation: chemical and enzymatic approaches. 2014 , 53, 12091-6	66
1616	CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?. 2014 , 86, 430-7	159
1615	Physicochemical properties, form, and formulation selection strategy for a biopharmaceutical classification system class II preclinical drug candidate. 2014 , 103, 3007-21	20
1614	The Impact of Patents on Innovation, Technology Transfer and Health: A Pre- and Post-TRIPs Analysis of India's Pharmaceutical Industry. 2014 , 19, 384-406	17
1613	Protections for clinical trials in low and middle income countries need strengthening not weakening. 2014 , 349, g4254	17
1612	The 41st David A. Karnofsky Memorial Award Lecture: Academic research worldwide--quo vadis?. 2014 , 32, 347-54	31
1611	Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how. 2014 , 19, 1131-6	72
1610	Financing drug discovery for orphan diseases. 2014 , 19, 533-8	29
1609	Consideration of the cellular microenvironment: physiologically relevant co-culture systems in drug discovery. 2014 , 69-70, 190-204	41
1608	Pricing pharmaceutical compounds under development. 2014 , 35, 217-8	1
1607	Current status and future prospects of toxicogenomics in drug discovery. 2014 , 19, 562-78	26
1606	Addressing toxicity risk when designing and selecting compounds in early drug discovery. 2014 , 19, 688-93	75
1605	Binding Free Energy Calculations for Lead Optimization: Assessment of Their Accuracy in an Industrial Drug Design Context. 2014 , 10, 3331-44	104
1604	Orphan drugs and rare diseases: a scientometric review (2000-2014). 2014 , 2, 709-724	105

1603	Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model. 2014 , 28, 273-89	38
1602	State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. 2014 , 187, 133-44	360
1601	Approaching the in vitro clinical trial: engineering organs on chips. 2014 , 14, 3181-6	82
1600	Modulators of protein-protein interactions. 2014 , 114, 4695-748	341
1599	Multiple system atrophy as emerging template for accelerated drug discovery in α -Synucleinopathies. 2014 , 20, 793-9	18
1598	High-throughput epitope binning of therapeutic monoclonal antibodies: why you need to bin the fridge. 2014 , 19, 1040-4	19
1597	The development speed paradox: can increasing development speed reduce R&D productivity?. 2014 , 19, 209-14	6
1596	Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development. 2014 , 19, 348-55	7
1595	Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. 2014 , 110, 72-80	58
1594	Toward more specific and transparent research and development costs: the case of seasonal influenza vaccines. 2014 , 32, 3336-40	12
1593	Pay-for-Delay Agreements in the Pharmaceutical Sector: Towards a Coherent EU Approach?. 2014 , 5, 79-86	1
1592	The effect of Affordable Care Act on the competition in the post-patent ethical drug market. 2014 , 8, 314-347	3
1591	Molecular dynamics simulation-based evaluation of the binding free energies of computationally designed drug candidates: importance of the dynamical effects. 2014 , 62, 661-7	9
1590	Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches. 2014 , 3, e122	3
1589	Clinical translation in the virtual liver network. 2014 , 3, e127	10
1588	Bristol-Myers Squibb and the Medicines Patent Pool – An Unlikely Marriage?. 2014 , 5, 68-72	
1587	Nahtlose Integration von Dosis-Wirkungs-basiertem Screening und Flusschemie: effiziente Erzeugung von Struktur-Aktivitäts-Beziehungen von β -Sekretase(BACE1)-Hemmern. 2014 , 126, 1730-1735	3
1586	A focus on translational medicine is necessary to close the innovation gap in pharmaceutical medicine. 2014 , 4, 675-677	

1585	Seamless integration of dose-response screening and flow chemistry: efficient generation of structure-activity relationship data of β -secretase (BACE1) inhibitors. 2014 , 53, 1704-8	39
1584	Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence. 2016 , 18, 74-8	15
1583	Relating Translational Neuroimaging and Amperometric Endpoints: Utility for Neuropsychiatric Drug Discovery. 2016 , 28, 397-421	5
1582	Introduction. 2015 , 1-9	1
1581	Access to Compound Collections. 2015 , 61-76	1
1580	Fragment-Based Drug Discovery. 2015 , 221-249	1
1579	Key role of publication of clinical data for target validation. 2015 , 3, e00163	2
1578	The NIMH experimental medicine initiative. 2015 , 14, 151-3	81
1577	Marine Natural Products in Pharma: How Industry Missed the Boat. 2015 , 531-540	
1576	Accessing Chemical Diversity through Metagenomics. 2015 , 3-22	
1575	Drug Discovery and Development: the Role of NMR. 2015 , 137-150	7
1574	The Role of NMR in Target Identification and Validation for Pharmaceutical R&D. 2015 , 305-314	
1573	Identification of potential inhibitors based on compound proposal contest: Tyrosine-protein kinase Yes as a target. 2015 , 5, 17209	27
1572	Compound Attrition at the Preclinical Phase. 2015 , 46-82	
1571	Best Practices in Assessment of Developability of Biopharmaceutical Candidates. 2015 , 155-174	1
1570	Clinical Validation. 2015 , 207-230	1
1569	From Marine Organism to Potential Drug: Using Innovative Techniques to Identify and Characterize Novel Compounds β Bottom-Up Approach. 2015 , 443-472	1
1568	In silico ADME/T modelling for rational drug design. 2015 , 48, 488-515	137

1567	Bibliography. 2015 , 402-432	
1566	Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study. 2015 , 5, e009333	6
1565	Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapies. 2015 , 9 Suppl 5, S4	14
1564	R&D performance measurement: A process perspective revisited. 2015 ,	
1563	Application of Cost Analysis Methods in Pharmacoeconomic Decisions. 2015 , 32, 416-422	4
1562	Sample size planning for phase II trials based on success probabilities for phase III. 2015 , 14, 515-24	15
1561	Medication Nonadherence, "Professional Subjects," and Apparent Placebo Responders: Overlapping Challenges for Medications Development. 2015 , 35, 566-73	41
1560	Experimental Screening Strategies to Reduce Attrition Risk. 2015 , 180-214	
1559	Professional translational research: a new hybrid paradigm in early drug discovery. 2015 , 7, 1879-89	2
1558	Exposure-response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development. 2015 , 9, 5185-94	1
1557	Multi-target drug discovery in medicinal chemistry: current status and future perspectives. 2015 , 15, 606-7	1
1556	Microbiome and Asthma: What Have Experimental Models Already Taught Us?. 2015 , 2015, 614758	14
1555	Excitation-contraction coupling of human induced pluripotent stem cell-derived cardiomyocytes. 2015 , 3, 59	37
1554	3D Cell Culture in Alginate Hydrogels. 2015 , 4, 133-61	231
1553	An IPTG Inducible Conditional Expression System for Mycobacteria. 2015 , 10, e0134562	6
1552	Reverse Innovation and Reverse Technology Transfer: From Made in China to Discovered in China in the Pharmaceutical Sector. 2015 , 19, 49-69	9
1551	Funding Translational Medicine via Public Markets: The Business Development Company. 2015 ,	
1550	R&D Productivity in the Pharmaceutical Industry. 2015 , 6, 1-16	2

1549	. 2015,	5
1548	. 2015,	5
1547	Editorial: medicinal chemistry studies of neglected diseases. 2015, 15, 180-1	
1546	Human iPSC-based cardiac microphysiological system for drug screening applications. 2015, 5, 8883	330
1545	Benchmarking Data Sets for the Evaluation of Virtual Ligand Screening Methods: Review and Perspectives. 2015, 55, 1297-307	51
1544	High-throughput screening for modulators of cellular contractile force. 2015, 7, 1318-24	47
1543	Nanoscale monitoring of drug actions on cell membrane using atomic force microscopy. 2015, 36, 769-82	34
1542	Machines that Go 'Ping': Medical Technology and Health Expenditures in OECD Countries. 2015, 24, 1027-41	14
1541	Antimicrobial and docking studies of (R)-catechin derivatives. 2015, 58, 581-585	4
1540	Innovative approaches to the design and synthesis of small molecule libraries. 2015, 23, 2613	14
1539	Advances in measuring single-cell pharmacology in vivo. 2015, 20, 1087-92	26
1538	Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets. 2015, 55, 1231-45	78
1537	The Life Sciences Translational Challenge: The European Perspective. 2015, 49, 415-424	2
1536	Label-free cardiac contractility monitoring for drug screening applications based on compact high-speed lens-free imaging. 2015,	2
1535	Time for a change: addressing R&D and commercialization challenges for antibacterials. 2015, 370, 20140086	51
1534	Digital Microfluidic Cell Culture. 2015, 17, 91-112	49
1533	Cell analytics in compound hit selection of bacterial inhibitors. 2015,	0
1532	Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity. 2015, 7, 1853-9	12

1531	Melt-processed polymeric cellular dosage forms for immediate drug release. 2015 , 220, 397-405	11
1530	R&D Planning System Approach at Organizational Level. 2015 , 213, 812-816	2
1529	Bioprinting of Dynamic Human Organs-on-Chips: Enabling Technologies for Rapid Drug Development and Personalized Medicine. 2015 , 123-137	2
1528	Combinatorial screening for specific drug solubilizers with switchable release profiles. 2015 , 15, 82-9	10
1527	Endogenous transport price and international R&D rivalry. 2015 , 46, 36-43	2
1526	A pharma perspective on the systems medicine and pharmacology of inflammation. 2015 , 260, 2-5	2
1525	Repurposing the antipsychotic trifluoperazine as an antimetastasis agent. 2015 , 87, 501-12	37
1524	Closing the gap between the molecular and systemic actions of anesthetic agents. 2015 , 72, 229-62	5
1523	A multi-organ chip co-culture of neurospheres and liver equivalents for long-term substance testing. 2015 , 205, 36-46	113
1522	Multitasking models for quantitative structure-biological effect relationships: current status and future perspectives to speed up drug discovery. 2015 , 10, 245-56	35
1521	Mass spectrometric detection of short-lived drug metabolites generated in an electrochemical microfluidic chip. 2015 , 87, 1527-35	46
1520	Target engagement in lead generation. 2015 , 25, 998-1008	75
1519	Use of uniform designs in combination with neural networks for viral infection process development. 2015 , 31, 532-40	3
1518	Progression-seeking bias and rational optimism in research and development. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 219-21	64.1 8
1517	Marine Bioactive Compounds from Cnidarians. 2015 , 823-849	5
1516	Guidelines for translational research in heart failure. 2015 , 8, 3-22	24
1515	The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?. 2015 , 2, 105-10	106
1514	The impact of CRISPR-Cas9 on target identification and validation. 2015 , 20, 450-7	49

1513	Nonconventional chemical inhibitors of microRNA: therapeutic scope. 2015 , 51, 820-31	28
1512	A bidirectional drug repositioning approach for Parkinson's disease through network-based inference. 2015 , 457, 280-7	7
1511	Addressing the right targets in oncology: challenges and alternative approaches. 2015 , 20, 305-17	11
1510	Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis. 2015 , 10, 465-81	38
1509	The pain of pain: challenges of animal behavior models. 2015 , 753, 183-90	22
1508	Genetic Approaches to Facilitate Antibacterial Drug Development. 2015 , 5, a021139	10
1507	Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. 2015 , 7, 229-42	31
1506	How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy, and practice. 2015 , 13, 1	137
1505	Do We Need New Endpoints in Clinical Trials. 2015 , 159-170	
1504	Smart Program Design Through a Common Information Model. 2015 , 49, 116-125	1
1503	Development of broad-spectrum antibiofilm drugs: strategies and challenges. 2015 , 10, 1035-48	8
1502	Role of computer-aided drug design in modern drug discovery. 2015 , 38, 1686-701	272
1501	Propeller-shaped molecules with a thiazole hub: structural landscape and hydrazone cap mediated tunable host behavior in 4-hydrazino-1,3-thiazoles. 2015 , 17, 5978-5986	2
1500	Molecular mechanism matters: Benefits of mechanistic computational models for drug development. 2015 , 99, 149-54	20
1499	Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders. 2015 , 97, 388-398	33
1498	Convergence of regenerative medicine and synthetic biology to develop standardized and validated models of human diseases with clinical relevance. 2015 , 35, 127-32	31
1497	Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. 2015 , 30 Suppl 4, iv105-112	15
1496	Chemical biology databases: from aggregation, curation to representation. 2015 , 14, 25-9	2

1495	From G Protein-coupled Receptor Structure Resolution to Rational Drug Design. 2015 , 290, 19489-95	74
1494	Novel Approaches for the Delivery of Biologics to the Central Nervous System. 2015 , 59-88	5
1493	Morphological and Functional Characterization and Assessment of iPSC-Derived Hepatocytes for In Vitro Toxicity Testing. 2015 , 147, 39-54	82
1492	Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again. 2015 , 20, 934-45	27
1491	Academic drug discovery: current status and prospects. 2015 , 10, 937-44	33
1490	From cardiac tissue engineering to heart-on-a-chip: beating challenges. 2015 , 10, 034006	96
1489	High-throughput measurements of the optical redox ratio using a commercial microplate reader. 2015 , 20, 010503	14
1488	BalestraWeb: efficient online evaluation of drug-target interactions. 2015 , 31, 131-3	18
1487	Assessing external innovation in drug discovery and development. 2015 , 10, 579-89	10
1486	Competing events and costs of clinical trials: Analysis of a randomized trial in prostate cancer. 2015 , 115, 114-9	4
1485	Computational toxicology, friend or foe?. 2015 , 4, 1159-1172	17
1484	Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association. 2015 , 131, 1715-36	32
1483	Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. 2015 , 16, 165-72	13
1482	Clustered distribution of natural product leads of drugs in the chemical space as influenced by the privileged target-sites. 2015 , 5, 9325	16
1481	Modeling Pulmonary Disease Pathways Using Recombinant Adeno-Associated Virus 6.2. 2015 , 53, 291-302	16
1480	[The German Pharmaceutical Market Reorganization Act (AMNOG) from an economic point of view]. 2015 , 58, 291-7	2
1479	Product and Process Innovation in the Development Cycle of Biopharmaceuticals. 2015 , 10, 156-165	7
1478	Big Data in Pharmaceutical R&D: Creating a Sustainable R&D Engine. 2015 , 29, 87-92	14

1477	The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. 2015 , 11, 515-34	79
1476	Label-free screening of single biomolecules through resistive pulse sensing technology for precision medicine applications. 2015 , 26, 182502	13
1475	Open data partnerships between firms and universities: The role of boundary organizations. 2015 , 44, 1133-1143	106
1474	Sustainable Development for the Health-Care Industry: Setting the Stage. 2015 , 1-37	
1473	Validation and characterization of optical redox ratio measurements with a microplate reader in breast cancer cells. 2015 ,	1
1472	Cystic Fibrosis from Laboratory to Bedside: The Role of A20 in NF- κ -Mediated Inflammation. 2015 , 24, 301-10	12
1471	Induced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous System. 2015 , 24, 1852-64	28
1470	Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach. 2015 , 94, 378-85	14
1469	A new application of value-stream mapping in new drug development: a case study within Novartis. 2015 , 20, 301-5	6
1468	Cancer Research UK Centre for Drug Development: translating 21st-century science into the cancer medicines of tomorrow. 2015 , 20, 995-1003	5
1467	In silico tools used for compound selection during target-based drug discovery and development. 2015 , 10, 901-23	13
1466	Recent advances in combinatorial biosynthesis for drug discovery. 2015 , 9, 823-33	40
1465	A Novel Scoring Based Distributed Protein Docking Application to Improve Enrichment. 2015 , 12, 1464-9	9
1464	Translational Medicine and Biomarkers. 2015 , 415-446	
1463	Organizational Considerations and Trends in the Pharmaceutical Industry. 2015 , 447-469	
1462	Intellectual Property and Patents in Drug Discovery. 2015 , 471-498	1
1461	Drug Discovery and Development. 2015 , 1-34	8
1460	Barriers to new drug development in respiratory disease. 2015 , 45, 1197-207	70

1459	Achieving successful delivery of oligonucleotides--From physico-chemical characterization to in vivo evaluation. 2015 , 33, 1294-309	33
1458	Mitigating risk in academic preclinical drug discovery. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 279-94	64.1 94
1457	Novel methods and technologies for 21st-century clinical trials: a review. 2015 , 72, 582-8	72
1456	Organs-on-chips at the frontiers of drug discovery. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 248-60	64.1 765
1455	Pharmaceutical applications of cyanobacteria: a review. 2015 , 5, 15-23	111
1454	Lead optimization attrition analysis (LOAA): a novel and general methodology for medicinal chemistry. 2015 , 20, 978-87	13
1453	Flow Cytometry: Impact on Early Drug Discovery. 2015 , 20, 689-707	44
1452	Translational Medicine: The Changing Role of Big Pharma. 2015 , 313-325	3
1451	The Pharmaceutical R&D Productivity Crisis. 2015 , 227-228	1
1450	One Programme, Four Stakeholders: An Overview of the Utilisation of Patient-Reported Outcomes in Intervention Development to Meet the Needs of Regulators, Payers, Healthcare Professionals and Patients. 2015 , 29, 69-78	2
1449	Bioprinting of human pluripotent stem cells and their directed differentiation into hepatocyte-like cells for the generation of mini-livers in 3D. 2015 , 7, 044102	296
1448	The importance of triaging in determining the quality of output from high-throughput screening. 2015 , 7, 1847-52	12
1447	The promise of open innovation in drug discovery: an industry perspective. 2015 , 7, 1835-8	5
1446	Using gene expression signatures to identify novel treatment strategies in gulf war illness. 2015 , 8, 36	16
1445	Heteromers of μ opioid receptors: new pharmacology and novel therapeutic possibilities. 2015 , 172, 375-87	66
1444	High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. 2015 , 21, 1318-25	752
1443	Of drug administration, war and oikos: mediating cancer with nanomedicines. 2015 , 10, 3261-74	4
1442	Compound Passport Service: supporting corporate collection owners in open innovation. 2015 , 20, 1250-5	3

1441	Unknown unknowns in biomedical research: does an inability to deal with ambiguity contribute to issues of irreproducibility?. 2015 , 97, 133-6	29
1440	Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action. 2015 , 49, 929-939	95
1439	Managing Team Innovation in the Research and Development (R&D) Organization: Critical Determinants of Team Effectiveness. 2015 , 49, 877-885	3
1438	Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective. 2015 , 20, 1310-6	75
1437	Identification of in vitro and in vivo disconnects using transcriptomic data. 2015 , 16, 615	10
1436	Conquering the barriers: are antibody therapeutics feasible for CNS indications?. 2015 , 10, 67-70	2
1435	Specific Drug Formulation Additives: Revealing the Impact of Architecture and Block Length Ratio. 2015 , 16, 3308-12	12
1434	Why is it hard to terminate failing projects in pharmaceutical R&D?. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 663-4	64.1 34
1433	Analytical models for biopharmaceutical operations and supply chain management: a survey of research literature. 2015 , 3, 61-73	7
1432	Challenges and opportunities toward enabling phenotypic screening of complex and 3D cell models. 2015 , 7, 513-25	16
1431	Network-based discovery through mechanistic systems biology. Implications for applications--SMEs and drug discovery: where the action is. 2015 , 15, 41-8	9
1430	Patient-centered drug discovery as the means to improved R&D productivity. 2015 , 20, 1044-8	6
1429	Thermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry. 2015 , 10, 1567-93	293
1428	Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. 2015 , 56, 1793-9	8
1427	Designing a broad-spectrum integrative approach for cancer prevention and treatment. 2015 , 35 Suppl, S276-S304	179
1426	Modeling and Simulation of In Vivo Drug Effects. 2016 , 232, 313-29	4
1425	Assessing End of Phase 2 Decision Criteria. 2015 , 7, 230-237	2
1424	Mendelian randomisation applied to drug development in cardiovascular disease: a review. 2015 , 52, 71-9	37

1423	Advancing drug discovery: a pharmaceuticals perspective. 2015 , 104, 865-71		9
1422	A decade of innovation in pharmaceutical R&D: the Chorus model. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 17-28	64.1	47
1421	Prediction of drug gene associations via ontological profile similarity with application to drug repositioning. 2015 , 74, 71-82		16
1420	Paper - a potential platform in pharmaceutical development. 2015 , 33, 4-9		45
1419	A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells. 2015 , 20, 37-49		29
1418	A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation. 2015 , 104, 191-206		63
1417	Grants4Targets: an open innovation initiative to foster drug discovery collaborations. <i>Nature Reviews Drug Discovery</i> , 2015 , 14, 74-6	64.1	22
1416	Outbound open innovation in bio-pharmaceutical out-licensing. 2015 , 35, 46-58		55
1415	Selective conversion of fibroblasts into peripheral sensory neurons. 2015 , 18, 25-35		114
1414	R&D productivity rides again?. 2015 , 14, 1-3		16
1413	Integration of drug, protein, and gene delivery systems with regenerative medicine. 2015 , 5, 168-86		36
1412	Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?. 2015 , 25, 713-24		52
1411	A strategic approach to the synthesis of functionalized spirooxindole pyrrolidine derivatives: in vitro antibacterial, antifungal, antimalarial and antitubercular studies. 2015 , 39, 520-528		73
1410	Databases and collaboration require standards for human stem cell research. 2015 , 20, 247-54		4
1409	Discontinued in 2013: oncology drugs. 2015 , 24, 95-110		48
1408	Overcoming barriers to green chemistry in the pharmaceutical industry [The Green Aspiration Level] concept. 2015 , 17, 752-768		208
1407	A unified lead-oriented synthesis of over fifty molecular scaffolds. 2015 , 13, 859-65		43
1406	A perspective on the clinical translation of scaffolds for tissue engineering. 2015 , 43, 641-56		128

1405	High-growth firms in changing competitive environments: the US pharmaceutical industry (1963 to 2002). 2015 , 44, 145-170	38
1404	Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects. 2015 , 6, 24-50	74
1403	Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics. 2016 , 7, 40348-40361	17
1402	Cell-Based Assay Design for High-Content Screening of Drug Candidates. 2016 , 26, 213-25	52
1401	Quantitative Structure-Activity Relationships. 2016 , 163-192	4
1400	Pharmaceuticals, Money, and the Health Care Organizational Field. 2016 ,	
1399	Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. 2016 , 33, 272-321	161
1398	In Vivo Imaging in Pharmaceutical Development and Its Impact on the 3Rs. 2016 , 57, 212-220	9
1397	Translational science in drug development: challenges and possible solutions. 2016 , 148, 290-295	
1396	Prioritizing Adverse Drug Reaction and Drug Repositioning Candidates Generated by Literature-Based Discovery. 2016 ,	8
1395	Prediscovery Research: Challenges and Opportunities. 2016 , 85-108	
1394	Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets. 2016 , 4,	16
1393	A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers. 2016 , 8,	40
1392	Mimicking the Kidney: A Key Role in Organ-on-Chip Development. 2016 , 7,	23
1391	Identification of Novel Human Breast Carcinoma (MDA-MB-231) Cell Growth Modulators from a Carbohydrate-Based Diversity Oriented Synthesis Library. 2016 , 21,	1
1390	"Omics"-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives. 2016 , 4,	83
1389	Using Clinical Trial Simulators to Analyse the Sources of Variance in Clinical Trials of Novel Therapies for Acute Viral Infections. 2016 , 11, e0156622	6
1388	Current Status of Computer-Aided Drug Design for Type 2 Diabetes. 2016 , 12, 167-177	16

1387 Animal Modelling in Psychiatry. **2016**, 47-73

1386 Expectations for the methodology and translation of animal research: a survey of the general public, medical students and animal researchers in North America. **2016**, 44, 361-381 4

1385 Functional genetics-directed identification of novel pharmacological inhibitors of FAS- and TNF-dependent apoptosis that protect mice from acute liver failure. **2016**, 7, e2145 11

1384 Predictive Methods in Lead Generation. **2016**, 425-450

1383 Generalizing the Concept of Specific Compound Formulation Additives towards Non-Fluorescent Drugs: A Solubilization Study on Potential Anti-Alzheimer-Active Small-Molecule Compounds. **2016**, 55, 8752-6 18

1382 The interaction between internal R&D and different types of external knowledge sourcing: an empirical study of Chinese innovative firms. **2016**, 46, 1006-1023 71

1381 Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development. **2016**, 40, 1368-79 44

1380 Collaborative Approaches to Lead Generation. **2016**, 307-328 1

1379 Use of Three-Dimensional Arterial Models To Predict the In Vivo Behavior of Nanoparticles for Drug Delivery. **2016**, 55, 4461-6 9

1378 Identification of 1H-indene-(1,3,5,6)-tetrol derivatives as potent pancreatic lipase inhibitors using molecular docking and molecular dynamics approach. **2016**, 63, 765-778 5

1377 A Risk Management Approach for Collaborative NPD Project. **2016**, 1

1376 Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms. **2016**, 8, 104-22 30

1375 Erweiterung des Konzeptes spezifischer Wirkstoff-Formulierungsadditive auf nichtfluoreszierende Wirkstoffe: eine Studie zur Solubilisierung potenzieller Anti-Alzheimer-Wirkstoffe. **2016**, 128, 8894-8899 4

1374 Ligandability of Drug Targets: Assessment of Chemical Tractability via Experimental and In Silico Approaches. **2016**, 35-62 3

1373 Use of Three-Dimensional Arterial Models To Predict the In Vivo Behavior of Nanoparticles for Drug Delivery. **2016**, 128, 4537-4542 1

1372 Unblocking the cancer drug development bottleneck via innovative partnering. **2016**, 12, 1857-60

1371 Towards knowledge-driven cross-species extrapolation. **2016**, 22, 21-26 2

1370 The use of dynamic computational models of neural circuitry to streamline new drug development. **2016**, 19, 69-75 3

1369	DRABAL: novel method to mine large high-throughput screening assays using Bayesian active learning. 2016 , 8, 64	15
1368	Using Placebo Response to Pain as a Predictor of Placebo Response in Mood Disorders. 2016 , 3, 360-367	
1367	A Laminated Microfluidic Device for Comprehensive Preclinical Testing in the Drug ADME Process. 2016 , 6, 25022	28
1366	Using Systems Pharmacology to Advance Oncology Drug Development. 2016 , 421-463	1
1365	Systems Pharmacology Modeling in Type 2 Diabetes Mellitus. 2016 , 465-507	3
1364	Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. 2016 , 7, 10787	102
1363	Data integration to prioritize drugs using genomics and curated data. 2016 , 9, 21	9
1362	The art and science of the drug discovery pipeline. 1-16	1
1361	Increasing the odds of effective drug development: Elevating regulatory affairs professionals to strategic partners. 2016 , 33, 59-65	1
1360	Putting translational science on to a global stage. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 217-8	64.1 16
1359	Determination of the mechanical properties of solid and cellular polymeric dosage forms by diametral compression. 2016 , 509, 444-453	8
1358	Gastrointestinal Behavior of Weakly Acidic BCS Class II Drugs in Man--Case Study of Diclofenac Potassium. 2016 , 105, 687-696	31
1357	New Formulations of Old Analgesics and Repurposing of Old Drugs as "New" Analgesics. 2016 , 38, 988-9	1
1356	The evolution of drug discovery: from phenotypes to targets, and back. 2016 , 7, 788-798	21
1355	Future Directions in Pain Management: Integrating Anatomically Selective Delivery Techniques With Novel Molecularly Selective Agents. 2016 , 91, 522-33	6
1354	On the exfoliating polymeric cellular dosage forms for immediate drug release. 2016 , 103, 210-218	7
1353	Empowering openness: the case of CROs-related innovation networks in the Italian bio-pharmaceutical sector. 2016 , 13, 184	3
1352	Ion channels find a pathway for therapeutic success. 2016 , 113, 5472-4	16

1351	The Commercial Market For Priority Review Vouchers. 2016 , 35, 776-83	22
1350	In vivo phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents. 2016 , 7, 1093-1101	9
1349	From the Bench to the Pharmacy: Protecting Innovation During Vaccine Development and Commercialization. 2016 , 1404, 813-834	2
1348	Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. 2016 , 59, 4697-710	30
1347	Longevity-Promoting Pharmaceuticals: Is it a Time for Implementation?. 2016 , 37, 331-333	22
1346	Screening out irrelevant cell-based models of disease. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 751-769	297
1345	Novel naïve Bayes classification models for predicting the carcinogenicity of chemicals. 2016 , 97, 141-149	37
1344	Bioprinting 3D microfibrinous scaffolds for engineering endothelialized myocardium and heart-on-a-chip. 2016 , 110, 45-59	495
1343	Humanized mice in infectious diseases. 2016 , 49, 29-38	29
1342	Toward An integrative CSDS based model of industrial R&D division efficiency. 2016 , 49, 1785-1790	2
1341	Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid. 2016 , 105, 3243-3255	15
1340	Unreliability as a threat to understanding psychopathology: The cautionary tale of attentional bias. 2016 , 125, 840-51	146
1339	Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environment. 2016 , 33, 860-867	2
1338	High-Throughput Excipient Discovery Enables Oral Delivery of Poorly Soluble Pharmaceuticals. 2016 , 2, 748-755	47
1337	Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations. 2016 , 138, 14257-14263	100
1336	Nociceptin Receptor as a Target to Treat Alcohol Use Disorder: Challenges in Advancing Medications Development. 2016 , 40, 2299-2304	3
1335	Antimicrobial Resistance And New Antibiotics. 2016 , 35, 1935	1
1334	Enhancing Virtual Screening Performance of Protein Kinases with Molecular Dynamics Simulations. 2016 , 56, 1923-1935	14

1333	Reflection of successful anticancer drug development processes in the literature. 2016 , 21, 1740-1744	8
1332	Anti-aging pharmacology: Promises and pitfalls. 2016 , 31, 9-35	96
1331	Industry perspectives on biomarker qualification. 2016 , 99, 208-13	19
1330	Designing Multi-target Compound Libraries with Gaussian Process Models. 2016 , 35, 192-8	5
1329	Pharmacometabolomics in Early-Phase Clinical Development. 2016 , 9, 128-38	25
1328	Justification for conducting neurological clinical trials as part of patient care within private practice. 2016 , 70, 365-71	0
1327	Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation. 2016 , 1, 293-304	81
1326	Discovery of New Drugs for Weight Loss and Prevention of Weight Regain. 2016 , 247-284	
1325	Mathematical Modeling and Omic Data Integration to Understand Dynamic Adaptation of Apicomplexan Parasites and Identify Pharmaceutical Targets. 2016 , 455-486	1
1324	Computational Approaches to the Chemical Equilibrium Constant in Protein-ligand Binding. 2016 , 35, 555-567	5
1323	Crowdsourcing in pharmaceutical R&D: a revolutionary concept or nothing new?. 2016 , 5, 355-360	0
1322	Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. 2016 , 2, 687-701	44
1321	Should network biology be used for drug discovery?. 2016 , 11, 1135-1137	4
1320	Translational Health Economics. 2016 , 405-440	3
1319	Bayesian predictive power: choice of prior and some recommendations for its use as probability of success in drug development. 2016 , 15, 438-46	8
1318	The emerging role of biosensor-based epitope binning and mapping in antibody-based drug discovery. 2016 , 11, 925-37	15
1317	Aptamer-Based Microfluidic Electrochemical Biosensor for Monitoring Cell-Secreted Trace Cardiac Biomarkers. 2016 , 88, 10019-10027	137
1316	Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry. 2016 , 5, 692	20

1315	Navigating the Solid Form Landscape with Structural Informatics. 2016 , 15-35	8
1314	Tumor deconstruction as a tool for advanced drug screening and repositioning. 2016 , 111, 815-819	2
1313	Ionic liquids as a potential tool for drug delivery systems. 2016 , 7, 1881-1897	162
1312	Using the gini coefficient to measure the chemical diversity of small-molecule libraries. 2016 , 37, 2091-7	10
1311	Reducing the risk of failure: biomarker-guided trial design. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 517-541	13
1310	Introduction to the Book. 2016 , 1-9	
1309	The Patient-Centric Pharma Company: Evolution, Reboot, or Revolution?. 2016 , 308-333	
1308	New Innovation Models in Pharmaceutical R&D. 2016 , 400-415	1
1307	A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities. 2016 , 60-79	5
1306	Challenges and Options for Drug Discovery. 2016 , 106-139	1
1305	Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. 2016 , 21, 1719-1727	55
1304	Creating commercial value from patents: the interplay between patent protection and patent information management. 2016 , 5, 361-365	1
1303	Assessing R&D productivity: Perspectives of Research Organizations. 2016 ,	
1302	3D microtumors in vitro supported by perfused vascular networks. 2016 , 6, 31589	209
1301	Disciplined approach to drug discovery and early development. 2016 , 8, 349ps15	59
1300	Pharmaceutical Organizational Size and Phase 3 Clinical Trial Completion Times. 2016 , 50, 801-807	1
1299	Identification of Potential Therapeutics to Conquer Drug Resistance in Salmonella typhimurium: Drug Repurposing Strategy. 2016 , 30, 593-605	6
1298	Re-energizing the Development of Pain Therapeutics in Light of the Opioid Epidemic. 2016 , 92, 294-297	44

1297	Induced Pluripotent Stem Cell-Derived Outer-Blood-Retinal Barrier for Disease Modeling and Drug Discovery. 2016 , 436-457	
1296	Performance of Dark Chemical Matter in High Throughput Screening. 2016 , 59, 9806-9813	10
1295	Functional metabolic interactions of human neuron-astrocyte 3D in vitro networks. 2016 , 6, 33285	15
1294	Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files. 2016 , 20, 789-803	4
1293	Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials. 2016 , 33, 895-906	83
1292	Perspective for new pharmacological interventions. 250-255	
1291	Health care's ills: A Catholic diagnosis. 2016 , 83, 402-422	1
1290	Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information. 2016 , 22, 2562-2570	8
1289	Drug-target interaction prediction via class imbalance-aware ensemble learning. 2016 , 17, 509	60
1288	Derisking Psychiatric Drug Development: The NIMH's Fast Fail Program, A Novel Precompetitive Model. 2016 , 36, 419-21	14
1287	In silico methods for drug repurposing and pharmacology. 2016 , 8, 186-210	174
1286	Utilizing Zebrafish to Identify Anti-(Lymph)Angiogenic Compounds for Cancer Treatment: Promise and Future Challenges. 2016 , 23, 389-405	7
1285	Bringing New Products from Marine Microorganisms to the Market. 2016 , 435-452	3
1284	Changing R&D models in research-based pharmaceutical companies. 2016 , 14, 105	166
1283	Drug Development and Challenges for Neuromuscular Clinical Trials. 2016 , 58, 374-8	3
1282	Molecular Imaging in Alzheimer Clinical Trials. 2016 , 523-563	
1281	Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. 2016 , 59, 6101-20	7
1280	Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds. 2016 , 12, 559-66	81

1279	Managing risks in drug discovery: reproducibility of published findings. 2016 , 389, 353-60	29
1278	Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development. 2016 , 2, 82-96	95
1277	Novel multiple assessment of hepatocellular drug disposition in a single packaged procedure. 2016 , 31, 167-71	2
1276	Towards 3D in vitro models for the study of cardiovascular tissues and disease. 2016 , 21, 1437-1445	22
1275	Integration of Affinity Selection-Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF- κ B Pathway. 2016 , 21, 608-19	23
1274	DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing. 2016 , 17, 202	16
1273	The ethics of animal research: a survey of the public and scientists in North America. 2016 , 17, 17	11
1272	DASPfind: new efficient method to predict drug-target interactions. 2016 , 8, 15	59
1271	Have microfluidics delivered for drug discovery?. 2016 , 11, 745-8	14
1270	Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. 2017 , 18, 682-697	47
1269	Is there a role of synovial biopsy in drug development?. 2016 , 17, 172	7
1268	Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis. 2016 , 113, E3725-34	43
1267	Trends in Innovation and the Business of Drug Discovery. 2016 , 29-55	1
1266	Synergistic approach for treatment of chicken coccidiosis using berberine--A plant natural product. 2016 , 93, 56-62	16
1265	Translational Medicine Guide transforms drug development processes: the recent Merck experience. 2016 , 21, 517-26	36
1264	Compound high-quality criteria: a new vision to guide the development of drugs, current situation. 2016 , 21, 573-84	27
1263	Alternatives to antibiotics-a pipeline portfolio review. 2016 , 16, 239-51	495
1262	Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline. 2016 , 151, 167-72	10

1261	Clinical Trial Risk in Chronic Obstructive Pulmonary Disease: The Effects of Drug Class and Inclusion Criteria. 2016 , 91, 79-86	4
1260	Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. 2016 , 44, D1069-74	193
1259	Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD. 2016 , 19, 319-55	6
1258	Drug self-assembly: A phenomenon at the nanometer scale with major impact in the structureBiological properties relationship and the treatment of disease. 2016 , 82, 39-82	18
1257	Advances and Challenges in Recapitulating Human Pulmonary Systems: At the Cusp of Biology and Materials. 2016 , 2, 473-488	21
1256	Engineering EMT using 3D micro-scaffold to promote hepatic functions for drug hepatotoxicity evaluation. 2016 , 91, 11-22	38
1255	Analysis of cost escalations in pharmaceutical projects. 2016 , 9, 433-450	3
1254	Process change evaluation framework for allogeneic cell therapies: impact on drug development and commercialization. 2016 , 11, 287-305	14
1253	The race for Ebola drugs: pharmaceuticals, security and global health governance. 2016 , 37, 487-506	24
1252	Innovation in the pharmaceutical industry: New estimates of R&D costs. 2016 , 47, 20-33	1486
1251	Stimulated Raman scattering microscopy: an emerging tool for drug discovery. 2016 , 45, 2075-89	141
1250	Design and Synthesis of Molecular Scaffolds with Anti-infective Activity. 2016 , 72, 3579-3592	4
1249	Strategies for the discovery, identification and validation of milk protein-derived bioactive peptides. 2016 , 50, 26-43	62
1248	Two-photon Fluorescence Anisotropy Microscopy for Imaging and Direct Measurement of Intracellular Drug Target Engagement. 2016 , 22,	7
1247	Drug discovery in ophthalmology: past success, present challenges, and future opportunities. 2016 , 16, 11	27
1246	Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. 2016 , 29, 564-616	112
1245	A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine. 2016 , 21, 521-34	29
1244	Open Access Could Transform Drug Discovery: A Case Study of JQ1. 2016 , 11, 321-32	19

1243	Open innovation in early drug discovery: roadmaps and roadblocks. 2016 , 21, 779-88	19
1242	Drug Repurposing for the Development of Novel Analgesics. 2016 , 37, 172-183	37
1241	Systems Medicine in Pharmaceutical Research and Development. 2016 , 1386, 87-104	5
1240	Enabling Synthesis of Triple Reuptake Inhibitor (+)-BMS-820836, a Potential Therapeutic Agent for the Treatment of Depression. 2016 , 20, 44-50	
1239	The influences of different R&D types on productivity growth in OECD countries. 2016 , 28, 651-663	9
1238	Translating Oxytocin Neuroscience to the Clinic: A National Institute of Mental Health Perspective. 2016 , 79, 153-4	41
1237	A Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of Molecules. 2016 , 88, 1864-70	37
1236	Systems Immunology. 2016 , 3-44	
1235	Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. 2016 , 38, 87-95	61
1234	Whole/Intact Cell MALDI MS Biotyping in Mammalian Cell Analysis. 2016 , 249-262	2
1233	Pharmaceutical Technology Licensing: An Analysis in the Field of Cardiovascular Disease. 2016 , 11, 34-45	2
1232	Microfluidics for cell-based high throughput screening platforms - A review. 2016 , 903, 36-50	165
1231	Quantifying, Visualizing, and Monitoring Lead Optimization. 2016 , 59, 4189-201	25
1230	A new paradigm for navigating compound property related drug attrition. 2016 , 21, 72-81	30
1229	Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. 2016 , 37, 24-34	333
1228	The changing model of big pharma: impact of key trends. 2016 , 21, 379-84	61
1227	Why and how have drug discovery strategies in pharma changed? What are the new mindsets?. 2016 , 21, 239-49	43
1226	Drug-target interaction prediction: databases, web servers and computational models. 2016 , 17, 696-712	319

1225	Coordinating Knowledge Creation in Multidisciplinary Teams: Evidence from Early-Stage Drug Discovery. 2016 , 59, 1308-1338	64
1224	A survey of current trends in computational drug repositioning. 2016 , 17, 2-12	309
1223	Delivering an Automated and Integrated Approach to Combination Screening Using Acoustic-Droplet Technology. 2016 , 21, 143-52	4
1222	New targets for rapid antidepressant action. 2017 , 152, 21-37	92
1221	Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology. 2017 , 152, 38-57	11
1220	The current and future burden of late-onset dementia in the United Kingdom: Estimates and interventions. 2017 , 13, 38-44	7
1219	Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. 2017 , 22, 581-615	41
1218	Interrogating open issues in cancer precision medicine with patient-derived xenografts. 2017 , 17, 254-268	369
1217	Preclinical Development of Oncology Drugs. 2017 , 685-707	1
1216	Novel iodinated gold nanoclusters for precise diagnosis of thyroid cancer. 2017 , 9, 2219-2231	27
1215	Screening-based approaches to identify small molecules that inhibit protein-protein interactions. 2017 , 12, 293-303	19
1214	Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations. 2017 , 31, 201-211	69
1213	Retinal biomarkers provide "insight" into cortical pharmacology and disease. 2017 , 175, 151-177	22
1212	Integrated, High-Throughput, Multiomics Platform Enables Data-Driven Construction of Cellular Responses and Reveals Global Drug Mechanisms of Action. 2017 , 16, 1364-1375	25
1211	Tiered analytics for purity assessment of macrocyclic peptides in drug discovery: Analytical consideration and method development. 2017 , 138, 166-174	4
1210	Recent lab-on-chip developments for novel drug discovery. 2017 , 9, e1381	38
1209	Genetics of coronary artery disease: discovery, biology and clinical translation. 2017 , 18, 331-344	267
1208	Novel naïve Bayes classification models for predicting the chemical Ames mutagenicity. 2017 , 41, 56-63	40

1207	Drug Design Workshop: A Web-Based Educational Tool To Introduce Computer-Aided Drug Design to the General Public. 2017 , 94, 335-344	30
1206	Emerging RNA editing biomarkers will foster drug development. 2017 , 22, 1056-1063	5
1205	The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization. 2017 , 60, 3552-3579	126
1204	Epigenetics in cancer: Fundamentals and Beyond. 2017 , 173, 118-134	128
1203	Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. 2017 , 114, E2293-E2302	416
1202	Label-Free and Regenerative Electrochemical Microfluidic Biosensors for Continual Monitoring of Cell Secretomes. 2017 , 4, 1600522	80
1201	Improving the publication delay model to characterize the patent granting process. 2017 , 111, 621-637	4
1200	Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation. 2017 , 19, 607-618	4
1199	Translational Research in Drug Discovery and Development. 2017 , 55-87	1
1198	Introducing Therioepistemology: the study of how knowledge is gained from animal research. 2017 , 46, 103-113	48
1197	Implementing WebGL and HTML5 in Macromolecular Visualization and Modern Computer-Aided Drug Design. 2017 , 35, 559-571	21
1196	Gene and Variant Annotation for Mendelian Disorders in the Era of Advanced Sequencing Technologies. 2017 , 18, 229-256	32
1195	Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery. 2017 , 76, 4-21	31
1194	The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). 2017 , 42, 1894-1903	58
1193	Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture. 2017 , 33, 854-866	91
1192	Supporting the Project Portfolio Selection Decision of Research and Development Investments by Means of Multi-Criteria Resource Allocation Modelling. 2017 , 89-103	6
1191	Gaining Insights into Specific Drug Formulation Additives for Solubilizing a Potential Anti-Alzheimer Disease Drug B4A1. 2017 , 17, 1700109	4
1190	3D bioprinting for drug discovery and development in pharmaceuticals. 2017 , 57, 26-46	162

1189	On the role of forces governing particulate interactions in pharmaceutical systems: A review. 2017 , 526, 516-537	15
1188	The Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D. 2017 , 12, 786-818	21
1187	Planning the First Clinical Trials with Clinical Manufacturing Organization (CMO). 2017 , 115-137	
1186	Outlook for the Future. 2017 , 421-447	
1185	Current application of conformal prediction in drug discovery. 2017 , 81, 145-154	3
1184	LRSSL: predict and interpret drug-disease associations based on data integration using sparse subspace learning. 2017 , 33, 1187-1196	42
1183	Intra-Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing. 2017 , 10, 337-350	5
1182	Information Retrieval and Text Mining Technologies for Chemistry. 2017 , 117, 7673-7761	124
1181	Pharmaceutical Industry Performance. 2017 , 3-25	
1180	Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors. 2017 , 128, 78-94	26
1179	Speeding up Early Drug Discovery in Antiviral Research: A Fragment-Based in Silico Approach for the Design of Virtual Anti-Hepatitis C Leads. 2017 , 19, 501-512	44
1178	High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model. 2017 , 13, 335-346	44
1177	Target Engagement Measures in Preclinical Drug Discovery: Theory, Methods, and Case Studies. 2017 , 41-80	2
1176	Are Oxygen and Sulfur Atoms Structurally Equivalent in Organic Crystals?. 2017 , 17, 827-833	25
1175	Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery. 2017 , 11, 6691-6702	85
1174	Concise Review: Induced Pluripotent Stem Cell-Based Drug Discovery for Mitochondrial Disease. 2017 , 35, 1655-1662	22
1173	To be rational, or not to be rational? That is the question. 2017 , 26, 487-491	
1172	Do large mergers increase or decrease the productivity of pharmaceutical R&D?. 2017 , 22, 1749-1753	8

1171	Optimizing drug development in oncology by clinical trial simulation: Why and how?. 2018 , 19, 1203-1217	6
1170	Privileged Electrophile Sensors: A Resource for Covalent Drug Development. 2017 , 24, 787-800	48
1169	Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate. 2017 , 60, 5889-5908	40
1168	Lipophilicity and biomimetic properties to support drug discovery. 2017 , 12, 885-896	48
1167	An engineering design approach to systems biology. 2017 , 9, 574-583	14
1166	Organ-on-a-chip devices advance to market. 2017 , 17, 2395-2420	224
1165	Droplet control technologies for microfluidic high throughput screening (HTS). 2017 , 17, 2372-2394	62
1164	Bioinformatics in translational drug discovery. 2017 , 37,	30
1163	Why Do Promising Therapies Stall in Development and How Can We Move Them Forward?. 2017 , 36, 340-349	1
1162	High-content drug screening for rare diseases. 2017 , 40, 601-607	23
1161	A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. 2017 , 13, 771-778	27
1160	High-resolution bioelectrical imaging of A β -induced network dysfunction on CMOS-MEAs for neurotoxicity and rescue studies. 2017 , 7, 2460	20
1159	Three-Dimensional Cell Cultures in Drug Discovery and Development. 2017 , 22, 456-472	428
1158	Assessing therapeutic potential of molecules: molecular property diagnostic suite for tuberculosis (($\mathbf{MPDS}^{\mathbf{TB}}$)). 2017 , 129, 515-531	12
1157	Photochemical Bionanoreactor for Efficient Visible-Light-Driven in Vitro Drug Metabolism. 2017 , 89, 7365-7372	8
1156	The potential use of single-particle electron microscopy as a tool for structure-based inhibitor design. 2017 , 73, 534-540	5
1155	Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation. 2017 , 77, 2869-2880	14
1154	PROCESS ECONOMIC DRIVERS IN INDUSTRIAL MONOCLONAL ANTIBODY MANUFACTURE. 2017 , 445-466	2

1153	The ascendance of microphysiological systems to solve the drug testing dilemma. 2017 , 3, FSO185	45
1152	Enabling Chemistry Technologies and Parallel Synthesis-Accelerators of Drug Discovery Programmes. 2017 , 56, 1-35	12
1151	[Early clinical trials in paediatric oncology in Spain: a nationwide perspective]. 2017 , 87, 155-163	1
1150	Continuous manufacture of polymeric cellular dosage forms. 2017 , 320, 549-560	7
1149	High-Throughput Screening of Vascular Endothelium-Destructive or Protective Microenvironments: Cooperative Actions of Extracellular Matrix Composition, Stiffness, and Structure. 2017 , 6, 1601426	16
1148	Improving machine learning in early drug discovery. 2017 , 81, 155-166	5
1147	A mapping for managers: open innovation for R&D intensive SMEs in the life sciences sector. 2017 , 20, 210-229	6
1146	Personalized and Cancer Models to Guide Precision Medicine. 2017 , 7, 462-477	477
1145	Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases. 2017 , 22, 805-813	14
1144	The druggable genome and support for target identification and validation in drug development. 2017 , 9,	212
1143	The value of PET ligand discovery to CNS drug development. 2017 , 9, 351-356	3
1142	Three-Dimensional Cell Cultures in Drug Discovery and Development. 2017 , 247255521769679	8
1141	The academic-industrial complex: navigating the translational and cultural divide. 2017 , 22, 976-993	12
1140	A new era of disease modeling and drug discovery using induced pluripotent stem cells. 2017 , 40, 1-12	25
1139	Enabling Anyone to Translate Clinically Relevant Ideas to Therapies. 2017 , 34, 1-6	15
1138	Fine-tuning Nanocarriers Specifically toward Cargo: A Competitive Study on Solubilizing Related Photosensitizers for Photodynamic Therapy. 2017 , 28, 760-767	17
1137	Illuminating Phenylazopyridines To Photoswitch Metabotropic Glutamate Receptors: From the Flask to the Animals. 2017 , 3, 81-91	43
1136	DNA-encoded chemistry: enabling the deeper sampling of chemical space. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 131-147	64.1 351

1135	Combining Molecular Scaffolds from FDA Approved Drugs: Application to Drug Discovery. 2017 , 60, 1638-1647	36
1134	Characterization of stem cell-derived liver and intestinal organoids as a model system to study nuclear receptor biology. 2017 , 1863, 687-700	10
1133	On p53 revival using system oriented drug dosage design. 2017 , 415, 53-57	6
1132	High-Throughput Screening. 2017 , 50, 149-195	12
1131	In Vitro Design of Nanoparticles Using an Artificial 3D-Blood Vessel Wall Model for Atherosclerosis Treatment. 2017 , 195-225	
1130	Turbocharging Matched Molecular Pair Analysis: Optimizing the Identification and Analysis of Pairs. 2017 , 57, 2424-2436	9
1129	Extending 'predict first' to the design-make-test cycle in small-molecule drug discovery. 2017 , 9, 533-536	7
1128	In Search of System-Wide Productivity Gains - The Role of Global Collaborations in Preclinical Translation. 2017 , 10, 423-425	
1127	The Evaluation of Proof-of-Concept Trial Design for Compound Selection. 2017 , 9, 315-320	0
1126	Human genetics contributes to the understanding of disease pathophysiology and drug discovery. 2017 , 22, 977-981	2
1125	Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements. 2017 , 36, 4616-4626	10
1124	Relationships between response surfaces for tablet characteristics of placebo and API-containing tablets manufactured by direct compression method. 2017 , 532, 82-89	8
1123	Human Creative Abduction Assaulted. 2017 , 161-197	
1122	Promethazine Hydrochloride Inhibits Ectopic Fat Cell Formation in Skeletal Muscle. 2017 , 187, 2627-2634	7
1121	Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. 2017 , 177, 1569-1575	206
1120	Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. 2017 , 121, 1025-1030	33
1119	Designer bacteria as intratumoural enzyme biofactories. 2017 , 118, 8-23	15
1118	Interrogation of drug effects on HeLa cells by exploiting new AFM mechanical biomarkers. 2017 , 7, 43764-43771	18

1117	Internationalization Effects in a Global Knowledge-Based Industry: A Study of Multinational Pharmaceutical Companies. 2017 , 87-124		
1116	Directing evolution: the next revolution in drug discovery?. <i>Nature Reviews Drug Discovery</i> , 2017 , 16, 681-698	64.1	49
1115	An iterative compound screening contest method for identifying target protein inhibitors using the tyrosine-protein kinase Yes. 2017 , 7, 12038		18
1114	Diblock Terpolymers Are Tunable and pH Responsive Vehicles To Increase Hydrophobic Drug Solubility for Oral Administration. 2017 , 14, 4121-4127		8
1113	Bi-functional oxidized dextran-based hydrogel inducing microtumors: An in vitro three-dimensional lung tumor model for drug toxicity assays.. 2017 , 8, 2041731417718391		5
1112	Three-dimensional automated reporter quantification (3D-ARQ) technology enables quantitative screening in retinal organoids. 2017 , 144, 3698-3705		41
1111	Drug repurposing in cancer. 2017 , 124, 74-91		146
1110	Improving the economics of NASH/NAFLD treatment through the use of systems biology. 2017 , 22, 1532-1538		16
1109	Drug discovery and development for rare genetic disorders. 2017 , 173, 2307-2322		41
1108	The pharmaceutical industry needs more clinical pharmacologists. 2017 , 83, 2343-2346		3
1107	Divergent Synthesis of Cyclopropane-Containing Lead-Like Compounds, Fragments and Building Blocks through a Cobalt Catalyzed Cyclopropanation of Phenyl Vinyl Sulfide. 2017 , 2017, 5015-5024		25
1106	Piperidine and octahydropyrano[3,4-c] pyridine scaffolds for drug-like molecular libraries of the European Lead Factory. 2017 , 25, 5160-5170		3
1105	The Effect of Intellectual Property Rights on Domestic Innovation in the Pharmaceutical Sector. 2017 , 99, 15-27		13
1104	The Business of Anti-Aging Science. 2017 , 35, 1062-1073		80
1103	Intra-Target Microdosing - A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans. 2017 , 10, 351-359		4
1102	The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures. 2017 , 10, 470-479		10
1101	Early clinical trials in paediatric oncology in Spain: A nationwide perspective. 2017 , 87, 155-163		
1100	Medicinal and Biological Chemistry (MBC) Library: An Efficient Source of New Hits. 2017 , 57, 2143-2151		20

1099	Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins. 2017 , 96, 989-1001	41
1098	iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease. 2017 , 21, 2304-2312	109
1097	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. 2017 , 6, 157-163	39
1096	Drug discovery and development: Role of basic biological research. 2017 , 3, 651-657	178
1095	Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily. 2017 , 12, 3113-3125	37
1094	Nanoparticles Penetrate into the Multicellular Spheroid-on-Chip: Effect of Surface Charge, Protein Corona, and Exterior Flow. 2017 , 14, 4618-4627	40
1093	A Computational Methodology to Overcome the Challenges Associated With the Search for Specific Enzyme Targets to Develop Drugs Against. 2017 , 11, 1177932217712471	3
1092	A Flexible and Robust Multi-Source Learning Algorithm for Drug Repositioning. 2017 ,	11
1091	De novo computational design of compounds virtually displaying potent antibacterial activity and desirable in vitro ADMET profiles. 2017 , 26, 2345-2356	32
1090	Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry. 2017 , 46, 1255-1271	18
1089	A new lot sizing and scheduling heuristic for multi-site biopharmaceutical production. 2017 , 23, 231-256	5
1088	Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations. 2017 , 31, 217-233	3
1087	mD3DOCKxb: An Ultra-Scalable CPU-MIC Coordinated Virtual Screening Framework. 2017 ,	3
1086	Cultural, geographical and ethical questions when looking to enroll pediatric patients in rare disease clinical trials. 2017 , 5, 613-621	2
1085	A framework for the targeted selection of herbs with similar efficacy by exploiting drug repositioning technique and curated biomedical knowledge. 2017 , 208, 117-128	2
1084	Genome annotation for clinical genomic diagnostics: strengths and weaknesses. 2017 , 9, 49	27
1083	Longitudinal assessment of bleomycin-induced lung fibrosis by Micro-CT correlates with histological evaluation in mice. 2017 , 12, 8	38
1082	Industrial medicinal chemistry insights: neuroscience hit generation at Janssen. 2017 , 22, 1478-1488	4

1081	A Micropatterned Human Pluripotent Stem Cell-Based Ventricular Cardiac Anisotropic Sheet for Visualizing Drug-Induced Arrhythmogenicity. 2017 , 29, 1602448	20
1080	Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments. 2017 , 36, 563-580	11
1079	Active fragments-guided drug discovery and design of selective tropane alkaloids using ultra-high performance liquid chromatography-quadrupole time-of-flight tandem mass spectrometry coupled with virtual calculation and biological evaluation. 2017 , 409, 1145-1157	12
1078	Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening. 2017 , 80, 198-207	15
1077	Automated Integration of a UPLC Glycomic Profile. 2017 , 1503, 217-233	9
1076	Cognitive 'Omics': Pattern-Based Validation of Potential Drug Targets. 2017 , 38, 113-126	10
1075	Challenging the dominant logic in the healthcare industry: the case of precision medicine. 2017 , 29, 843-856	2
1074	Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept. 2017 , 27, 88-99	15
1073	Fragmentation in the biopharmaceutical industry. 2017 , 22, 433-439	3
1072	New drug developments in psychosis: Challenges, opportunities and strategies. 2017 , 152, 3-20	43
1071	Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide. 2017 , 14, 657-672	20
1070	Early Development Challenges for Drug Products Containing Nanomaterials. 2017 , 19, 92-102	20
1069	Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?. 2017 , 174, 3749-3765	82
1068	Raising awareness of the importance of funding for tuberculosis small-molecule research. 2017 , 22, 487-491	6
1067	Leveraging human genetics to guide drug target discovery. 2017 , 27, 352-359	20
1066	Shrinking the Psoriasis Assessment Gap: Early Gene-Expression Profiling Accurately Predicts Response to Long-Term Treatment. 2017 , 137, 305-312	34
1065	Modular multi-organ-on-chips platform with physicochemical sensor integration. 2017 ,	1
1064	Voting-based ensemble method for prediction of bioactive molecules. 2017 ,	0

1063	The Responsive Global Organization. 2017,	
1062	Autofluorescence imaging captures heterogeneous drug response differences between 2D and 3D breast cancer cultures. 2017, 8, 1911-1925	15
1061	5.17 Three-Dimensional Bioengineered Cancer Models. 2017, 303-328	1
1060	Biofunctional Hydrogels for Three-Dimensional Stem Cell Culture. 2017, 345-362	
1059	Computer-Aided Drug Design Applied to Marine Drug Discovery: Meridianins as Alzheimer's Disease Therapeutic Agents. 2017, 15,	25
1058	Drug Repurposing Review. 2017, 11-47	4
1057	Drug discovery. 2017, 281-420	1
1056	The drug-maker's guide to the galaxy. 2017, 549, 445-447	47
1055	Integrins as Therapeutic Targets: Successes and Cancers. 2017, 9,	131
1054	Organ-on-Chip Technology: Current State and Future Developments. 2017, 8,	18
1053	Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations. 2017, 18,	13
1052	Contemporary Considerations for Discovering a Successful Medicine. 2017, 560-576	
1051	Metabolic Imaging of Head and Neck Cancer Organoids. 2017, 12, e0170415	35
1050	Free Energy Calculation Guided Virtual Screening of Synthetically Feasible Ligand R-Group and Scaffold Modifications: An Emerging Paradigm for Lead Optimization. 2017, 50, 237-262	4
1049	A systematic analysis of FDA-approved anticancer drugs. 2017, 11, 87	150
1048	Translatability score revisited: differentiation for distinct disease areas. 2017, 15, 226	9
1047	Speeding Up the Virtual Design and Screening of Therapeutic Peptides: Simultaneous Prediction of Anticancer Activity and Cytotoxicity. 2017, 127-147	7
1046	Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies.. 2017,	0

1045	Drug discovery: Chaos can be your friend or your enemy. 2017 , 183-279	1
1044	Model-Based Design of Process Strategies for Cell Culture Bioprocesses: State of the Art and New Perspectives. 2017 ,	3
1043	Exploring targeted therapy of osteosarcoma using proteomics data. 2017 , 10, 565-577	16
1042	Preclinical Pharmacology and Toxicology - Contributions to the Translational Interface ?. 2017 ,	3
1041	Academic Drug Discovery Centers: Key Players in the Future of the Pharmaceutical Industry. 2017 , 1-10	1
1040	Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays. 2017 , 8, 8854-8866	49
1039	Drug Metabolism in Preclinical Drug Development: A Survey of the Discovery Process, Toxicology, and Computational Tools. 2017 , 18, 556-565	52
1038	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. 2017 , 64-93	
1037	Anti-Aging Drugs. 2017 , 349-378	
1036	The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. 2017 , 8, 12576-12595	25
1035	Predicting Target and Chemical Druggability. 2017 , 429-439	2
1034	High-content imaging assays on a miniaturized 3D cell culture platform. 2018 , 50, 147-159	19
1033	Human Stakeholders and the Use of Animals in Drug Development. 2018 , 123, 3-58	6
1032	Public sector R&D and relative efficiency measurement of global comparators working on similar research streams. 2018 , 25, 1059-1084	3
1031	Novel 3D Liquid Cell Culture Method for Anchorage-independent Cell Growth, Cell Imaging and Automated Drug Screening. 2018 , 8, 3627	24
1030	Toward an integrative organizational framework for outsourced R&D efficiency. 2018 , 12, 1515-1525	
1029	High-throughput organ-on-a-chip systems: Current status and remaining challenges. 2018 , 6, 33-41	68
1028	Multiple grid arrangement improves ligand docking with unknown binding sites: Application to the inverse docking problem. 2018 , 73, 139-146	20

1027	Optimum catalyst selection over continuous and discrete process variables with a single droplet microfluidic reaction platform. 2018 , 3, 301-311	41
1026	Prediction, Analysis, and Comparison of Active Sites. 2018 , 283-311	1
1025	New Trends in Drug Discovery. 2018 , 1-39	
1024	Probing the Amorphous State of Pharmaceutical Compounds Within Mesoporous Material Using Pair Distribution Function Analysis. 2018 , 107, 2216-2224	8
1023	Systems biology in hepatology: approaches and applications. 2018 , 15, 365-377	70
1022	DR2DI: a powerful computational tool for predicting novel drug-disease associations. 2018 , 32, 633-642	16
1021	The 13th Round: Article 39(3) TRIPS and the struggle over "Unfair Commercial Use" 2018 , 21, 201-242	
1020	Microfluidics in nanoparticle drug delivery; From synthesis to pre-clinical screening. 2018 , 128, 29-53	100
1019	Personalizing therapy for atrial fibrillation: the role of stem cell and in silico disease models. 2018 , 114, 931-943	11
1018	Advanced Microengineered Lung Models for Translational Drug Discovery. 2018 , 23, 777-789	11
1017	Advances in nanotechnology for cancer biomarkers. 2018 , 18, 103-123	51
1016	Accelerated multi-reagent copper catalysed coupling reactions in micro droplets and thin films. 2018 , 3, 206-209	7
1015	Molecular Imaging in Drug Discovery and Development. 2018 , 11, e005355	15
1014	Molecular activity prediction by means of supervised subspace projection based ensembles of classifiers. 2018 , 29, 187-212	5
1013	The current state of GPCR-based drug discovery to treat metabolic disease. 2018 , 175, 4060-4071	24
1012	DDR: efficient computational method to predict drug-target interactions using graph mining and machine learning approaches. 2018 , 34, 1164-1173	87
1011	New application of the commercial sweetener rebaudioside a as a hepatoprotective candidate: Induction of the Nrf2 signaling pathway. 2018 , 822, 128-137	21
1010	Estimating dose-specific cell division and apoptosis rates from chemo-sensitivity experiments. 2018 , 8, 2705	3

1009	Multistage inhibitors of the malaria parasite: Emerging hope for chemoprotection and malaria eradication. 2018 , 38, 1511-1535		18
1008	The Societal Value of Pharmaceutical Innovation. 2018 , 147-187		1
1007	Integrating dose estimation into a decision-making framework for model-based drug development. 2018 , 17, 155-168		0
1006	Green synthesis of new pyrrolidine-fused spirooxindoles three-component domino reaction in EtOH/HO.. 2018 , 8, 5702-5713		28
1005	Ionic Liquids in Pharmaceutical Industry. 2018 , 539-577		12
1004	Global Innovation and Economic Value. 2018 ,		3
1003	Bright Side of Lignin Depolymerization: Toward New Platform Chemicals. 2018 , 118, 614-678		934
1002	A design of experiment approach for efficient multi-parametric drug testing using a <i>Caenorhabditis elegans</i> model. 2018 , 10, 48-56		4
1001	Evolutionary and genetic features of drug targets. 2018 , 38, 1536-1549		10
1000	Impact of a five-dimensional framework on R&D productivity at AstraZeneca. <i>Nature Reviews Drug Discovery</i> , 2018 , 17, 167-181	64.1	203
999	The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?. 2018 , 7, e1701174		50
998	Chemical Space Expansion of Bromodomain Ligands Guided by in Silico Virtual Couplings (AutoCouple). 2018 , 4, 180-188		19
997	Research in Rare Disease: From Genomics to Proteomics. 2018 , 16, 12-14		2
996	Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development. 2018 , 22, 17-34		32
995	Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data. 2018 , 96, 1-11		35
994	The Digital and In Silico Therapeutics Revolution. 2018 , 197-214		
993	A dynamic map for learning, communicating, navigating and improving therapeutic development. <i>Nature Reviews Drug Discovery</i> , 2018 , 17, 150	64.1	27
992	Using network-based expert engagement to advance pharmaceutical research and development. 2018 , 23, 755-757		1

991	Progress with covalent small-molecule kinase inhibitors. 2018 , 23, 727-735	120
990	Ligandomics: a paradigm shift in biological drug discovery. 2018 , 23, 636-643	9
989	Drug Discovery and Development. 2018 , 19-32	18
988	Advances in Polymer Design for Enhancing Oral Drug Solubility and Delivery. 2018 , 29, 939-952	58
987	A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. 2018 , 52, 158-165	4
986	Principles of designing a clinical trial: optimizing chances of trial success. 2018 , 5, 143-152	1
985	Effects of Cannabinoid Type 2 Receptor Agonist AM1241 on Morphine-Induced Antinociception, Acute and Chronic Tolerance, and Dependence in Mice. 2018 , 19, 1113-1129	10
984	Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. 2018 , 11, 8	13
983	Sustainability: A foundation for pharma, generic and Government partnerships?. 2018 , 11, 54-57	7
982	ECoFFeS: A Software Using Evolutionary Computation for Feature Selection in Drug Discovery. 2018 , 6, 20950-20963	9
981	Big Data in Drug Discovery. 2018 , 57, 277-356	25
980	Can we accelerate medicinal chemistry by augmenting the chemist with Big Data and artificial intelligence?. 2018 , 23, 1373-1384	20
979	Adversarial Threshold Neural Computer for Molecular de Novo Design. 2018 , 15, 4386-4397	89
978	Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis. 2018 , 11, 1434935	3
977	Pioneering topological methods for network-based drug-target prediction by exploiting a brain-network self-organization theory. 2018 , 19, 1183-1202	36
976	3D-micro-patterned fibrous dosage forms for immediate drug release. 2018 , 84, 218-229	8
975	Next generation organoids for biomedical research and applications. 2018 , 36, 132-149	63
974	Drug repurposing: An approach to tackle drug resistance in <i>S. typhimurium</i> . 2018 , 119, 2818-2831	3

973	Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome. 2018 , 110,	124
972	Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. <i>Nature Reviews Drug Discovery</i> , 2018 , 17, 19-33	64.1 76
971	Microfluidic Cell Culture Systems for Drug Research. 2018 , 339-370	
970	Novel compounds targeting InhA for TB therapy. 2018 , 70, 217-226	14
969	Guiding principles of value creation through collaborative innovation in pharmaceutical research. 2018 , 23, 213-218	3
968	3D Miniaturization of Human Organs for Drug Discovery. 2018 , 7, 1700551	23
967	A Computational-Based Method for Predicting Drug-Target Interactions by Using Stacked Autoencoder Deep Neural Network. 2018 , 25, 361-373	85
966	Humanity in a Dish: Population Genetics with iPSCs. 2018 , 28, 46-57	17
965	Computational Support of Medicinal Chemistry in Industrial Settings. 2018 , 1705, 345-350	
964	Establishment and proteomic characterization of patient-derived clear cell sarcoma xenografts and cell lines. 2018 , 54, 163-176	5
963	Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2. 2018 , 32, 21-44	16
962	Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial. 2018 , 75, 11-19	60
961	The Importance of Collaboration between Industry, Academics, and Nonprofits in Tropical Disease Drug Discovery. 2018 , 4, 445-448	9
960	Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art. 2018 , 145, 219-236	52
959	Public-private collaborations in drug development: boosting innovation or alleviating risk?. 2018 , 20, 273-292	3
958	Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug development. 2018 , 46, 335-346	13
957	Project Selection and Success: Insights from the Drug Discovery Process. 2018 ,	1
956	The research domain criteria framework in drug discovery for neuropsychiatric diseases: focus on negative valence. 2018 , 2, 2398212818804030	7

955	Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry. 2018 , 47, 281-316	26
954	Trends of clinical trials from 2014 to 2016 in South Korea. 2018 , 26, 172-176	2
953	Trial Termination and Drug Misclassification in Sequential Adaptive Clinical Trials. 2018 , 10, 354-377	3
952	Drug Development Accelerated by PET imaging-based pharmacokinetics and DDS research. 2018 , 33, 204-213	
951	A Portfolio Approach to Accelerate Therapeutic Innovation in Ovarian Cancer. 2018 ,	
950	MODEL-BASED RUN-TO-RUN OPTIMIZATION FOR PROCESS DEVELOPMENT. 2018 , 35, 1063-1080	1
949	Early Identification of Patentable Medical Innovations. 2018 , 2018, 4924-4926	1
948	Protocol for the development of a CONSORT extension for RCTs using cohorts and routinely collected health data. 2018 , 3, 9	21
947	Step II: Target Validation. 2018 , 33-76	
946	Generation of uniform-sized multicellular tumor spheroids using hydrogel microwells for advanced drug screening. 2018 , 8, 17145	59
945	Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval. 2018 , 3, 690-703	9
944	Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe. 2018 , 11, 121-130	40
943	Statistics in Drug Discovery. 2018 , 1-8	
942	The impact of policy on the growth of precision medicine. 2018 , 7, 347-357	5
941	Computational drug repositioning using meta-path-based semantic network analysis. 2018 , 12, 134	7
940	Predicting Strategies for Lead Optimization via Learning to Rank. 2018 , 11, 41-47	4
939	Perspectives on the Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Biomedical Research. 2018 , 11, 1306-1311	34
938	Solid State and Polymorphism of the Drug Substance in the Context of Quality by Design and ICH Guidelines Q8Q12. 2018 , 1-30	

937	Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. 2018 , 16, 304	114
936	Net Present Value-Based Analyses of Products in Development by Pharmaceutical and Biotech Firms: NPV-Based Analyses of Biopharmaceutical Products. 2018 ,	1
935	Tox_(R)CNN: Deep learning-based nuclei profiling tool for drug toxicity screening. 2018 , 14, e1006238	24
934	Bioactive molecule prediction using majority voting-based ensemble method. 2018 , 35, 383-392	4
933	A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. 2018 , 17, 2702-2709	19
932	Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients. 2018 , 2,	34
931	Development and evaluation of in silico prediction model for drug-induced respiratory toxicity by using naïve Bayes classifier method. 2018 , 121, 593-603	18
930	Challenges in designing and executing clinical trials in a dish studies. 2018 , 94, 73-82	9
929	Best Practices in Clinical Trial Simulations for Adaptive Study Designs. 2018 , 101-114	1
928	Collaborative Evaluation of Commercially Available Automated Powder Dispensing Platforms for High-Throughput Experimentation in Pharmaceutical Applications. 2018 , 22, 1500-1508	24
927	Management of Process Economy Case Studies. 2018 , 1191-1223	2
926	Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. 2018 , 6, e1386-e1396	150
925	A Standardized Collagen-Based Scaffold Improves Human Hepatocyte Shipment and Allows Metabolic Studies over 10 Days. 2018 , 5,	17
924	Modeling the value of predictive affinity scoring in preclinical drug discovery. 2018 , 52, 103-110	9
923	Realizing private and practical pharmacological collaboration. 2018 , 362, 347-350	27
922	Stewardship Approaches to Reducing Health-Care Contaminants. 2018 , 199-223	1
921	Clotrimazole inhibits the Wnt/ β -catenin pathway by activating two eIF2 β kinases: The heme-regulated translational inhibitor and the double-stranded RNA-induced protein kinase. 2018 , 506, 183-188	4
920	Strategic decision-making in the pharmaceutical industry: A unified decision-making framework. 2018 , 119, 171-189	6

919	The potential to treat lung cancer via inhalation of repurposed drugs. 2018 , 133, 107-130	39
918	Nanotheranostics and theranostic nanomedicine for diseases and cancer treatment. 2018 , 41-68	2
917	Using improved Restricted Boltzmann Machines for drug-disease Prediction. 2018 ,	0
916	Future of Regulatory Safety Assessments. 2018 , 1-24	
915	Machine Learning for Drug-Target Interaction Prediction. 2018 , 23,	82
914	Human stomach-on-a-chip with luminal flow and peristaltic-like motility. 2018 , 18, 3079-3085	43
913	When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions. 2018 , 46, 1487-1496	6
912	Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability. 2018 , 9, 899	18
911	The mouse as a model for neuropsychiatric drug development. 2018 , 28, R909-R914	15
910	Companion animals in comparative oncology: One Medicine in action. 2018 , 240, 6-13	29
909	A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target. 2018 , 9, 3561	45
908	Small-Molecule Screening for Genetic Diseases. 2018 , 19, 263-288	7
907	Action of antimicrobial peptides and their prodrugs on model and biological membranes. 2018 , 24, e3086	8
906	NCI Program for Natural Product Discovery: A Publicly-Accessible Library of Natural Product Fractions for High-Throughput Screening. 2018 , 13, 2484-2497	58
905	Orphan Drugs and Their Impact on Pharmaceutical Development. 2018 , 39, 525-535	27
904	R&D Success in Pharmaceutical Markets: A Duration Model Approach. 2018 , 201-233	1
903	Predicting Binding Free Energies in a Large Combinatorial Chemical Space Using Multisite Dynamics. 2018 , 9, 3328-3332	17
902	An Industry Perspective on Dengue Drug Discovery and Development. 2018 , 1062, 333-353	3

891	An optimization framework to combine operable space maximization with design of experiments. 2018 , 64, 3944-3957	6
900	In vivo MR in the drug pipeline. 2018 , 292, 117-128	3
899	Organ-on-a-Chip: New Tool for Personalized Medicine. 2018 , 29, 823-824	15
898	Human-based systems: Mechanistic NASH modelling just around the corner?. 2018 , 134, 257-267	23
897	Potential of Tree Endophytes as Sources for New Drug Compounds. 2018 , 441-462	
896	The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development. 2018 , 11, 597-606	75
895	System Biology to Access Target Relevance in the Research and Development of Molecular Inhibitors. 2018 , 221-242	2
894	Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science. 2018 , 25, 1318-1329	7
893	A Start-Up's R&D Stages and the Evolution of Financing Sources: Evidence from the Biotechnology Industry. 2018 , 8,	2
892	Bioinformatics approaches for new drug discovery: a review. 2018 , 34, 243-260	27
891	Knowledge-based drug discovery intensifies private appropriation of publicly financed research. 2018 , 19, 1017-1018	3
890	Advances in organ-on-a-chip engineering. 2018 , 3, 257-278	426
889	Aromatic Rings Commonly Used in Medicinal Chemistry: Force Fields Comparison and Interactions With Water Toward the Design of New Chemical Entities. 2018 , 9, 395	23
888	Streamlining bioactive molecular discovery through integration and automation. 2018 , 2, 174-183	18
887	. 2018 ,	5
886	Prediction of Drug-Disease Associations for Drug Repositioning Through Drug-miRNA-Disease Heterogeneous Network. 2018 , 6, 45281-45287	13
885	Pharmacokinetic-based multi-organ chip for recapitulating organ interactions. 2018 , 146, 183-197	10
884	Filling the drug discovery gap: is high-content screening the missing link?. 2018 , 42, 40-45	16

883	Compound property enhancement by virtual compound synthesis. 2018 , 16, 1840016	4
882	Seizing Opportunities for Markets of Discovery: The Reconfigurations of Value Chains in Pharmaceutical Industry in the Global South. 2018 , 23, 418-443	
881	Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline. 2018 , 9, 703	54
880	Innovation: Key to Success in the Pharmaceutical Industry. 2018 , 1-16	0
879	Radiopharmaceutical enhancement by drug delivery systems: A review. 2018 , 287, 177-193	17
878	Preformulation in Drug Research and Pharmaceutical Product Development. 2018 , 1-55	3
877	Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology. 2018 , 5, 6	9
876	Functional three-dimensional scaffolds for skeletal muscle tissue engineering. 2018 , 279-304	4
875	Development of an Experimental Model for Analyzing Drug Resistance in Colorectal Cancer. 2018 , 10,	12
874	Diffusion of complementary evolving pharmaceutical innovations: The case of Abacavir and its pharmacogenetic companion diagnostic in Italy. 2018 , 134, 223-233	2
873	Changing Trends in Computational Drug Repositioning. 2018 , 11,	91
872	Chemoproteomics and Chemical Probes for Target Discovery. 2018 , 36, 1275-1286	57
871	Optimizing the Therapeutic Efficacy of Boron Neutron Capture Therapy (BNCT) for Different Pathologies. 2018 , 416-461	0
870	Microfluidics contribution to pharmaceutical sciences: From drug discovery to post marketing product management. 2018 , 159, 348-362	18
869	Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine. 2018 , 20, 83	6
868	Electrohydrodynamic atomization and spray-drying for the production of pure drug nanocrystals and co-crystals. 2018 , 131, 79-100	25
867	Stem cells are the most sensitive screening tool to identify toxicity of GATA4-targeted novel small-molecule compounds. 2018 , 92, 2897-2911	14
866	Prediction of Chemical Toxicity for Drug Design Using Machine Learning Methods and Structural Alerts. 2018 , 6, 30	93

865	Leading Pharmaceutical Innovation. 2018 ,	14
864	Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?. 2018 , 16, 119	22
863	DNA-interaction studies of a copper(II) complex containing ceftobiprole drug using molecular modeling and multispectroscopic methods. 2018 , 71, 2843-2855	2
862	Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis?. 2018 , 24, 577-598	40
861	Patient-Derived Xenograft Models for Endometrial Cancer Research. 2018 , 19,	18
860	A selective method for optimizing ensemble docking-based experiments on an InhA Fully-Flexible receptor model. 2018 , 19, 235	7
859	Protocol for a scoping review to support development of a CONSORT extension for randomised controlled trials using cohorts and routinely collected health data. 2018 , 8, e025266	8
858	Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development. 2018 , 23, 765-776	35
857	Recent Updates on Computer-aided Drug Discovery: Time for a Paradigm Shift. 2017 , 17, 3296-3307	37
856	Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature. 2018 , 8, 8857	100
855	Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases. 2019 , 20, 1878-1912	155
854	Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint. 2019 , 29, 189-202	1
853	Food for thought: formulating away the food effect - a PEARRL review. 2019 , 71, 510-535	47
852	High throughput scaffold-based 3D micro-tumor array for efficient drug screening and chemosensitivity testing. 2019 , 198, 167-179	26
851	The Clinical Innovation Network: a policy for promoting development of drugs and medical devices in Japan. 2019 , 24, 4-8	9
850	IDENTIFYING FACTORS INFLUENCING THE PRICE OF TECHNOLOGY LICENSES: A FRAMEWORK GROUNDED IN NEGOTIATION RESEARCH. 2019 , 23, 1950039	0
849	Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. 2019 , 40, 1771-1777	49
848	An overview of late-stage functionalization in today's drug discovery. 2019 , 14, 1137-1149	68

847	Consortium-Based Open Innovation: Exploring a Unique and Optimal Model for Regional Biotechnology Industry. 2019 , 141-171	1
846	Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work. 2019 , 182, 111602	33
845	Medicinal Biotechnology for Disease Modeling, Clinical Therapy, and Drug Discovery and Development. 2019 , 89-128	3
844	Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors. 2019 , 59, 3782-3793	33
843	Improving the Rate of Translation of Tissue Engineering Products. 2019 , 8, e1900538	9
842	Organs-on-Chips: a new paradigm for safety assessment of drug-induced thrombosis. 2019 , 17, 1-8	1
841	Convolutional Neural Network and Bidirectional Long Short-Term Memory-Based Method for Predicting Drug-Disease Associations. 2019 , 8,	10
840	Drug repositioning based on bounded nuclear norm regularization. 2019 , 35, i455-i463	55
839	Fibrosis in tissue engineering and regenerative medicine: treat or trigger?. 2019 , 146, 17-36	11
838	Quantitative Kinetic Models from Intravital Microscopy: A Case Study Using Hepatic Transport. 2019 , 123, 7302-7312	4
837	Sensor-free and Sensor-based Heart-on-a-chip Platform: A Review of Design and Applications. 2018 , 24, 5375-5385	6
836	Microgravity protein crystallization for drug development: a bold example of public sector entrepreneurship. 2019 , 46, 1442	2
835	Biomarker-Guided Drug Development for Better Defined Early Patient Studies and Clinical Trial Efficiency. 2019 , 17-23	0
834	New Approaches in Translational Medicine for Phase I Clinical Trials of CNS Drugs. 2019 , 29, 81-91	0
833	Regulatory Science Objectives and Biomarker Qualification Through Public-Private Partnerships Are Critical to Delivering Innovative Treatments for CNS Diseases. 2019 , 29, 277-296	
832	Expert clinical consulting for early drug development programs in Korea. 2019 , 27, 2-5	
831	Molecular Computing and Bioinformatics. 2019 , 24,	6
830	Phase II Trials in Drug Development and Adaptive Trial Design. 2019 , 4, 428-437	26

829	A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology (A Case Study in Glioblastoma). 2019 , 10, 681	3
828	The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force. 2019 , 14, 225	13
827	Computer-Assisted and Data Driven Approaches for Surveillance, Drug Discovery, and Vaccine Design for the Zika Virus. 2019 , 12,	8
826	Computational prediction of toxicity of small organic molecules: state-of-the-art. 2019 , 4,	1
825	Pharmaceutical crisis. 2019 , 1-10	
824	A modelling framework for improved design and decision-making in drug development. 2019 , 14, e0220812	7
823	Research Techniques Made Simple: An Introduction to Drug Discovery for Dermatology. 2019 , 139, 2252-2257. e1	
822	Predicting Drug-Target Interactions With Multi-Label Classification and Label Partitioning. 2021 , 18, 1596-1607. 20	
821	Enhanced Drug Delivery by Dissolution of Amorphous Drug Encapsulated in a Water Unstable Metal-Organic Framework (MOF). 2019 , 58, 16790-16794	98
820	Drug Discovery Strategies for Neglected Tropical Diseases: Repurposing Knowledge, Mechanisms and Therapeutics to Increase Discovery Efficiency. 2019 , 1-13	2
819	Enhanced Drug Delivery by Dissolution of Amorphous Drug Encapsulated in a Water Unstable Metal-Organic Framework (MOF). 2019 , 131, 16946-16950	20
818	Prediction of Potential Drug-Disease Associations through Deep Integration of Diversity and Projections of Various Drug Features. 2019 , 20,	0
817	In Silico Prediction of Drug-Induced Liver Injury Based on Ensemble Classifier Method. 2019 , 20,	14
816	Virtual Reality Inspired Drugs (VRID): the Future Arena of Drug Discovery. 2019 , 1, 745-748	1
815	Deep learning enables rapid identification of potent DDR1 kinase inhibitors. 2019 , 37, 1038-1040	338
814	The "rights" of precision drug development for Alzheimer's disease. 2019 , 11, 76	93
813	Recent Insights from Molecular Dynamics Simulations for G Protein-Coupled Receptor Drug Discovery. 2019 , 20,	9
812	Drug transport across the human placenta: review of placenta-on-a-chip and previous approaches. 2019 , 9, 20190031	35

811	Strategy, Value and Risk. 2019,	1
810	Exploring the Impact of the Rational Antibiotic Use System on Hospital Performance: The Direct Effect and the Spillover Effect. 2019, 16,	0
809	A Green Chemistry Continuum for a Robust and Sustainable Active Pharmaceutical Ingredient Supply Chain. 2019, 7, 16937-16951	22
808	Collision cross section compendium to annotate and predict multi-omic compound identities. 2019, 10, 983-993	107
807	In silico approaches and tools for the prediction of drug metabolism and fate: A review. 2019, 106, 54-64	38
806	Learning patterns in early stage R&D projects: empirical evidence from the fibre raw material technology project in the Netherlands. 2019, 49, 684-695	3
805	CLSP: Real Life Applications and Motivation to Study Lot Sizing Problems in Process Industries. 2019, 33-45	1
804	Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA). 2019, 34, 148-154	1
803	Optimization of Protein-Protein Interaction Measurements for Drug Discovery Using AFM Force Spectroscopy. 2019, 18, 509-517	1
802	Probing the Environmental Toxicity of Deep Eutectic Solvents and Their Components: An In Silico Modeling Approach. 2019, 7, 10649-10660	51
801	The Use of Tick Salivary Proteins as Novel Therapeutics. 2019, 10, 812	19
800	New designs in early clinical drug development. 2019, 30, 1460-1465	7
799	Leveraging Image-Derived Phenotypic Measurements for Drug-Target Interaction Predictions. 2019, 18, 1176935119856595	3
798	Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. 2019, 8,	94
797	The role of mouse tumour models in the discovery and development of anticancer drugs. 2019, 121, 101-108	56
796	Machine learning and molecular descriptors enable rational solvent selection in asymmetric catalysis. 2019, 10, 6697-6706	44
795	Genetic Insights for Drug Development in NAFLD. 2019, 40, 506-516	34
794	Biomechanical System Versus Observational Rating Scale for Parkinson's Disease Tremor Assessment. 2019, 9, 8117	3

793	The role of intellectual capital in new product development: Can it become a liability?. 2019 , 65, 517-535	16
792	An outlook on using serial femtosecond crystallography in drug discovery. 2019 , 14, 933-945	16
791	Trends in Sigma-1 Receptor Research: A 25-Year Bibliometric Analysis. 2019 , 10, 564	39
790	Impact of organ-on-a-chip technology on pharmaceutical R&D costs. 2019 , 24, 1720-1724	57
789	Exploration of interaction scoring criteria in the CANDO platform. 2019 , 12, 318	9
788	Computational Model Development of Drug-Target Interaction Prediction: A Review. 2019 , 20, 492-494	12
787	Deep learning for molecular design— review of the state of the art. 2019 , 4, 828-849	197
786	ReSimNet: drug response similarity prediction using Siamese neural networks. 2019 , 35, 5249-5256	18
785	Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector. 2019 , 33, 193-198	4
784	Process Intensification through Continuous Manufacturing: Implications for Unit Operation and Process Design. 2019 , 153-190	3
783	TractaViewer: a genome-wide tool for preliminary assessment of therapeutic target druggability. 2019 , 35, 4509-4510	3
782	Digital Medicine: A Primer on Measurement. 2019 , 3, 31-71	56
781	Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells. 2019 , 11, 25-30	7
780	3D Print Technology for Cell Culturing. 2019 , 83-114	0
779	Exploiting machine learning for end-to-end drug discovery and development. 2019 , 18, 435-441	191
778	Template-Based Method for Conformation Generation and Scoring for Congeneric Series of Ligands. 2019 , 59, 2690-2701	1
777	Imaging tools to enhance animal tumor models for cancer research and drug discovery. 2019 , 75-106	
776	2018 International Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly Questions. 2019 , 37, 997-1006	105

775	Molecular Biotechnology: From DNA Sequence to Therapeutic Protein. 2019 , 1-18	0
774	Clinical protein science in translational medicine targeting malignant melanoma. 2019 , 35, 293-332	20
773	Orthogonal co-cultivation of smooth muscle cell and endothelial cell layers to construct -like vasculature. 2019 , 13, 014115	10
772	Optimized protocol for the hepatic differentiation of induced pluripotent stem cells in a fluidic microenvironment. 2019 , 116, 1762-1776	24
771	In Silico Drug Design Methods for Drug Repurposing. 2019 , 47-84	6
770	Reducing Drug Wastage in Pharmaceuticals Dosed by Weight or Body Surface Areas by Optimising Vial Sizes. 2019 , 17, 391-397	6
769	Computational Drug Repurposing for Neurodegenerative Diseases. 2019 , 85-118	4
768	Financing paths, firms' governance and corporate entrepreneurship: Accessing and applying operant and operand resources in biotechnology firms. 2020 , 153, 119935	9
767	The Medicinal Chemistry in the Era of Machines and Automation: Recent Advances in Continuous Flow Technology. 2020 , 63, 6624-6647	33
766	International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies. 2020 , 12, 867	7
765	Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. 2020 , 323, 844-853	261
764	Current Perspectives on the Development of Industry 4.0 in the Pharmaceutical Sector. 2020 , 18, 100131	48
763	Machine-Learning-Assisted De Novo Design of Organic Molecules and Polymers: Opportunities and Challenges. 2020 , 12,	51
762	Predicting partition coefficients of drug-like molecules in the SAMPL6 challenge with Drude polarizable force fields. 2020 , 34, 421-435	4
761	Utility of Physicochemical Properties for the Prediction of Toxicological Outcomes: Takeda Perspective. 2020 , 11, 203-209	8
760	DRIMC: an improved drug repositioning approach using Bayesian inductive matrix completion. 2020 , 36, 2839-2847	13
759	Deep Learning Based Drug Metabolites Prediction. 2019 , 10, 1586	7
758	Domain-adversarial multi-task framework for novel therapeutic property prediction of compounds. 2020 , 36, 2848-2855	4

757	Structural Chemogenomics. 2020 , 53-77	1
756	Technical Blossom in Medical Care: The Influence of Big Data Platform on Medical Innovation. 2020 , 17,	4
755	Metabolomics in pharmacology - a delve into the novel field of pharmacometabolomics. 2020 , 13, 115-134	11
754	Cellular Target Engagement Approaches to Monitor Epigenetic Reader Domain Interactions. 2020 , 25, 163-175	5
753	NegStacking: Drug-Target Interaction Prediction Based on Ensemble Learning and Logistic Regression. 2021 , 18, 2624-2634	4
752	MONN: A Multi-objective Neural Network for Predicting Compound-Protein Interactions and Affinities. 2020 , 10, 308-322.e11	40
751	Advances of droplet-based microfluidics in drug discovery. 2020 , 15, 969-979	11
750	Accurate prediction of relative binding affinities of a series of HIV-1 protease inhibitors using semi-empirical quantum mechanical charge. 2020 , 41, 1773-1780	1
749	Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D. 2020 , 72, 102332	
748	Novel Target Discovery of Existing Therapies: Path to Personalized Cancer Therapy. 2020 , 2, 1-13	1
747	Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs. 2020 , 74, 1013-1028	19
746	Water-Templated, Polysaccharide-rich Bioartificial 3D Microarchitectures as Extra-Cellular Matrix Bioautomatons. 2020 , 12, 20912-20921	2
745	The impact of crowdsourcing in modern drug discovery. 2020 , 15, 865-867	1
744	Selecting Projects on the Brazilian R&D Energy Sector: A Fuzzy-Based Approach for Criteria Selection. 2020 , 8, 50209-50226	3
743	Enhancing the Financial Returns of R&D Investments through Operations Management. 2020 , 29, 1658-1678	8
742	Positional Analogue Scanning: An Effective Strategy for Multiparameter Optimization in Drug Design. 2020 , 63, 8956-8976	19
741	Multisolvant Models for Solvation Free Energy Predictions Using 3D-RISM Hydration Thermodynamic Descriptors. 2020 , 60, 2977-2988	6
740	Revealing Acquired Resistance Mechanisms of Kinase-Targeted Drugs Using an on-the-Fly, Function-Site Interaction Fingerprint Approach. 2020 , 16, 3152-3161	3

739	Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery. 2020 , 60, 4144-4152	7
738	Efficient Drug Screening and Nephrotoxicity Assessment on Co-culture Microfluidic Kidney Chip. 2020 , 10, 6568	28
737	The endless frontier? The recent increase of R&D productivity in pharmaceuticals. 2020 , 18, 162	20
736	Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions. 2021 , 57, 603-634	
735	Rushed Innovation: Evidence from Drug Licensing. 2021 , 67, 257-278	3
734	Old drugs, new uses: Drug repurposing in hematological malignancies. 2021 , 68, 242-248	18
733	Drug-pathway association prediction: from experimental results to computational models. 2021 , 22,	8
732	Drug rechanneling: A novel paradigm for cancer treatment. 2021 , 68, 279-290	12
731	Identifying drug-target interactions based on graph convolutional network and deep neural network. 2021 , 22, 2141-2150	59
730	Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). 2021 , 23, 183-189	8
729	Inducing Compliance with Postmarket Studies for Drugs Under FDA's Accelerated Approval Pathway. 2021 , 23, 170-190	1
728	Exploration of databases and methods supporting drug repurposing: a comprehensive survey. 2021 , 22, 1656-1678	25
727	Special issue: Drug repurposing for cancer therapy. 2021 , 68, 1-2	1
726	The past, present and future of open innovation. 2021 , 24, 1130-1161	29
725	Three dimensional bioprinting technology: Applications in pharmaceutical and biomedical area. 2021 , 197, 111396	19
724	Regulatory review time and pharmaceutical research and development. 2021 , 30, 113-128	3
723	Improving target assessment in biomedical research: the GOT-IT recommendations. <i>Nature Reviews Drug Discovery</i> , 2021 , 20, 64-81	64.1 23
722	An Oculus to Profile and Probe Target Engagement In Vivo: How T-REX Was Born and Its Evolution into G-REX. 2021 , 54, 618-631	7

721	Biosynthetic, biomimetic, and self-assembled vascularized Organ-on-a-Chip systems. 2021 , 268, 120556	9
720	Extrapolation of drug induced liver injury responses from cancer cell lines using machine learning approaches. 2021 , 17, 100147	1
719	Innovative approaches in CNS drug discovery. 2021 , 76, 101-109	4
718	The Role of Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. 2021 , 62, 438-445	9
717	Outlook of the future landscape of artificial intelligence in medicine and new challenges. 2021 , 503-526	1
716	Neurodegenerative diseases and effective drug delivery: A review of challenges and novel therapeutics. 2021 , 330, 1152-1167	26
715	Parameterization of Microsomal and Cytosolic Scaling Factors: Methodological and Biological Considerations for Scalar Derivation and Validation. 2021 , 46, 173-183	3
714	Repurposing mesalazine against cardiac fibrosis in vitro. 2021 , 394, 533-543	8
713	Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs. 2021 , 14, 20-28	22
712	Scopy: an integrated negative design python library for desirable HTS/VS database design. 2021 , 22,	6
711	Organs-on-chips: into the next decade. <i>Nature Reviews Drug Discovery</i> , 2021 , 20, 345-361	64.1 193
710	Regulatory and market influences on innovation pathways for the development of new antimicrobial drugs. 2021 , 33, 283-295	0
709	Drug repurposing for breast cancer therapy: Old weapon for new battle. 2021 , 68, 8-20	33
708	Repurposing quinacrine for treatment-refractory cancer. 2021 , 68, 21-30	27
707	Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets. 2021 , 68, 59-74	33
706	A Novel Drug Repositioning Approach Based on Collaborative Metric Learning. 2021 , 18, 463-471	7
705	Optimal Designs for Multi-Arm Phase II/III Drug Development Programs. 2021 , 13, 71-81	1
704	Phytochemical candidates repurposing for cancer therapy and their molecular mechanisms. 2021 , 68, 164-174	2

703	COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. 2016 , 7, 41363-41379	82
702	Translational medicine and biomarkers. 2021 , 523-560	
701	Advances in Docking-Based Drug Design for Microbial and Cancer Drug Targets. 2021 , 407-424	
700	Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis. 2021 , 11, 4	3
699	Yeast-based high-throughput screens for discovery of kinase inhibitors for neglected diseases. 2021 , 124, 275-309	
698	An integrated microfluidic bubble pocket for long-term perfused three-dimensional intestine-on-a-chip model. 2021 , 15, 014110	2
697	Cytochrome P450: In Vitro Methods and Protocols. 2021 , 1-25	
696	SARS-CoV-2 host cell interactions and pathways: understanding its physiology, pathology, and targeted drug therapy. 2021 , 185-210	
695	Medicinal Plants of Himalayan Forests. 2021 , 175-212	2
694	The right tools for the job: the central role for next generation chemical probes and chemistry-based target deconvolution methods in phenotypic drug discovery. 2021 , 12, 646-665	2
693	A neighborhood-based global network model to predict drug-target interactions. 2021 , PP,	0
692	Holistic Assessment of Compound Properties In Vitro to In Vivo Pharmacology. 2021 ,	
691	A Multi-graph Deep Learning Model for Predicting Drug-Disease Associations. 2021 , 580-590	3
690	Selecting Approaches for Hit Identification and Increasing Options by Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries. 2021 , 26, 263-280	13
689	The pharmaceutical research and development productivity crisis: can exploratory clinical studies be of any help?. 2021 , 239-245	
688	PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs. 2021 , 60, 67-190	6
687	Nanoscale, automated, high throughput synthesis and screening for the accelerated discovery of protein modifiers. 2021 , 12, 809-818	4
686	Aim in Genomics. 2021 , 1-15	

685	Organizational consideration and trends in the pharmaceutical industry. 2021 , 561-593	
684	A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development. 2021 , 211-227	
683	Mendelian randomization for studying the effects of perturbing drug targets. 2021 , 6, 16	15
682	A review on compound-protein interaction prediction methods: Data, format, representation and model. 2021 , 19, 1541-1556	8
681	Future Prospects and Challenges in Targeting Cellular and Molecular Mechanisms in Respiratory Diseases. 2021 , 903-926	
680	Novel active pharmaceutical ingredients from India: The issues part-II. 2021 , 8, 155	
679	In Silico Modeling of Anticancer Drugs: Recent Advances. 2021 , 275-296	
678	Automated and enabling technologies for medicinal chemistry. 2021 , 60, 191-272	1
677	Biomarkers. 2021 ,	0
676	Model-informed drug development and discovery: an overview of current practices. 2021 , 263-280	0
675	Imaging therapeutic peptide transport across intestinal barriers. 2021 , 2, 1115-1143	5
674	Monobodies as tool biologics for accelerating target validation and druggable site discovery. 2021 , 12, 1839-1853	2
673	Transformer neural network for protein-specific de novo drug generation as a machine translation problem. 2021 , 11, 321	24
672	3D-Bioprinting. 2021 , 201-232	0
671	Current In Silico Drug Repurposing Strategies. 2021 , 257-268	
670	3D printing equipment in medicine. 2021 , 223-261	
669	A Nickel(II)-Mediated Thiocarbonylation Strategy for Carbon Isotope Labeling of Aliphatic Carboxamides. 2021 , 27, 7114-7123	2
668	In silico drug repositioning based on the integration of chemical, genomic and pharmacological spaces. 2021 , 22, 52	3

667	Friction and Decision Rules in Portfolio Decision Analysis.	0
666	Toward Developing Immunocompetent Diabetic Foot Ulcer-on-a-Chip Models for Drug Testing. 2021 , 27, 77-88	4
665	Preliminary approach to evaluate the drug-drug interaction potential of EST73502, a dual μ -opioid receptor partial agonist and κ receptor antagonist. 2021 , 51, 501-512	0
664	Improving the Prediction of Clinical Success Using Machine Learning.	4
663	A Critical Perspective on 3D Liver Models for Drug Metabolism and Toxicology Studies. 2021 , 9, 626805	19
662	A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions. 2021 , 64, 2312-2338	41
661	X-change symposium: status and future of modern radiation oncology-from technology to biology. 2021 , 16, 27	1
660	Repositioning of antidepressant drugs and synergistic effect with ciprofloxacin against multidrug-resistant bacteria. 2021 , 37, 53	2
659	Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders. 2021 , 46, E97-E110	6
658	DRDOCK: A Drug Repurposing platform integrating automated docking, simulations and a log-odds-based drug ranking scheme.	1
657	Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders. 2021 , 22,	0
656	Organ-on-a-Chip: The Future of Therapeutic Aptamer Research?. 2021 , 15, 109	5
655	A Novel Metric to Quantify the Effect of Pathway Enrichment Evaluation With Respect to Biomedical Text-Mined Terms: Development and Feasibility Study (Preprint).	
654	To Push or To Pull? In a Post-COVID World, Supporting and Incentivizing Antimicrobial Drug Development Must Become a Governmental Priority. 2021 , 7, 2029-2042	8
653	Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. 2021 , 26, 511-524	39
652	Galactosemia: Towards Pharmacological Chaperones. 2021 , 11,	3
651	Appraisal of the Role of In silico Methods in Pyrazole Based Drug Design. 2021 , 21, 204-216	3
650	Mendelian randomization for studying the effects of perturbing drug targets. 2021 , 6, 16	11

649	In vitro models for accurate prediction of renal tubular xenobiotic transport in vivo. 2021 , 25, 15-22	2
648	A landscape for drug-target interactions based on network analysis. 2021 , 16, e0247018	1
647	Combining explainable machine learning, demographic and multi-omic data to identify precision medicine strategies for inflammatory bowel disease.	0
646	Microfluidics in Sickle Cell Disease Research: State of the Art and a Perspective Beyond the Flow Problem. 2020 , 7, 558982	2
645	Alternative strategies in cardiac preclinical research and new clinical trial formats. 2021 ,	3
644	Lipophilicity Determines Routes of Uptake and Clearance, and Toxicity of an Alpha-Particle-Emitting Peptide Receptor Radiotherapy. 2021 , 4, 953-965	1
643	Cancer drug discovery as a low rank tensor completion problem.	
642	Value-Generating Exploratory Trials in Neurodegenerative Dementias. 2021 , 96, 944-954	5
641	Human iPSC modeling of heart disease for drug development. 2021 , 28, 271-282	4
640	A Brief Primer on Project Leadership, Project Management, and Cross-functional Teams. 1-7	
639	Perspectives on Drug Repurposing. 2021 , 28, 2085-2099	8
638	Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing. 2021 , 13,	2
637	Collagen molecular phenotypic switch between non-neoplastic and neoplastic canine mammary tissues. 2021 , 11, 8659	1
636	Drug Discovery and Development for Kinetoplastid Diseases. 1-79	
635	Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning. 2021 , 5, 600-612	34
634	A comprehensive review on anticancer mechanism of bazedoxifene. 2021 ,	3
633	Molecule Classification Using Visualization and Convolutional Neural Network. 2021 ,	
632	Microfluidic based human-on-a-chip: A revolutionary technology in scientific research. 2021 , 110, 711-728	6

631	Zebrafish Avatar to Develop Precision Breast Cancer Therapies. 2021,	1
630	Factors Affecting Outbound Open Innovation Performance in Bio-Pharmaceutical Industry-Focus on Out-Licensing Deals. 2021, 13, 4122	1
629	Development of a new simple spectroscopic determination coupled acid-motivated delivery system based on fluorescence turn-off MSNs@MPA-ZnS QDs for infection. 2021, 317, 110971	4
628	An Efficient Method for the Differentiation of Human iPSC-Derived Endoderm toward Enterocytes and Hepatocytes. 2021, 10,	1
627	Approval success rates of drug candidates based on target, action, modality, application, and their combinations. 2021, 14, 1113-1122	3
626	Experiences in Academic and Industry Partnerships [Forging a Path to Translational Drug Discovery. 1-101	
625	Auricular Vagus Neuromodulation-A Systematic Review on Quality of Evidence and Clinical Effects. 2021, 15, 664740	5
624	Application of network link prediction in drug discovery. 2021, 22, 187	7
623	Microfluidic System for In Vivo-Like Drug Permeation Studies with Dynamic Dilution Profiles. 2021, 8,	0
622	Challenges and perspectives in the discovery of dengue virus entry inhibitors. 2021,	0
621	End-to-end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies. 2021, 118, 3468-3485	3
620	Are Hsp90 inhibitors good candidates against Covid-19?. 2020,	3
619	The translational lag narrative in policy discourse in the United States and the European Union: a comparative study. 2021, 8,	2
618	The effects of universityindustry collaboration in preclinical research on pharmaceutical firms[R&D performance: Absorptive capacity] role. 2021, 38, 355-378	6
617	Applications of artificial intelligence in drug development using real-world data. 2021, 26, 1256-1264	13
616	AgNW-based functional polymer cantilever to improve maturity and contractility of cardiomyocytes. 2021, 30, 185-189	
615	Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance. 2021, 14,	4
614	Utilizing graph machine learning within drug discovery and development. 2021, 22,	18

613	Microbially Guided Discovery and Biosynthesis of Biologically Active Natural Products. 2021 , 10, 1505-1519	3
612	Pharmaceutical R&D project portfolio selection and scheduling under uncertainty: A robust possibilistic optimization approach. 2021 , 155, 107114	3
611	Retro Drug Design: From Target Properties to Molecular Structures. 2021 ,	2
610	Towards More Predictive, Physiological and Animal-free Models: Advances in Cell and Tissue Culture 2020 Conference Proceedings. 2021 , 49, 93-110	3
609	Mathematical Multidimensional Modelling and Structural Artificial Intelligence Pipelines Provide Insights for the Designing of Highly Specific AntiSARS-CoV2 Agents. 2021 , 15, 877	2
608	Microfluidics Integration into Low-Noise Multi-Electrode Arrays. 2021 , 12,	1
607	Graph neural networks for automated de novo drug design. 2021 , 26, 1382-1393	12
606	Translational precision medicine: an industry perspective. 2021 , 19, 245	12
605	A Cloud Computing Platform for Scalable Relative and Absolute Binding Free Energy Predictions: New Opportunities and Challenges for Drug Discovery. 2021 , 61, 2720-2732	7
604	Genome-wide discovery of hidden genes mediating known drug-disease association using KDDANet. 2021 , 6, 50	1
603	In vivo antidiabetic potential of standardized Forssk. Extract.. 2021 , 20, 1129-1135	0
602	Automation of Organoid Cultures: Current Protocols and Applications. 2021 , 26, 1138-1147	2
601	BIOMARKERS AND NEUROBEHAVIORAL DIAGNOSIS. 2021 , 4, 100029-100029	5
600	Comprehensive analysis of 2.4 million patent-to-research citations maps the biomedical innovation and translation landscape. 2021 , 39, 678-683	0
599	Academic collaborative models fostering the translation of physiological in vitro systems from basic research into drug discovery. 2021 , 26, 1369-1381	2
598	Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. 2021 , 48, 3-31	8
597	Lipid membrane-based therapeutics and diagnostics. 2021 , 704, 108858	1
596	Recent scientific/intellectual movements in biomedicine. 2021 , 278, 113950	1

595	CASTELO: clustered atom subtypes aided lead optimization-a combined machine learning and molecular modeling method. 2021 , 22, 338	0
594	Bioengineered model of the human motor unit with physiologically functional neuromuscular junctions. 2021 , 11, 11695	3
593	Validating ADME QSAR Models Using Marketed Drugs. 2021 , 26, 1326-1336	4
592	Characterization of the large-scale Japanese patient-derived xenograft (J-PDX) library. 2021 , 112, 2454-2466	2
591	A Novel Metric to Quantify the Effect of Pathway Enrichment Evaluation With Respect to Biomedical Text-Mined Terms: Development and Feasibility Study. 2021 , 9, e28247	0
590	Protein Domain-Based Prediction of Compound-Target Interactions and Experimental Validation on LIM Kinases.	
589	Mass spectrometry imaging in zebrafish larvae for assessing drug safety and metabolism. 2021 , 413, 5135-5146	5
588	Opportunities and challenges in translational science. 2021 , 14, 1629-1647	9
587	Agarose Micro-Well Platform for Rapid Generation of Homogenous 3D Tumor Spheroids. 2021 , 1, e199	0
586	Logistic matrix factorisation and generative adversarial neural network-based method for predicting drug-target interactions. 2021 , 25, 1497-1516	1
585	Systematic risk identification and assessment using a new risk map in pharmaceutical R&D. 2021 , 26, 2786-2793	1
584	Drug-target interaction prediction via an ensemble of weighted nearest neighbors with interaction recovery. 1	5
583	An Overview of Computer-aided Drug Design Tools and Recent Applications in Designing of Anti-diabetic Agents. 2021 , 22, 1158-1182	2
582	The distribution, number, and certain neurochemical identities of infracortical white matter neurons in the brains of a southern lesser galago, a black-capped squirrel monkey, and a crested macaque. 2021 , 529, 3676-3708	0
581	Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. 2021 , 1,	2
580	Deep imputation on large-scale drug discovery data. 2021 , 2, e31	3
579	Subcellular localization of biomolecules and drug distribution by high-definition ion beam imaging. 2021 , 12, 4628	4
578	Absorbing knowledge from an emerging field: The role of interfacing by proponents in big pharma. 2021 , 110, 102363	2

577	Fueling the Pipeline via Innovations in Organic Synthesis. 2021 , 12, 1365-1373	2
576	Feature importance of machine learning prediction models shows structurally active part and important physicochemical features in drug design. 2021 , 39, 100401	3
575	Computer aided drug discovery review for infectious diseases with case study of anti-Chagas project. 2021 , 83, 102366	2
574	Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan. 2021 , 1	0
573	R&D efficiency of leading pharmaceutical companies - A 20-year analysis. 2021 , 26, 1784-1789	4
572	Advances in Smoking Related In Vitro Inhalation Toxicology: A Perspective Case of Challenges and Opportunities from Progresses in Lung-on-Chip Technologies. 2021 , 34, 1984-2002	11
571	How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. 2021 , 39, 1243-1269	16
570	Effective Use of Empirical Data for Virtual Screening against APJR GPCR Receptor. 2021 , 26,	
569	A Novel Scalarized Scaffold Hopping Algorithm with Graph-Based Variational Autoencoder for Discovery of JAK1 Inhibitors. 2021 , 6, 22945-22954	3
568	Molecular design in drug discovery: a comprehensive review of deep generative models. 2021 , 22,	13
567	Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice. 2021 , 394, 2233-2244	0
566	TrendyGenes, a computational pipeline for the detection of literature trends in academia and drug discovery. 2021 , 11, 15747	2
565	Towards the sustainable discovery and development of new antibiotics. 2021 , 1-24	77
564	Stepping to the exit. 2021 , 39, 1048-1054	0
563	AI models and the future of genomic research and medicine: True sons of knowledge?: Artificial intelligence needs to be integrated with causal conceptions in biomedicine to harness its societal benefits for the field. 2021 , 43, e2100025	0
562	Building better biobetters: From fundamentals to industrial application. 2021 ,	3
561	A computational method for identifying an optimal combination of existing drugs to repair the action potentials of SQT1 ventricular myocytes. 2021 , 17, e1009233	2
560	Predicting drug metabolism and pharmacokinetics features of in-house compounds by a hybrid machine-learning model. 2021 , 39, 100395	3

559	Recent advances in human respiratory epithelium models for drug discovery. 2021 , 107832	2
558	Exploring How and Why to Develop Patient-Centered Packaging: A Multiple-Case Study with Pharmaceutical Companies. 2021 , 1	
557	Pyronaridine Protects Against SARS-CoV-2 in Mouse.	0
556	Challenging the pipeline. 2021 , 16, 2033-2037	1
555	Theoretical Studies on the Molecular Properties, Toxicity, and Biological Efficacy of 21 New Chemical Entities. 2021 , 6, 24891-24901	6
554	Tackling Current Biomedical Challenges With Frontier Biofabrication and Organ-On-A-Chip Technologies. 2021 , 9, 732130	4
553	A novel multi-objective mutation flower pollination algorithm for the optimization of industrial enterprise R&D investment allocation. 2021 , 109, 107530	1
552	Drug repurposing: Iron in the fire for older drugs. 2021 , 141, 111638	6
551	Designing small molecules for therapeutic success: A contemporary perspective. 2021 ,	2
550	The rise of deep learning and transformations in bioactivity prediction power of molecular modeling tools. 2021 , 98, 954-967	3
549	Social Non-profit Bioentrepreneurship: Current Status and Future Impact on Global Health. 2021 , 9, 541191	2
548	Discovery of novel inhibitors of human phosphoglycerate dehydrogenase by activity-directed combinatorial chemical synthesis strategy. 2021 , 115, 105159	
547	In silico methods and tools for drug discovery. 2021 , 137, 104851	23
546	Growth contributions of technological change: Is there a burden of knowledge effect?. 2021 , 172, 121076	2
545	Team Size, Research Variety, and Research Performance: Do Coauthors Coauthors Matter?. 2021 , 15, 101205	0
544	Searching for an ideal SERM: Mining tamoxifen structure-activity relationships. 2021 , 52, 128383	0
543	Recent advances in drug repurposing using machine learning. 2021 , 65, 74-84	5
542	An pipeline for the discovery of multitarget ligands: A case study for epi-polypharmacology based on DNMT1/HDAC2 inhibition.. 2021 , 1,	

541	Organ-on-a-chip. 2022 , 181-198	1
540	Classification, material types, and design approaches of long-acting and implantable drug delivery systems. 2022 , 17-59	1
539	Drug discovery and development: An overview of modern methods and principles. 2021 , 1-41	
538	Expression and manufacturing of protein therapeutics in spirulina.	2
537	Machine Learning Application in COVID-19 Drug Development. 2021 , 229-244	
536	Generation of Human iPSC-derived Neural Progenitor Cells (NPCs) as Drug Discovery Model for Neurological and Mitochondrial Disorders. 2021 , 11, e3939	0
535	Anti-Virulence Therapeutic Approaches for. 2021 , 10,	1
534	Nanoscale Drug Delivery Systems for Glaucoma: Experimental and Advances. 2021 , 21, 115-125	4
533	Construction of a high fidelity epidermis-on-a-chip for scalable irritation evaluation. 2021 , 21, 3804-3818	6
532	Attrition in Drug Discovery and Development. 5-45	2
531	Current and Future Strategies for Improving Drug Discovery Efficiency. 287-328	1
530	Compound Attrition in Phase II/III. 106-127	2
529	Influence of Phenotypic and Target-Based Screening Strategies on Compound Attrition and Project Choice. 229-263	1
528	Generating a High-Quality Compound Collection. 9-21	3
527	Evaluating the Economic and Operational Feasibility of Continuous Processes for Monoclonal Antibodies. 433-456	5
526	Computational Approaches for De Novo Drug Design: Past, Present, and Future. 2021 , 2190, 139-165	5
525	Reducing systems biology to practice in pharmaceutical company research; selected case studies. 2012 , 736, 607-15	19
524	Policies and Practices to Enhance Multi-sectorial Collaborations and Commercialization of Regenerative Medicine. 2014 , 67-87	3

523	Development of Pilosebaceous Unit-Targeted Drug Products. 2014 , 181-215	3
522	Developability Assessment and Risk Management During Drug Discovery. 2015 , 3-47	2
521	Coculture and Long-Term Maintenance of Hepatocytes. 2015 , 1250, 161-73	7
520	NMR Metabolomics Protocols for Drug Discovery. 2019 , 2037, 265-311	9
519	Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?. 2020 , 2076, 1-30	5
518	Biomaterials and Microfluidics for Drug Discovery and Development. 2020 , 1230, 121-135	5
517	The Impact of Research and Development Expenditures on the Value Relevance of Accounting Items. 2020 , 41-67	6
516	QSAR/QSPR Modeling in the Design of Drug Candidates with Balanced Pharmacodynamic and Pharmacokinetic Properties. 2017 , 339-384	2
515	Computational Methods for the Prediction of Drug-Target Interactions from Drug Fingerprints and Protein Sequences by Stacked Auto-Encoder Deep Neural Network. 2017 , 46-58	11
514	Können die Preise für neue Medikamente sinken?. 2020 , 209-237	1
513	Network Pharmacology to Aid the Drug Discovery Process. 2012 , 161-172	1
512	Artificial Intelligence in Drug Discovery: A Comprehensive Review of Data-driven and Machine Learning Approaches. 2020 , 25, 895-930	12
511	Patents and Other Incentives for Pharmaceutical Innovation. 2014 , 434-442	2
510	Deep Graph Learning with Property Augmentation for Predicting Drug-Induced Liver Injury. 2021 , 34, 495-506	3
509	CHAPTER 1:Introduction: Biomarkers in Translational and Personalized Medicine. 2013 , 3-39	1
508	From Reproducibility to Translation in Neurodegenerative Disease. 2017 , 58, 106-114	6
507	Cross-species neuroscience: closing the explanatory gap. 2021 , 376, 20190633	16
506	Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing.	12

505	Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs.	3
504	Navigating Chemical Space By Interfacing Generative Artificial Intelligence and Molecular Docking.	3
503	Benchmarking ensemble docking methods as a scientific outreach project.	1
502	VenomKB v2.0: A knowledge repository for computational toxinology.	3
501	Drug repurposing through joint learning on knowledge graphs and literature.	6
500	Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.	9
499	Subcellular localization of drug distribution by super-resolution ion beam imaging.	4
498	Deep learning enables therapeutic antibody optimization in mammalian cells by deciphering high-dimensional protein sequence space.	23
497	Transformer neural network for protein-specific de novo drug generation as a machine translation problem.	2
496	Drug repositioning in cancer: The current situation in Japan. 2020 , 111, 1039-1046	13
495	MoFlow: An Invertible Flow Model for Generating Molecular Graphs. 2020 ,	18
494	Collaboration for rare disease drug discovery research. 2014 , 3, 261	15
493	Current status and future prospects for enabling chemistry technology in the drug discovery process. 2016 , 5, 2426	5
492	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. 2, 23	4
491	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. 2018 , 2, 23	14
490	Cheminformatics workflows using mobile apps. 2013 , 13, 1-18	11
489	Identification of direct target engagement biomarkers for kinase-targeted therapeutics. 2011 , 6, e26459	24
488	A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. 2012 , 7, e37608	261

487	Tracking 20 years of compound-to-target output from literature and patents. 2013 , 8, e77142	17
486	SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for computer-aided drug discovery. 2013 , 8, e79568	63
485	Construction of drug network based on side effects and its application for drug repositioning. 2014 , 9, e87864	70
484	Are global and regional improvements in life expectancy and in child, adult and senior survival slowing?. 2015 , 10, e0124479	6
483	Meta-Analysis of Large-Scale Toxicogenomic Data Finds Neuronal Regeneration Related Protein and Cathepsin D to Be Novel Biomarkers of Drug-Induced Toxicity. 2015 , 10, e0136698	7
482	Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials. 2015 , 10, e0138095	51
481	Bilayer Effects of Antimalarial Compounds. 2015 , 10, e0142401	7
480	When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis. 2016 , 11, e0147215	152
479	Genetic Polymorphisms Affect Mouse and Human Trace Amine-Associated Receptor 1 Function. 2016 , 11, e0152581	38
478	Health and Ethical Consequences of Outsourcing Pivotal Clinical Trials to Latin America: A Cross-Sectional, Descriptive Study. 2016 , 11, e0157756	9
477	Non-antibiotic pharmaceutical agents as antibiotic adjuvants. 2020 , 64, 17-24	0
476	Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. 2016 , 3, 114-120	31
475	Dark Suite: a comprehensive toolbox for computer-aided drug design. 2020 , 25,	1
474	Computational methods for calculation of protein-ligand binding affinities in structure-based drug design. 2020 ,	1
473	Drug repositioning: computational approaches and research examples classified according to the evidence level. 2017 , 5, e75	2
472	COVID-19: a pandemic experience that illuminates potential reforms to health research. 2020 , 12, e13278	3
471	Study on the Electrochemical Array Sensor using pn Junctions of the Inorganic Semiconductor. 2018 , 138, 204-207	1
470	A Three-Layer Microfluidic Kidney Chip for Drug Nephrotoxicity Test. 2019 , 9, 237-247	4

469	Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections. 2020 , 12, 6492-6510	52
468	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. 2018 , 9, 4758-4772	9
467	Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. 2015 , 6, 23548-60	29
466	New Financing Methods in the Biopharma Industry: A Case Study of Royalty Pharma, Inc..	1
465	High Growth Firms, Innovation and Competition: The Case of the US Pharmaceutical Industry.	2
464	Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. 2018 , 25, 2595-2607	43
463	The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization. 2019 , 26, 3838-3873	17
462	Computational Drug Repurposing: Current Trends. 2019 , 26, 5389-5409	29
461	Five Years of the KNIME Vernalis Cheminformatics Community Contribution. 2020 , 27, 6495-6522	7
460	Survey of Similarity-Based Prediction of Drug-Protein Interactions. 2020 , 27, 5856-5886	17
459	Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform. 2016 , 22, 3109-23	33
458	Current Strategies and Future Perspectives of Skin-on-a-Chip Platforms: Innovations, Technical Challenges and Commercial Outlook. 2018 , 24, 5437-5457	10
457	TNF superfamily protein-protein interactions: feasibility of small- molecule modulation. 2015 , 16, 393-408	17
456	Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions. 2018 , 18, 674-699	44
455	Virtual Screening Techniques in Drug Discovery: Review and Recent Applications. 2019 , 19, 1751-1767	32
454	Cheminformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold. 2017 , 15, 1117-1135	3
453	Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders. 2018 , 16, 740-748	40
452	From Target Identification to Drug Development in Space: Using the Microgravity Assist. 2020 , 17, 45-56	13

451	Recent Advances on Drug Analyses Using Ultra Performance Liquid Chromatographic Techniques and their Application to the Biological Samples. 2019 , 15, 277-293	5
450	Translational science: Key features, issues and future perspectives. 2019 , 1, 1-3	1
449	New drugs are not enough-drug repositioning in oncology: An update. 2020 , 56, 651-684	22
448	2. De la sant� publique internationale � la sant� globale. L'OMS, la Banque mondiale et le gouvernement des th�rapies chimiques. 2014 , 65-96	10
447	Drug Discovery Processes to Drug Targeting Mechanisms. 2017 , 13, 773-784	2
446	Cancer biomarker discovery and validation. 2015 , 4, 256-269	259
445	Drug Discovery. 2019 , 1-46	1
444	Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. 2016 , 48, 629-636	43
443	Organoids: An invaluable tool in pharmacology. 2020 , 52, 422-429	2
442	Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. 2016 , 8, 439-55	7
441	Ans�tze zur Begegnung der Hochpreisigkeit. 2021 , 139-153	
440	A Drug Repositioning Method Based on Heterogeneous Graph Neural Network. 2021 , 183-194	
439	Generative AI Models for Drug Discovery. 2021 , 221-243	
438	Late-Stage Amination of Drug-Like Benzoic Acids: Access to Anilines and Drug Conjugates through Directed Iridium-Catalyzed C-H Activation. 2021 , 27, 18188	11
437	Toward the institutionalization of quantum computing in pharmaceutical research. 2021 , 27, 378-378	2
436	Multi-Organs-on-Chips for Testing Small-Molecule Drugs: Challenges and Perspectives. 2021 , 13,	2
435	Human Genomics and Drug Development. 2021 ,	2
434	Nanoparticles as Drug Delivery Systems.	1

433	Adversarial Deep Evolutionary Learning for Drug Design. 2021 ,	0
432	R&D Costs of New Medicines: A Landscape Analysis. 2021 , 8, 760762	4
431	BAPST. A Combo of Common use drugs as metabolic therapy of cancer-a theoretical proposal. 2021 ,	
430	Navigating Chemical Space by Interfacing Generative Artificial Intelligence and Molecular Docking. 2021 , 61, 5589-5600	3
429	Recent applications of quantitative systems pharmacology and machine learning models across diseases. 2021 , 49, 19	2
428	References. 2012 , 459-595	1
427	Psychopharmaka-Entwicklung: von der Entdeckung bis zur Zulassung. 2012 , 87-104	
426	The Role of Chemical Biology in Drug Discovery. 1	
425	LIMS Deployment in an Assay Service Environment. 2012 , 14, 14-34	2
424	The Role of Chemical Biology in Drug Discovery. 1-21	
423	Commercial Opportunities for Induced Pluripotent Stem Cells. 2013 , 177-199	
422	Prescription Drug and Pharmaceutical Policy. 2013 , 101-118	
421	Projecting Expenditure on Medicines in the NHS.	
420	Encyclopedia of Creativity, Invention, Innovation and Entrepreneurship. 2013 , 1828-1834	
419	The Rationale and Implementation of Translational Systems Biology as a New Paradigm for the Study of Inflammation. 2013 , 283-287	
418	Operationalizing Data Quality through Data Governance. 2013 , 65-92	
417	Toxicological Assessment of Nanomedicine.	
416	Concluding Thoughts. 2014 , 163-170	

415 Outlook. **2014**, 305-313

414 Background of Pharmacologic Modeling. **2014**, 1-20

413 Optic Neuritis. **2014**, 307-321

412 Projecting Expenditure on Medicines in the NHS (Second Edition).

1

411 In silico?????????????. **2014**, 34, 291-296

410 Delivering Solutions and Clinical Benefits for Diseases with Small and Intermediate-Size Patient Populations. **2014**, 140-147

0

409 eHealth in Drug Discovery and Disease Research. **2014**, 230-243

408 Memos. **2014**, 13, 54-95

407 References. **2014**, 405-416

406 Can Innovation Still Be the Main Growth Driver of the Pharmaceutical Industry?. **2015**, 39-68

405 Gesundheitspolitisches Umfeld und zukünftige Entwicklungen in der Pharmabranche **2015**, 1-14

404 Drug development. **2015**, 395-400

0

403 CHAPTER 18: Pharmacokinetic/Pharmacodynamic Modeling in Drug Development with Special Reference to Oncology. **2015**, 391-413

402 Managerial Cognition, Strategic Behavior and Innovation: Biopharmaceutical R & D. **2015**, 2,

401 Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value.

1

400 Drug Discovery and Repurposing for Retinoblastoma. **2015**, 73-84

1

399 Stratégie de recherche translationnelle sur la maladie d'Alzheimer : cibles, modèles animaux et biomarqueurs. **2015**, 199, 893-908

398 ADME for Therapeutic Biologics: What Can We Leverage from Great Wealth of ADME Knowledge and Research for Small Molecules. 1-11

- 397 6. Current Status and Future Outlook of New Drug Development in Industry and Academia. **2016**, 47, 77-84
- 396 Security and the Role of New Technologies and Innovation in Medical Ethics. **2016**, 52-77
- 395 Anwendende Sektoren und Märkte der Biotechnologie. **2016**, 143-309
- 394 Searching for the Devil in the Details: Learning About Development Program Design.
- 393 Growth and Returns to New Products and Pack Varieties: The Case of UK Pharmaceuticals.
- 392 Structure and Dynamics of the Pharmaceutical Industry. **2016**, 195-208
- 391 Clinical trials in Latin America: implications for the sustainability and safety of pharmaceutical markets and the wellbeing of research subjects. **2016**, 12, 317-345 0
- 390 Basic Concepts in Drug Targeting. **2016**, 1-23
- 389 The Drug Development Process and Evolution of Regulations. **2017**, 33-43
- 388 Security and the Role of New Technologies and Innovation in Medical Ethics. **2017**, 1346-1371
- 387 Construction of Enriched Resource for Primary Therapeutic Targets of Approved and Clinical Trial Drugs. **2017**, 05, 1-6
- 386 Introduction. **2017**, 1-13
- 385 Novel Targets and Advancements in Drug Discovery: The Case of HIV-AIDS. **2017**, 419-438 0
- 384 Conclusions and Perspectives. **2017**, 139-143
- 383 The Effects of Working Memory Training on Cognitive Flexibility in Man. **2017**, 77-87 1
- 382 Intermittent Access to Ethanol Induces Escalated Alcohol Consumption in Primates. **2017**, 6, 4
- 381 Topical Versus Oral/Systemic Drug Discovery. **2017**, 39-48
- 380 A Systems-Level Framework for Drug Discovery Identifies Csf1R As A Novel Anti-Epileptic Drug Target.

- 379 Case I: 3DMed: An R&D Platform for Personalised Precision Anti-cancer Drugs. **2018**, 1-32 0
- 378 Flipping the odds of drug development success through human genomics.
- 377 Stage 2: Transformation III Translating Discoveries into Impact for the Market Through Design Thinking. **2018**, 43-65
- 376 13: Essential Oil-Based Nanomedicines against Trypanosomatides. **2017**, 258-278
- 375 Developing a genetic signature to predict drug response in ovarian cancer. **2018**, 9, 14828-14848 3
- 374 Adverse Selection in Tax Credit Programs for Biotechnology and Other Technology Startups.
- 373 Continuous Evaluation of Ligand Protein Predictions: A Weekly Community Challenge for Drug Docking.
- 372 A New Compound-ensemble Strategy for Validating Cancer Drug Targets Confirms that Inhibiting Glycolysis Blocks Leukemic Cell Proliferation..
- 371 Optimal Patient Enrollment in Sequential Adaptive Clinical Trials with Binary Response. 2
- 370 A big data approach with artificial neural network and molecular similarity for chemical data mining and endocrine disruption prediction. **2018**, 50, 169-176 1
- 369 Drug development challenges in liver disease clinical trials. **2018**, 8, 1-5
- 368 Encyclopedia of Creativity, Invention, Innovation and Entrepreneurship. **2018**, 1-7
- 367 Ethical to using Rats in the Scientific Researches. **2018**, 6, 0
- 366 Using the Encoder Embedded Framework of Dimensionality Reduction Based on Multiple Drugs Properties for Drug Recommendation. **2018**, 258-266 0
- 365 Label-free detection of protein biomolecules secreted from a heart-on-a-chip model for drug cardiotoxicity evaluation. **2018**,
- 364 Tox_(R)CNN: Deep Learning-Based Nuclei Profiling tool For Drug Toxicity Screening. 1
- 363 Pharmamarketing, Strafrecht, Selbstregulierung [Einführung in den Band. **2019**, 1-26
- 362 Identification of evolutionarily conserved virulence factor by selective pressure analysis of *Streptococcus pneumoniae*.

- 361 Continuous Evaluation of Ligand Protein Predictions: A Weekly Community Challenge for Drug Docking. 0
- 360 Statistical Considerations in Proof-of-Concept Studies. **2019**, 221-245
- 359 Improving Clinical Trial Design in Gastrointestinal Oncology. **2019**, 493-507
- 358 Measuring the Economic and Academic Impact of Philanthropic Funding: The Breast Cancer Research Foundation.
- 357 [Study on colorectal cancer using air-liquid interface organoid culture method]. **2019**, 154, 50-55
- 356 Surrogate Biomarkers. **2019**, 39-52
- 355 Crowdsourcing in Innovation Activity of Enterprises on an Example of Pharmaceutical Industry. **2019**, 58-70
- 354 Towards Personalized Vaccines—Tailoring Peptide Vaccines to Demographic Groups and Individuals.
- 353 Pharmaceuticals and Biotechnology. **2019**, 181-195
- 352 Rushed Innovation: Reactive Licensing in the Pharmaceutical Industry.
- 351 Biomarkers for capturing disease pathology as molecular process hyperstructure. 1
- 350 Exploration of interaction scoring criteria in the CANDO platform. 1
- 349 Genome-wide discovery of hidden genes mediating known drug-disease association using KDDANet.
- 348 Decision-Making in Sequential Adaptive Clinical Trials, with Implications for Drug Misclassification and Resource Allocation. **2020**, 321-345 0
- 347 High-Throughput Assessment of Metabolism-Induced Toxicity of Compounds on a 384-Pillar Plate. **2020**, 2089, 191-207 0
- 346 Predicting Drug Target Interactions Using Dimensionality Reduction with Ensemble Learning. **2020**, 79-89 1
- 345 Revealing acquired resistance mechanisms of kinase-targeted drugs using an on-the-fly, function-site interaction fingerprint approach.
- 344 5.In vitro?????????????????. **2019**, 87, 318-322

- 343 MONN: a Multi-Objective Neural Network for Predicting Pairwise Non-Covalent Interactions and Binding Affinities between Compounds and Proteins.
- 342 Drug Formulations. **2020**, 57-88
- 341 Future of Regulatory Safety Assessments. **2020**, 1145-1168
- 340 Role of ADMET Tools in Current Scenario: Application and Limitations. **2020**, 71-87 3
- 339 Biomarkers from Bench to Bedside and Back [Back-Translation of Clinical Studies to Preclinical Models. **2020**, 307-331
- 338 Bioengineered model of the human motor unit with physiologically functional neuromuscular junctions.
- 337 Nanopharmaceuticals: Healthcare Applications and Safety Evaluations. **2021**, 265-288 1
- 336 The Impact of Plant Bioactive Compounds on Aging and Fertility of Diverse Organisms: A Review. **2020**, 20, 1287-1299 3
- 335 Predicting Physiological Effects of Chemical Substances Using Natural Language Processing. **2021**,
- 334 Drug Repositioning Based on the Reversal of Gene Expression Signatures Identifies as a Therapeutic Target for Rectal Cancer. **2021**, 13, 0
- 333 Downstream Processes. **2020**, 105-136
- 332 Encyclopedia of Creativity, Invention, Innovation and Entrepreneurship. **2020**, 2340-2347
- 331 Prospects for Discovering the Secondary Metabolites of Sensu Lato by the Integrated Strategy. **2021**, 17, 97-120 2
- 330 Multi-objective optimization methods in novel drug design. **2021**, 16, 647-658 4
- 329 Factors Impacting Pharmaceutical Prices and Affordability: Narrative Review. **2020**, 9, 1
- 328 Web-based Tools for Drug Repurposing: Successful Examples of Collaborative Research. **2021**, 28, 181-195 1
- 327 TREAP: A New Topological Approach to Drug Target Inference. **2020**, 119, 2290-2298 1
- 326 Drug discovery. **2022**, 563-572

- 325 The Development of a Drug: A Pharmaceutical Drug Development Perspective. **2020**, 1-15
- 324 R&D Management in Rare Disease Focused Biotechnology Companies: The Case of Shire. **2020**, 267-283
- 323 A Test of the Monopoly Pricing Hypothesis of Patents.
- 322 Network Insights into Improving Drug Target Inference Algorithms. 2
- 321 Market Access Management [Konzeption und Prozess. **2020**, 3-35
- 320 Database Resources for Drug Discovery. **2020**, 89-114
- 319 New Medicines for Serious Diseases: The Case of the FDA's Breakthrough Designation.
- 318 Apprehensions about Excessive Belief in Digital Therapeutics: Points of Concern Excluding Merits. **2020**, 35, e373 4
- 317 [Strategic assessment for nonclinical safety in drug discovery]. **2020**, 155, 248-252
- 316 The Impact of the Leahy-Smith America Invents Act on Firms' R&D Disclosure.
- 315 Proteome Exploration of Legionella pneumophila for Identifying Novel Therapeutics: A Hierarchical Subtractive Genomics and Reverse Vaccinology Approach.
- 314 The Pharmaceutical Drug Development Process: Selecting a Suitable Drug Candidate. **2021**, 53-71
- 313 Agent Clustering Strategy Based on Metabolic Flux Distribution and Transcriptome Expression for Novel Drug Development. **2021**, 9,
- 312 Artificial intelligence for the discovery of novel antimicrobial agents for emerging infectious diseases. **2021**, 0
- 311 Generation and Culture of Cardiac Microtissues in a Microfluidic Chip with a Reversible Open Top Enables Electrical Pacing, Dynamic Drug Dosing and Endothelial Cell Co-Culture.
- 310 Artificial Intelligence in Compound Design. **2022**, 2390, 349-382 0
- 309 R&D Productivity in the Pharmaceutical Industry. 302-320
- 308 Defining a Global Map of Functional Group Based 3D Ligand-binding Motifs.

307	SETTING THE RIGHT GOAL: POST M&A INNOVATION PERFORMANCE AND GOAL ORIENTATION. 2020 , 21, 555-565	
306	Auricular Vagus Neuromodulation: A Systematic Review on Quality of Evidence and Clinical Effects.	0
305	Cross-Modality Protein Embedding for Compound-Protein Affinity and Contact Prediction.	
304	The Rationale and Implementation of Model-Based Precision Medicine for Inflammatory Diseases. 2021 , 295-299	
303	Helping science and drug development to succeed through pharma-academia partnerships: Yale Healthcare Conference 2013. 2013 , 86, 429-32	1
302	Rewarding innovation in drug development. 2014 , 7, 373-4	5
301	Pioneering better science through the 3Rs: an introduction to the national centre for the replacement, refinement, and reduction of animals in research (NC3Rs). 2015 , 54, 198-208	52
300	Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity. 2014 , 2014, 1258-67	33
299	The Zebrafish as a Tool to Cancer Drug Discovery. 2015 , 3, 1069	16
298	Medicines as a Service: A New Commercial Model for Big Pharma in the Postblockbuster World. 2012 , 2, 13	1
297	Is Open Science the Future of Drug Development?. 2017 , 90, 147-151	8
296	Regulatory requirements for clinical trials in India: What academicians need to know. 2017 , 61, 192-199	8
295	[Leukocyte count of puerperal sows]. 1996 , 109, 330-5	
294	Prediction of Lipophilicity and Pharmacokinetics of Chloroacetamides by Chemometric Approach. 2018 , 17, 100-114	8
293	Word-of-Mouth Innovation: Hypothesis Generation for Supplement Repurposing based on Consumer Reviews. 2017 , 2017, 689-695	1
292	Learning from low-rank multimodal representations for predicting disease-drug associations. 2021 , 21, 308	1
291	The roles of computer-aided drug synthesis in drug development. 2021 ,	0
290	Artificial Intelligence for Autonomous Molecular Design: A Perspective. 2021 , 26,	1

289	Microvalve Bioprinting of MSC-Chondrocyte Co-Cultures.. 2021 , 10,	
288	Improving Translational Paradigms in Drug Discovery and Development. 2021 , 1, e273	2
287	A unified drug-target interaction prediction framework based on knowledge graph and recommendation system. 2021 , 12, 6775	11
286	Cardiovascular Drugs: an Insight of In Silico Drug Design Tools.	1
285	Enhancing preclinical drug discovery with artificial intelligence. 2021 ,	4
284	State of the Art: Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design. 2021 , 111, 77	1
283	Protein domain-based prediction of drug/compound-target interactions and experimental validation on LIM kinases. 2021 , 17, e1009171	1
282	AI-based forecasting of ethanol fermentation using yeast morphological data. 2021 ,	1
281	Innovation crisis in the pharmaceutical industry? A survey. 2021 , 1, 1	1
280	Maxsmi: Maximizing molecular property prediction performance with confidence estimation using SMILES augmentation and deep learning. 2021 , 1, 100014	1
279	Alginate-based 3D cell culture technique to evaluate the half-maximal inhibitory concentration: an in vitro model of anticancer drug study for anaplastic thyroid carcinoma. 2021 , 14, 27	3
278	Public consultation in the evaluation of animal research protocols. 2021 , 16, e0260114	0
277	Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology. 2021 , 12, 20417314211055015	1
276	Artificial Intelligence in Medicine: Biochemical 3D Modeling and Drug Discovery. 2021 , 1-12	
275	Drug-Target Interaction Prediction Based on Gaussian Interaction Profile and Information Entropy. 2021 , 388-399	
274	Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors.. 2022 , 1	2
273	SCREENER, an educational game for teaching the Drug Discovery and Development process. 2021 , 54, e11786	0
272	Drug repurposing for rheumatoid arthritis: Identification of new drug candidates bioinformatics and text mining analysis.. 2022 , 1-10	2

271	Antibiotic Discovery and Resistance: The Chase and the Race.. 2022 , 11,	6
270	Naturally occurring anthraquinones as potential inhibitors of SARS-CoV-2 main protease: an integrated computational study.. 2022 , 77, 1-14	1
269	Clinical pharmacology: Current innovations and future challenges.. 2021 ,	0
268	Human iPSC-Cardiomyocytes as an Experimental Model to Study Epigenetic Modifiers of Electrophysiology.. 2022 , 11,	1
267	DDA-SKF: Predicting Drug-Disease Associations Using Similarity Kernel Fusion.. 2021 , 12, 784171	0
266	Molecular substructure tree generative model for de novo drug design.. 2022 ,	0
265	The applications of deep learning algorithms on in silico druggable proteins identification. 2022 ,	0
264	Drug discovery of sclerostin inhibitors. 2022 ,	1
263	Computer-Aided Drug Design (CADD) to De-Orphanize Marine Molecules: Finding Potential Therapeutic Agents for Neurodegenerative and Cardiovascular Diseases.. 2022 , 20,	1
262	Process intensification in the biopharma industry: Improving efficiency of protein manufacturing processes from development to production scale using synergistic approaches. 2022 , 171, 108727	3
261	Microphysiological Neurovascular Barriers to Model the Inner Retinal Microvasculature.. 2022 , 12,	1
260	Synthesis and evaluation of 2-aryl-1H-benzo[d]imidazole derivatives as potential microtubule targeting agents.. 2022 ,	1
259	M2PP: a novel computational model for predicting drug-targeted pathogenic proteins.. 2022 , 23, 7	
258	How paediatric drug development and use could benefit from OMICs: a c4c expert group white paper.. 2022 ,	0
257	Conventional laboratory housing increases morbidity and mortality in research rodents: results of a meta-analysis.. 2022 , 20, 15	2
256	A Bioprinted Heart-on-a-Chip with Human Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Evaluation.. 2022 , 9,	2
255	Drug repositioning based on multi-view learning with matrix completion.. 2022 ,	1
254	Molecular Pharmacological Tools Applied to Epidemiology. 2022 , 169-180	

253	Between Science and Big Business: Tapping Mary Jane's Uncharted Potential.. 2022 , 8, 156-168	0
252	BACPI: a bi-directional attention neural network for compound-protein interaction and binding affinity prediction.. 2022 ,	3
251	From GWAS to drug screening: repurposing antipsychotics for glioblastoma.. 2022 , 20, 70	0
250	Evolution of 3D bioprinting-from the perspectives of bioprinting companies. 2022 , 25, e00193	1
249	Emerging strategies for microbial screening of novel chemotherapeutics. 2022 , 1255, 132419	1
248	Big Data in Drug Discovery. 2022 , 17-48	1
247	A Review of Progress in the Construction and Application of Human-Derived Xenograft Models for Bladder Cancer. 2022 , 10, 27-38	
246	Multiview network embedding for drug-target Interactions prediction by consistent and complementary information preserving.. 2022 ,	0
245	GANs for Molecule Generation in Drug Design and Discovery. 2022 , 233-273	1
244	Generation and Culture of Cardiac Microtissues in a Microfluidic Chip with a Reversible Open Top Enables Electrical Pacing, Dynamic Drug Dosing and Endothelial Cell Co-Culture. 2101355	2
243	GDF15: a potential therapeutic target for type 1 diabetes.. 2022 , 1-11	3
242	Machine learning & deep learning in data-driven decision making of drug discovery and challenges in high-quality data acquisition in the pharmaceutical industry.. 2021 ,	0
241	Contemporary Molecular Analyses of Malignant Tumors for Precision Treatment and the Implication in Oral Squamous Cell Carcinoma.. 2021 , 12,	1
240	Regulatory requirements for clinical trials in India: What academicians need to know. 2017 , 61, 192	16
239	Estimating the Cost of Industry Investment in Drug Research and Development: A Review of Methods and Results.. 2021 , 58, 469580211059731	1
238	Views on artificial intelligence (AI) assisted clinical trials.. 2021 , 17, 616-622	
237	Modern machine learning for tackling inverse problems in chemistry: molecular design to realization.. 2022 ,	3
236	OUP accepted manuscript.	

235 Aim in Genomics. **2022**, 1073-1086

234 Computational prediction of drug phenotypic effects based on substructure-phenotype associations.. **2022**, PP,

233 Artificial Intelligence in Medicine: Biochemical 3D Modeling and Drug Discovery. **2022**, 661-672

232 Machine Learning Models for Predicting Liver Toxicity.. **2022**, 2425, 393-415

0

231 Network-based stage-specific drug repurposing for Alzheimer's disease.. **2022**, 20, 1427-1438

1

230 dunXai: DO-U-Net for Explainable (Multi-label) Image Classification. **2022**, 212-224

229 Emerging Bioinformatics Methods and Resources in Drug Toxicology.. **2022**, 2425, 133-146

1

228 Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease.. **2022**, 17, e0263248

2

227 Deep generative models for ligand-based de novo design applied to multi-parametric optimization.. **2022**,

2

226 Emerging Landscape of Computational Modeling in Pharmaceutical Development.. **2022**,

6

225 Open innovation and drug discovery startups in Japan: The importance of communication in licensing. **2022**,

1

224 Benchmarking ensemble docking methods in D3R Grand Challenge 4.. **2022**, 36, 87

223 Use of "Repurposed" Drugs in the Treatment of Epithelial Ovarian Cancer: A Systematic Review.. **2022**, 45, 168-174

0

222 High-Throughput Drug Library Screening in Primary -Rearranged Infant ALL Cells Favors the Identification of Drug Candidates That Activate P53 Signaling.. **2022**, 10,

221 Development of spirulina for the manufacture and oral delivery of protein therapeutics.. **2022**,

3

220 BridgeDPI: A Novel Graph Neural Network for Predicting Drug-Protein Interactions.. **2022**,

4

219 Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine.. **2022**, 14,

1

218 Affinity2Vec: drug-target binding affinity prediction through representation learning, graph mining, and machine learning.. **2022**, 12, 4751

1

217	Compound-protein interaction prediction by deep learning: databases, descriptors and models.. 2022,	1
216	Kidney microphysiological models for nephrotoxicity assessment.. 2022, 30,	2
215	A Change of Heart: Human Cardiac Tissue Engineering as a Platform for Drug Development.. 2022, 1	1
214	The Modular µSiM: a Mass Produced, Rapidly Assembled, and Reconfigurable Platform for the Study of Barrier Tissue Models In Vitro.	0
213	Defining a global map of functional group based 3D ligand-binding motifs.. 2022,	
212	Dihydromyricetin improves social isolation-induced cognitive impairments and astrocytic changes in mice.. 2022, 12, 5899	0
211	DTI-HETA: prediction of drug-target interactions based on GCN and GAT on heterogeneous graph.. 2022,	2
210	Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics.. 2022, 12, 147	3
209	Engineering complexity in human tissue models of cancer.. 2022, 114181	1
208	Inhibition of PDK3 by artemisinin, a repurposed antimalarial drug in cancer therapy. 2022, 355, 118928	5
207	Artificial Intelligence-based decision support model for new drug development planning.. 2022, 116825	1
206	Why medicines work.. 2022, 238, 108175	1
205	Comparative study on the efficacy and exposure of molecular target agents in non-small cell lung cancer PDX models with driver genetic alterations.. 2021,	0
204	Commercial SARS-CoV-2 Targeted, Protease Inhibitor Focused and Protein-Protein Interaction Inhibitor Focused Molecular Libraries for Virtual Screening and Drug Design.. 2021, 23,	2
203	Qualifying a human Liver-Chip for predictive toxicology: Performance assessment and economic implications.	3
202	Optical to Planar X-ray Mouse Image Mapping in Preclinical Nuclear Medicine Using Conditional Adversarial Networks.. 2021, 7,	1
201	A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets.. 2022, 119, e2110557119	1
200	Prediction of In Vivo Pharmacokinetic Parameters and Time-Exposure Curves in Rats Using Machine Learning from the Chemical Structure.. 2022,	1

199 Data_Sheet_1.PDF. **2020**,

198 DataSheet_1.docx. **2020**,

197 Table_1.PDF. **2018**,

196 Table_2.PDF. **2018**,

195 Table_3.PDF. **2018**,

194 Table_4.pdf. **2018**,

193 Table_5.pdf. **2018**,

192 Table_1.docx. **2018**,

191 Interdisciplinary analysis of drugs: Structural features and clinical data. **2022**, 6,

0

190 Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa.. **2022**, 28, 107602962210999

189 OUP accepted manuscript.

0

188 Ligand Binding Prediction using Protein Structure Graphs and Residual Graph Attention Networks.

187 The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery.. **2022**, 14,

1

186 Impact of expedited programs in the United States, as foreign regulatory factors, on clinical development time in Japan.. **2022**,

185 Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19. **2022**, 2,

0

184 Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing.. **2022**, 14,

3

183 SecMPNN: 3-Party Privacy-Preserving Molecular Structure Properties Inference. **2022**,

182 A Network-Biology led Computational Drug repurposing Strategy to prioritize therapeutic options for COVID-19.. **2022**, e09387

1

181	Designing clinically useful psychopharmacological trials: challenges and ways forward.. 2022 ,	2
180	Collaborative university-industry R&D practices supporting the pharmaceutical innovation process: insights from a bibliometric review.. 2022 ,	1
179	Design of freeze-drying cycles: the determination of heat transfer coefficient by using heat flux sensor and MicroFD.. 2022 , 121763	0
178	Topical Repute on Artificial Intelligence-Based Approaches in COVID-19 Supervision. 2022 , 180-210	
177	Nano-hydroxyapatite improves intestinal absorption of acetazolamide (BCS Class IV drug)-but how?. 2022 , 17, e0268067	1
176	Biomarkers for Cancer Drug Development. 2022 , 65-82	
175	Sphingolipids: A Roadmap from Biomarker Identification to Clinical Application. 2022 , 447-471	
174	In silico modelling demonstrates that user variability during tumor measurement can affect in vivo therapeutic efficacy outcomes.	0
173	Open innovation: A paradigm shift in pharma R&D?. 2022 ,	0
172	Functional diversification and exaptation: the emergence of new drug uses in the pharma industry.	
171	History and Present Scenario of Computers in Pharmaceutical Research and Development. 2022 , 1-38	
170	Transcriptomic analysis reveals mode of action of butyric acid supplementation in an intensified CHO cell fed-batch process.	0
169	Pyronaridine Protects against SARS-CoV-2 Infection in Mouse.	3
168	Human organoids in basic research and clinical applications. 2022 , 7,	5
167	Nanosafety: An Evolving Concept to Bring the Safest Possible Nanomaterials to Society and Environment. 2022 , 12, 1810	2
166	Retro Drug Design: From Target Properties to Molecular Structures.	0
165	Teaching Computer-Aided Drug Design Using TeachOpenCADD. 135-158	0
164	Jeopardizing Discoverability. 2022 , 79-103	

- 163 Proteomic analysis of spheroids of rhabdomyosarcoma cells cultured with decellularized muscle extracts. **2022**, 66, 1-4
- 162 Converting a drug from off-label to on-label use: Government subsidies and patient welfare.
- 161 Flow Chemistry in Medicinal Chemistry: Applications to Bcr - Abl Kinase Inhibitors. **2022**, 103-158
- 160 Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity. **2022**, 120731 0
- 159 DTITR: End-to-end drug-target binding affinity prediction with transformers. **2022**, 105772 0
- 158 Computational-Model-Based Biopharmaceutics for p53 Pathway Using Modern Control Techniques for Cancer Treatment. **2022**, 12, 5748 0
- 157 Philanthropic Investments in Deep Tech Start-Ups: An Exploratory Study.
- 156 Synthesis, Antimicrobial, Cytotoxic and Molecular Docking Studies of Bis(azolylsulfonyl)pyrrole Dicarboxamides. 1-27
- 155 A unified peptide array platform for antibody epitope binning, mapping, specificity and predictive off-target binding.
- 154 Ovarian cancer through a multi-modal lens. **2022**, 3, 662-664 0
- 153 Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system. 0
- 152 Proteome Exploration of Legionella pneumophila To Identify Novel Therapeutics: a Hierarchical Subtractive Genomics and Reverse Vaccinology Approach. 0
- 151 Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation?. **2022**, 179, 458-469 0
- 150 Computational Methods in Cooperation with Experimental Approaches to Design Protein Tyrosine Phosphatase 1B Inhibitors in Type 2 Diabetes Drug Design: A Review of the Achievements of This Century. **2022**, 15, 866 1
- 149 Industrializing AI-powered drug discovery: lessons learned from the Patrimony computing platform. 1-10 0
- 148 Harnessing systematic protein-ligand interaction fingerprints for drug discovery. **2022**, 2
- 147 Liver-on-a-Chip devices: The Pros and Cons of Complexity. 0
- 146 Investigation of novel compounds via in silico approaches of EGFR inhibitors as anticancer agents. **2022**, 99, 100601 1

145	The use of genomic variants to drive drug repurposing for chronic hepatitis B. 2022 , 31, 101307	0
144	Coverage Score: A Model Agnostic Method to Efficiently Explore Chemical Space.	1
143	Project, Risk, and Portfolio Management [Managing R & D Projects Today*. 2022 , 257-279	
142	Improved Time Resolved KPI and Strain Characterization of Multiple Hosts in Shake Flasks Using Advanced Online Analytics and Data Science. 2022 , 9, 339	2
141	Three-Dimensional In Vitro Cell Culture Models for Efficient Drug Discovery: Progress So Far and Future Prospects. 2022 , 15, 926	2
140	Ultrahigh resolution whole body photon counting computed tomography as a novel versatile tool for translational research from mouse to man. 2022 ,	
139	Mice in translational neuroscience: What R we doing?. 2022 , 217, 102330	3
138	Biomarker-Based Drug Discovery with Reverse Translational Approach. 2022 , 123-140	
137	Multi-arm covariate-adaptive randomization.	
136	Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept. 2022 , 2022, 1-12	
135	Principles and Methods of the Pharmaceutical Drug Discovery Process [From Idea over Target to a Development Candidate. 2022 , 37-61	
134	Ligand Binding Prediction Using Protein Structure Graphs and Residual Graph Attention Networks. 2022 , 27, 5114	
133	Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.	1
132	Phases of Drug Development and Drug Development Paradigms. 2022 , 79-100	
131	The Modular µSiM: A Mass Produced, Rapidly Assembled, and Reconfigurable Platform for the Study of Barrier Tissue Models In Vitro. 2200804	1
130	Current State of Affairs. 2022 , 333-352	
129	Absolute binding free energy calculations improve enrichment of actives in virtual compound screening. 2022 , 12,	1
128	Critical Assessment of State-of-the-Art Ligand-Based Virtual Screening Methods. 2200103	1

127	The past, present, and future of antibiotics. 2022 , 14,	13
126	Dividend policy issues in the European pharmaceutical industry: new empirical evidence.	
125	Biopharmaceutical R&D outsourcing: short-term gain for long-term pain?. 2022 ,	
124	Lung adenocarcinoma-related target gene prediction and drug repositioning. 13,	
123	Electrospinning and nanofibers: Building drug delivery systems and potential in pesticide delivery. 2022 , 33, 104399	0
122	General Strategies for Rational Design and Discovery of Multitarget Drugs. 2022 , 677-736	0
121	In Silico Drug Repositioning for COVID-19: Progress and Challenges. 2022 , 487-504	0
120	The drug-discovery process. 2022 , 383-422	0
119	Adult Mesenchymal Stem Cell Collection and Banking. 2023 , 81-88	0
118	Progress and Impact of Latin American Natural Product Databases. 2022 , 12, 1202	1
117	Entrepreneurial Orientation on Clinical Development in Pharmaceutical Industry: Fixed-Model Analysis. 2022 ,	0
116	Clinical trial design in the era of precision medicine. 2022 , 14,	3
115	Effect of External Innovation on Advanced Pharmaceutical R&D: The Case of Monoclonal Antibody Drug Development. 2022 ,	0
114	Acridone Alkaloids: In-Silico Investigation Against SARS-CoV-2 Main Protease.	0
113	Machine learning models for rat multigeneration reproductive toxicity prediction. 13,	0
112	On drug discovery against infectious diseases and academic medicinal chemistry contributions. 18, 1355-1378	0
111	Value-Based Clinical Trials: Selecting Recruitment Rates and Trial Lengths in Different Regulatory Contexts.	0
110	The Race for COVID-19 Vaccines: Accelerating Innovation, Fair Allocation and Distribution. 2022 , 10, 1450	1

109	GCMCDTI: graph convolutional autoencoder framework for predicting drug-target interactions based on matrix completion.	0
108	In Silico Positional Analogue Scanning with Amber GPU-TI. 2022 , 62, 4448-4459	1
107	Transparency in Non-Technical Project Summaries to Promote the Three Rs in Respiratory Disease Research. 2022 , 50, 349-364	0
106	Pharmacogenomics deliberations of 2-deoxy-d-glucose in the treatment of COVID-19 disease: an in silico approach. 2022 , 12,	0
105	Addressing artifacts of colorimetric anticancer assays for plant-based drug development. 2022 , 39,	0
104	Predictive validity in drug discovery: what it is, why it matters and how to improve it.	4
103	AlphaDrug: Protein target specific de novo molecular generation.	0
102	Evaluating molecular fingerprint-based models of drug side effects against a statistical control. 2022 , 27, 103364	0
101	Machine Learning Techniques for Development of Drugs Against Coronavirus Disease 2019 (COVID-19): A Case Study Protocol. 2021 , 307-325	0
100	3D in vitro cancer models for drug screening: A study of glucose metabolism and drug response in 2D and 3D culture models. 2021 ,	0
99	A Perspective on 30 Years of DNA-Encoded Chemistry. 2022 ,	0
98	Discovery of Novel HIV Protease Inhibitors Using Modern Computational Techniques. 2022 , 23, 12149	0
97	Technological development and patent analysis: the case of biopharmacy in the world and in Latin America. 2022 , 5,	0
96	Predicting FDA approvability of small-molecule drugs.	0
95	Drug-Disease Association Prediction Using Heterogeneous Networks for Computational Drug Repositioning. 2022 , 12, 1497	0
94	Drug Development of Small Molecule Cancer Therapeutics in an Academic Cancer Center. 1-9	0
93	Better Approaches to Derisking Psychiatric Drug Development are Needed, Not New Funding Mechanisms. Publish Ahead of Print,	0
92	An Artificial Intelligence Framework for Optimal Drug Design.	0

91	Structure and Computational Studies of New Sulfonamide Compound: {(4-nitrophenyl)sulfonyl}tryptophan. 2022 , 27, 7400	0
90	Possibility Extent and Possible Alternatives Preorder Type-2 Fuzzy Analytical Hierarchy Process (PE&PAP-AHP) to improve pharmaceutical R&D productivity. 2022 , 109770	0
89	Adversarial deep evolutionary learning for drug design. 2022 , 222, 104790	0
88	Developing clinically translatable screens using iPSC-derived neural cells. 2023 , 265-287	0
87	LEKI WIELOCELOWE ĆNOWY PARADYGMAT W PROJEKTOWANIU LEKŲ. 2013 , 11, 1-10	0
86	PPAEDTI: Personalized Propagation Auto-Encoder Model For Predicting Drug-Target Interactions. 2022 , 1-11	0
85	Magnetic hydrothermal carbonaceous nanospheres bonded cell membranes as a stable and reusable platform for discovering natural bioactive components. 2023 , 454, 140238	0
84	Empowering drug development: leveraging insights from imaging technologies to enable the advancement of digital health technologies.	0
83	Impact of Pharmaceutical R&D Activity on Financial Flexibility and Bargaining Power. 2022 , 10, 277	0
82	e-TSN: an interactive visual exploration platform for target-disease knowledge mapping from literature.	0
81	Improving combination drug trials using Ćdefinitive screening designsĆ	0
80	The Pharma/Biotech Model for Drug Development: Implications for Pediatric Cancer Therapeutics. 2022 , 89-107	0
79	In Silico Modeling Demonstrates that User Variability During Tumor Measurement Can Affect In Vivo Therapeutic Efficacy Outcomes. 2022 , 21, 117693512211392	1
78	Predicting drug-target binding affinity through molecule representation block based on multi-head attention and skip connection. 2022 , 23,	1
77	Improved graph-based multitask learning model with sparse sharing for quantitative structure-property relationship prediction of drug molecules.	0
76	RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides. 1-12	0
75	Pharmacokinetic Study and Metabolite Identification of 1-(3-bromophenyl)-heliamine in Rats. 2022 , 15, 1483	0
74	FINANCIAL MARKET REACTION TO R&D VOLATILITY IN THE PHARMACEUTICAL INDUSTRY. A MULTI-COUNTRY STUDY. 2022 , 23, 1234-1256	0

73	High-confidence cancer patient stratification through multiomics investigation of DNA repair disorders. 2022 , 13,	0
72	3D organ-on-a-chip: The convergence of microphysiological systems and organoids. 10,	0
71	A machine learning strategy with clustering under sampling of majority instances for predicting Drug Target Interactions.	0
70	Analytical Workflows to Unlock Predictive Power in Biotherapeutic Developability.	0
69	A weighted non-negative matrix factorization approach to predict potential associations between drug and disease. 2022 , 20,	0
68	Organ-on-a-chip: Its use in cardiovascular research. 2022 , 1-25	1
67	Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. 2022 , 2,	2
66	A proof-of-concept study poised to remodel the drug development process. 4,	0
65	Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery. 9,	0
64	Fighting antibiotic resistance—strategies and (pre)clinical developments to find new antibacterials.	1
63	Recombinant protein-based injectable materials for biomedical applications. 2022 , 114673	0
62	QuoteTarget : A sequence-based transformer protein language model to identify potentially druggable protein targets.	0
61	An Empirical Quantitative Structure-Activity Relationship Equation Assists the Discovery of High-Affinity Phosphodiesterase 4D Inhibitors as Leads to PET Radioligands.	0
60	Prediction of Drug-Disease Relationship on Heterogeneous Networks Based on Graph Convolution. 2022 , 243-254	0
59	Rival Signals and Project Selection: Insights from the Drug Development Process.	0
58	Maximizing the value of the open label extension phase of randomized clinical trials.	0
57	Antioxidant and Anti-Inflammatory Effects of 6,3,4- and 7,3,4-Trihydroxyflavone on 2D and 3D RAW264.7 Models. 2023 , 12, 204	0
56	Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems. 2023 , 30, 704-719	0

- 55 Editorial: Investigating drugs used off-label in various cancers. 13, ○
- 54 Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma Treatment. **2023**, 23, ○
- 53 Recent trends in interorganizational deal networks in pharmaceutical and biotechnology industries. **2023**, 28, 103483 ○
- 52 A Guide to In Silico Drug Design. **2023**, 15, 49 ○
- 51 Conformation specific antagonistic high affinity antibodies to the RON receptor kinase for imaging and therapy. **2022**, 12, ○
- 50 GraphATT-DTA: Attention-Based Novel Representation of Interaction to Predict Drug-Target Binding Affinity. **2023**, 11, 67 ○
- 49 An Open Source Graph-Based Weighted Cycle Closure Method for Relative Binding Free Energy Calculations. ○
- 48 Structure-based Drug Discovery and Advances in Protein Receptor Crystallography. **2017**, 45-72 ○
- 47 Der (lange) Weg zu einem Quantenvorteil in der Pharmabranche. **2022**, 157-165 ○
- 46 Mapping interaction between big spaces; active space from protein structure and available chemical space. **2023**, 299-332 ○
- 45 Machine Learning for Predicting Organ Toxicity. **2023**, 519-537 ○
- 44 Deep Learning Model for Prediction of Compound Activities Over a Panel of Major Toxicity-Related Proteins. **2023**, 579-593 ○
- 43 Emerging Selenium Nanoparticles for CNS Intervention. ○
- 42 Chemo- and Diastereoselective Acylfluorination of Nonactivated Olefins to Access Benzo[b]azepines. **2023**, 25, 726-731 ○
- 41 Drug Repurposing for Hematological Malignancies. **2023**, 217-252 ○
- 40 Chaotic Modified Binary Grey Wolf Optimizer Feature Selection method for Drug-Target interaction prediction Based on drug-protein Features. **2022**, ○
- 39 Experimental Medicine Approaches in Early-Phase CNS Drug Development. **2023**, 417-455 ○
- 38 Drug discovery: Standing on the shoulders of giants. **2023**, 207-338 ○

- 37 Digital therapeutics from bench to bedside. **2023**, 6,
- 36 From basic sciences and engineering to epileptology: A translational approach.
- 35 AB-Gen: Antibody Library Design with Generative Pre-trained Transformer and Deep Reinforcement Learning.
- 34 Keeping It Organized: Multicompartment Constructs to Mimic Tissue Heterogeneity.
- 33 Advanced model predictive control strategies for evaporation processes in the pharmaceutical industries. **2023**, 173, 108212
- 32 GenSMILES: An enhanced validity conscious representation for inverse design of molecules. **2023**, 268, 110429
- 31 Phytochemistry of the Vepris genus plants: A review and in silico analysis of their ADMET properties. **2023**, 157, 106-114
- 30 A microfluidic device integrated with a stretchable microporous membrane controlled by electro-conjugate fluid. **2023**, 356, 114332
- 29 In silico prediction of Antifungal compounds from Natural sources towards Lanosterol 14-alpha demethylase (CYP51) using Molecular docking and Molecular dynamic simulation. **2023**, 121, 108435
- 28 Assessing clinical site readiness for EHR-to-EDC automated data collection. **2023**, 128, 107144
- 27 The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19. 2,
- 26 Needles to Spheres: Evaluation of inkjet printing as a particle shape enhancement tool. **2023**, 184, 92-102
- 25 The gut microbiome Does stool represent right?. **2023**, 9, e13602
- 24 Bestatin analogs-4-quinolinone hybrids as antileishmanial hits: Design, repurposing rational, synthesis, in vitro and in silico studies. **2023**, 250, 115211
- 23 Leveraging the regulatory framework to facilitate drug development in Parkinson's disease. **2023**, 347-360
- 22 Computer-Aided Drug Design Project for Introductory High School Students. **2023**, 100, 1179-1188
- 21 NP-hard but no longer hard to solve? Using quantum computing to tackle optimization problems. 2,
- 20 Measuring research efficiency and its determining factors for Indonesian R&D institutions: does scientific publication make a difference?.

- 19 Assessing developability early in the discovery process for novel biologics. **2023**, 15, 1
- 18 Progress and Understandings in the Pharmacological Repositioning Scenario. **2023**, 5, 28-31 0
- 17 Computer-aided drug design-based system pharmacology applications for the treatment of diabetes mellitus. **2023**, 255-280 0
- 16 Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?. **2023**, 43, 227-239 0
- 15 Conjugation as a Tool in Therapeutics: Role of Amino Acids/Peptides-Bioactive (Including Heterocycles) Hybrid Molecules in Treating Infectious Diseases. **2023**, 12, 532 0
- 14 Drug discovery: Chaos can be your friend or your enemy. **2023**, 417-511 0
- 13 Biopharmaceutical product development strategies. **2023**, 121-142 0
- 12 Commentary on Bioassay: a pharmacological endeavour by Jacques M. van Rossum and J.Th.A. Hurkmans. **2023**, 131-136 0
- 11 Pharmacological Chaperones and Protein Conformational Diseases: Approaches of Computational Structural Biology. **2023**, 24, 5819 0
- 10 Prospects for using high-throughput sequencing methods to identify new biomarkers of response and resistance to antitumor therapy. 0
- 9 A scoping review of neurodegenerative manifestations in explainable digital phenotyping. **2023**, 9, 0
- 8 Reverse tracking from drug-induced transcriptomes through multilayer molecular networks reveals hidden drug targets. **2023**, 158, 106881 0
- 7 Predicting ExWAS findings from GWAS data: a shorter path to causal genes. 0
- 6 Matched Molecular Pair Analysis in Drug Discovery: Methods and Recent Applications. **2023**, 66, 4361-4377 0
- 5 Hemoglobin and cerebral hypoxic vasodilation in humans: Evidence for nitric oxide-dependent and S-nitrosothiol mediated signal transduction. 0271678X2311695 0
- 4 A Methodology for the Prediction of Drug Target Interaction Using CDK Descriptors. **2023**, 408-419 0
- 3 cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence. 0
- 2 Discovery of anticancer therapeutics: Computational chemistry and Artificial Intelligence-assisted approach. **2023**, 19-41 0

- 1 Who counts as an inventor? Seniority and gender in 430,000 biomedical inventor-researcher teams.
2023, 41, 610-614

○